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ABSTRACT 
MALARIAL INFECTIONS IN THE CONTEXT OF INVASIVE NON-TYPHOIDAL SALMONELLA 
 
Rebecca Eve Lewis 
 
Apicomplexan parasites of the genus Plasmodium have been infecting humans for 
millions of years, leaving their mark on the human genome and probably playing a role in 
shaping the distribution of global wealth. The disease they cause, malaria, continues to 
claim the lives of more than half a million people every year, mostly young children in 
Sub-Saharan Africa. Including deaths, immediate symptoms, and lasting complications of 
severe malaria syndromes, the disease causes an estimated annual loss of over 80 million 
life years due to ill health, disability, or early mortality.  
 
Populations in regions where malaria is endemic are also exposed to a number of other 
pathogenic organisms; co-infections occur between Plasmodium species and a wide 
variety of viruses, other eukaryotic parasites, and bacteria. Invasive bacterial species are a 
widespread threat in Sub-Saharan Africa, where up to 12% of people admitted to hospital 
with fever are reported to have culturable bacteria in their bloodstream. For decades, 
evidence has suggested that malaria may contribute to the prevalence of invasive 
bacterial disease in Sub-Saharan Africa; human and mouse studies have shown that 
indeed plasmodial infection increases susceptibility to invasive bacterial infection and 
mortality, in particular due to invasive non-typhoidal Salmonella (NTS). Invasive NTS 
are of especial interest as they are consistently among the most commonly identified 
bacteria isolated from blood culture.  
 
NTS rarely causes invasive disease in the developed world, remaining as an enteric 
infection and eliciting unpleasant but usually self-limiting symptoms. In contrast, 
multiple environmental and bacteria-intrinsic factors in Sub-Saharan Africa contribute to 
a greater propensity of NTS to breach the gut wall and spread systemically. Malaria, as 
mentioned, is well established as one such factor. However, other contributing 
determinants of invasion mean that a substantial number of Plasmodium infections may 
be contracted by people already harboring systemic NTS infection and may therefore 
exhibit altered parasite development or progression of malarial disease. 
 
The impact of existing invasive NTS infection on Plasmodium has not been elucidated. In 
this thesis we present our findings, using a mouse model of co-infection, that invasive 
NTS inhibits liver-stage Plasmodium berghei development. We demonstrate that this 
inhibition is at least in part through induction of a host response that is detrimental to the 
parasite and does not require live NTS infection. Invasive NTS-induced suppression of 
liver-stage growth was independent of Type I IFN, IFN-γ and TNF-α signaling, although 
all three of these factors are upregulated in NTS-infected mice in our model. 
 
Plasmodial disease is a consequence of asexual blood-stage parasite replication. Using 
our model of co-infection we show that progression to this stage of disease is hampered, 
not only through reduction of liver parasite burden, but also through direct suppression of 
blood-stage parasite population growth. Although we found that killed NTS do not 
suppress blood-stage P. berghei populations, mice treated with heat-killed NTS survived 
longer, indicating that killed bacteria may be sufficient to prevent development of 
experimental cerebral malaria. 
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CHAPTER 1 - INTRODUCTION 
 
OVERVIEW 
Great strides have been made over the past century in reducing the area of the globe over which 
people are threatened by malaria (figure 1.1). In spite of this, almost half of Earth’s 7.3 billion 
human inhabitants remains at risk of becoming infected and developing malarial disease (1). 
Malaria killed an estimated 584,000 people in 2013 and resulted in approximately 83 million 
disability-adjusted life years in 2010 (1, 2).  
 
The pathogens responsible for malarial disease are parasitic protozoa of the genus Plasmodium, 
comprising roughly 200 species and having a wide host range including humans, non-human 
primates, rodents, birds, bats, reptiles, and more (3-6). Of the roughly 200 recognized 
Plasmodium species, five are known to infect humans: Plasmodium falciparum (P. falciparum), 
P. vivax, P. malariae, P. ovale, and P. knowlesi. P. falciparum and P. vivax predominate. 
Although P. vivax has a wider global range P. falciparum imposes the far greater burden on 
Figure 1.1 Reduction in global distribution of malaria between 1900 and 2002. All 
human-infecting Plasmodium species are represented. Map reproduced from Simon I Hay et 
al., The Lancet Infectious Diseases 4(6):327-336 (June 2004) 
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human life: 90% of all malaria deaths occur in Sub-Saharan Africa, where cases are almost 
exclusively due to P. falciparum (1). 
 
THE IMPACT OF MALARIA ON THE HUMAN GENOME 
The assault by P. falciparum parasites on human populations has an ancient history. P. 
falciparum and its closest relative, P. reichenowi, which infects chimpanzees, are thought to 
have diverged from their last common ancestor 5 to 7 million years ago, around the same time as 
their respective hosts diverged from each other (7). The likely implication of this is that the 
human race has at no point in its existence been malaria-free. The selection pressures imposed by 
long-standing exposure to a disease as severe as malaria have left their mark on the human 
genome: hemoglobinopathies, altered or absent red blood cell (RBC) surface molecules, 
promoter polymorphisms in immune factors, and many other adaptations have been associated 
with protection against malaria. Some such adaptations defend the human host against 
Plasmodium infections becoming established, whereas others protect against development of 
severe disease. The most striking example of the former is the Duffy-negative blood group, 
which is so predominant in some regions of Sub-Saharan Africa that almost 100% of the 
population is Duffy-negative (8). The first Duffy antigens to be reported were Fya and Fyb in 
1950 and 1951 respectively (9, 10). In 1955, donations by black Americans to the Knickerbocker 
Blood Bank in New York were tested for reactivity to the recently developed anti-Fya and anti-
Fyb antibodies. Almost 70% of those samples were negative for both antigens, in stark contrast to 
the 160 “European” samples that had yet been tested with both antibodies, not one of which was 
negative for both Fya and Fyb (11). The predominance of the Duffy-negative blood group in Sub-
Saharan Africa in spite of its scarcity over other parts of the globe, along with the inverse 
 3 
prevalence of P. vivax infections, hinted at Duffy negativity being protective against P. vivax. 
Indeed, a small study introducing P. vivax infections into human volunteers in 1976 found no 
blood-stage infections in the Duffy-negative individuals, whilst people positive for Fya, Fyb, or 
both readily contracted P. vivax malaria (12). It was later shown that the Duffy antigen is 
required by P. vivax parasites for RBC invasion (13). More recently P. vivax infections in Duffy-
negative people have been reported, possibly indicating that the parasite has adapted to exploit 
alternative RBC-invasion strategies (14-16). Whilst Duffy-negative people are generally 
protected against infection becoming established, other genetic adaptations protect people 
against development of severe malaria syndromes. Probably the most famous such protective 
allele is the HbS allele of hemoglobin, which in homozygous (HbSS) individuals causes sickle 
cell anemia. Heterozygous (HbAS) people, carrying one HbS allele and one wild type HbA 
allele, have very few symptoms of the sickling disorder and are relatively protected, compared to 
HbAA individuals, against developing high Plasmodium parasite burdens or severe malaria 
syndromes (17, 18). Polymorphisms in various immune mediators, which will be discussed in 
more detail in Chapter 4, have also been associated with protection from infection and severe 
disease. However, there have been discrepant conclusions as to which cytokines are protective, 
or conversely may increase risk. Such differences may be explained in part by the fact that 
progression of disease depends on both host and parasite genetic factors, as exemplified in 
mouse models. For instance an individual mouse strain might be highly susceptible to one 
Plasmodium strain and resistant to another, while a separate mouse strain shows the exact 




THE IMPACT OF MALARIA ON CIVILIZATION 
Not only can the impact of malaria be seen in the genetic make-up of modern day populations, 
but the disease has been implicated in the fall of civilizations, in the failure of grand engineering 
projects, and in the defeat of invading armies. P. falciparum DNA found in the skeleton of a 
Roman child buried around the year 450, and cranial abnormalities indicative of P. falciparum 
infections in other skeletons buried alongside, supported the hypothesis of archaeologists who 
believe that malaria epidemics contributed to the decline of the Roman Empire (20). 20 years 
before the United States reinitiated construction of the Panama Canal, the French had attempted 
the project but been thwarted by yellow fever and malaria (21). In 1809 the largest British 
Expeditionary Force ever assembled was quickly defeated on the island of Walcheren, not by the 
Napoleonic army they had set out to repel, but by malaria and other fevers that killed almost 
4000 soldiers, 40 times as many as were killed in battle (22). This last example is just one of 
numerous military failures attributed to malaria. The seriousness of malaria as another force to 
contend with in battle is evident in the many 20th century posters that were produced warning 
United States armed forces serving in malaria-endemic areas to sleep under bed nets (figure 1.2) 
and take other precautions against mosquito exposure, as well as grisly reminders to take their 






To focus on the impact of malaria on war, however, is to disregard the massive impact of malaria 
on civilian populations living permanently in malaria endemic areas, who comprise the 
overwhelming majority of people at risk. It may be tempting to attribute the seeming 
intractability of malaria in some parts of the world to the substantial poverty in those regions. 
Maps of the world that adjust the size of countries depending on either wealth or malaria 
prevalence show a dramatic inverse correlation: the map of wealth distribution shows each 
continent as a recognizable landmass apart from Africa, which is barely visible, whilst the map 
of malaria incidence shows an Africa that is bloated beyond recognition with the rest of the 
world being barely visible (figure 1.3). Whilst the costs associated with prevention and treatment 
can undoubtedly be a barrier to reducing malaria cases and deaths, it has also been argued that 
malaria itself causes poverty (23): In multiple regression analyses, Gallup and Sachs found that 
Figure 1.2 Warnings to the United States armed forces. Left: WWII poster; US Government Printing Office; 
image in the public domain in the US. Right: reminder to take anti-malarial prophylaxis, photographed at the 




even when controlling for an array of factors contributing to national wealth, including climate 
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Produced by the SASI group (Sheffield) and Mark Newman (Michigan)
“The PPP rate is the exchange rate which would mean that the money you exchange would buy exactly the same basket
of goods in both countries ...”
Purchasing power is a measure of what
can be bought in the territory in which
that money is earned. It is cheaper to
live in some places than others.
Taking differences in local costs into
consideration, this map shows that 46%
of world wealth adjusted for purchasing
power is in North America and Western
Europe. The regions with the most
purchasing power per person are North
America, Japan and Western Europe.
Despite the lower prices found in
Central Africa, the people living there
still have the lowest purchasing power.
The proportion of world wealth found
in Central Africa is greater when
measured in purchasing power than
when measured using exchange rates.
• Data are from the United Nations Development
Programme’s 2004 Human Development Report.
• Gross Domestic Product is measured in Purchasing
Power Parity (PPP) US$, thus PPP US$1 has the
same purchasing power in every territory.
• See website for further information.
Territory size shows the proportion of worldwide wealth
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malaria cases per 100 people, 2003*
Rank Territory Value
1 Uganda 49
2 Sao Tome and Principe 32
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“Yet malaria remains the biggest cause of death for children under five in Africa.”
Of all the people living with malaria,
92% live in African territories. Parts
of Mediterranean Africa have very
low numbers of malaria cases. In
contrast, almost half the peo le living
in Uganda suffer from malaria.
Uganda also has th  most cases of
malaria in the world. Most territories
are barely visible due to the low
number of malaria cases found there.
Malaria is a parasitic infection that is
spread between people by
mosquitoes. Incidence can be reduced
by mosquito control and anti-malarial
prophylaxsis in some cases. It is
treatable but drug resistance and loss
of immunity occur. 72 million new
and existing cases of malaria were
recorded worldwide in 2003.
• Data are from World Health Organization’s 2004,
Human Resources for Health.
• *Data estimated from regional averages not
included in chart.
*Data reported are those most recently available
between 2000 and 2003.
• See website for further information.
Territory size shows the proportion of all people living




















3Figure 1.3 Maps with territory sizes adjusted for metrics of wealth and malaria burden. Top: territory size 
shows the proportion of the world’s wealth that is found in that territory in 2002, after adjusting for purchasing 
power; Bottom: territory size shows the proportion  ll people with malaria worldwide living in that territory in 
2003 (or most recent data pre-2003). Colors are to emphasize national boundaries and aid comparison between 
maps. They do not represent data values. Maps © 2006 SASI Group (University of Sheffield) and Mark 
Newman (University of Michigan). 
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public institutions, proximity to markets, level of fuel use, and trade openness, malaria incidence 
still had a strong inverse correlation with gross domestic product. They also cited the rapid 
economic growth, at rates higher than in neighboring countries, of nations that eliminated 
malaria in the 20th century as an indicator that malaria had been a factor in impeding prior 
growth. The conclusion of Gallup and Sachs addresses the impact of malaria on the wealth of 
entire countries. A number of studies have attempted to address whether malaria incidence 
accentuates poverty at the micro or household level, with a comprehensive review of these 
studies finding no consistent link between depressed socioeconomic status and increased malaria 
incidence (24). However, no studies included in this review displayed the opposite correlation of 
greater wealth associating with higher malaria incidence, and there was a consistently positive 
correlation between adoption of malaria preventive strategies and various indicators of greater 
wealth. 
 
The burden of malaria almost certainly both contributes to and is exacerbated by poverty. 
Controlling this disease is therefore not only important for reducing morbidity and mortality but 
also for alleviating the economic stresses it imposes. Control itself is a huge and expensive task: 
the Global Malaria Action Plan set a funding target of US$5.1 billion towards pursuing the aims 
of 1) achieving universal malaria prevention and case management, 2) drastically reducing 
malaria cases and deaths, 3) eliminating malaria country-by-country, and 4) eventually 
eradicating the disease (25). The World Health Organization estimates that yearly spending is 





THE PLASMODIUM LIFE CYCLE 
Over the course of their life cycle Plasmodium parasites undergo a number of drastic 
morphological changes, from the 11 × 1 µm eyelash-shaped sporozoite, to the 60 µm diameter 
spherical oocyst from which the sporozoites emerge. A number of these stages were noted by 
Alphonse Laveran, the French military doctor who in 1880 first identified Plasmodium parasites 
in blood as the causative agent of what he knew as marsh fever (or paludisme in his native 
French) and what we now know as malaria (figure 1.4). Laveran won the Nobel Prize in 
Physiology or Medicine for this and other discoveries in tropical disease. 
 
Each stage of the Plasmodium life cycle is finely tuned to the environment it inhabits, allowing 
for efficient uptake of all the nutrients necessary to support development, whilst evading the 
immune defenses of both the mosquito and vertebrate hosts. In contrast to the variety of genera 
exploited as vertebrate hosts by Plasmodium, the vector stages are restricted to female 
Figure 1.4 Drawings by Alphonse Laveran of 
Plasmodium parasites detected in blood samples. Blood-
stage development is represented. The bottom row shows 
exflagellation of a male gametocyte, a process that usually 
happens in the mosquito midgut. Image in the public 
domain. 
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mosquitoes of the genus Anopheles. An infectious mosquito carries Plasmodium sporozoites in 
her salivary glands from where they will be injected along with the mosquito’s saliva when she 
takes a blood meal (figure 1.5).  
 
The skin. When an infected Anopheles takes a blood meal, the haploid sporozoites in her 
salivary glands are not only ideally placed but also perfectly formed for slipping through the 
mosquito proboscis into the vertebrate host, gliding through the new host’s dermis to find a 
blood vessel that will carry it to the liver, and then invading the liver. Whilst on the journey from 
its injection site to the liver the sporozoite is vulnerable to attack by the new host’s immune 
system. Sporozoites appear to inhibit some of these host responses, with one study showing 
reduced polynuclear cell infiltration into the bite site following Plasmodium-infected compared 
with uninfected mosquito feed. (26). Nonetheless, intradermal injections of sporozoites have 
been found to induce neutrophil and inflammatory monocyte infiltration and sporozoites have 
been observed being internalized by these cells (27). Although a few sporozoites can survive 
Figure 1.5 The life cycle of Plasmodium. Female anopheline mosquitoes are the definitive host and act 
as the vector for transmission to the vertebrate secondary host. Host compartments are noted in 
uppercase and parasite forms in lowercase. Figure adapted from Su, X. et al., Nature Reviews Genetics 



























inside the infiltrating leukocytes, the majority are degraded. It is therefore to the sporozoite’s 
advantage to traverse its route as quickly as possible; live imaging of fluorescent sporozoites in 
the injection site have recorded the parasites moving at speeds of up to 4 µm per second (28). 
Once in the blood the sporozoites are carried swiftly to the liver.  
 
The liver. Upon reaching the liver a high-affinity interaction between the sporozoite and 
endothelial cells of the liver sinusoids allows the sporozoites to latch on and use the endothelial 
cells as a substrate along which to crawl until they find an appropriate point of entry into the 
liver parenchyma (29). The port of entry has been suggested to be mainly Kupffer Cells, the 
resident macrophages of the liver (29), but sporozoites traversing through endothelial cells or 
crossing from the blood into the liver parenchyma via apparently cell-free routes have also been 
demonstrated (30). Whatever the entrance route from liver sinusoid to parenchyma, the 
sporozoite must traverse through several hepatocytes before terminally infecting a hepatocyte. 
As such, motile sporozoites in the liver leave a trail of wounded hepatocytes behind them, which 
mostly undergo repair and survive, before establishing infection in a final cell (31). Hepatocyte 
traversal before terminal infection is thought to both activate the sporozoite for invasion and 
prime hepatocytes for infection. Activation of the sporozoite by host cell traversal leads to 
exocytosis of circumsporozoite protein, thrombospondin-related anonymous protein, and a 
peptide recognized by antiserum raised against erythrocyte binding antigen 175 (32). Blocking 
this exocytosis prevents hepatocyte invasion by sporozoites. Hepatocyte wounding due to 
sporozoite traversal causes the release of hepatocyte growth factor (HGF) from these cells, which 
in turn primes neighboring hepatocytes for infection by activating the HGF receptor MET by 
phosphorylation (33). Inactivation of MET, or otherwise blocking HGF signaling, inhibits 
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establishment of hepatocyte infection. To enter the hepatocyte that it will develop within, the 
sporozoite attaches to the liver cell membrane and forms a circular tight junction through which 
it actively glides into the cell (34). This process causes invagination of the hepatocyte membrane 
around the parasite, forming the parasitophorous vacuole membrane (PVM) within which the 
parasite will reside for the entirety of intrahepatic development (35). The PVM provides a barrier 
across which the parasite can achieve controlled and specific uptake of the nutrients necessary to 
meet its massive metabolic demands (36). Microarray analyses of Plasmodium-infected versus 
uninfected hepatocytes found that 1164 host genes were differentially expressed in at least one 
stage within the hepatocytes, reflecting extensive parasite manipulation of the host cell (37). 
When liver-stage development is complete the PVM disintegrates, the hepatocyte nucleus is 
destroyed, and the liver cell dies and detaches from its neighboring cells (with the plasma 
membrane still intact) (38). From injection of sporozoites by the mosquito to this point of 
parasite development takes 2 to 15 days, depending on the Plasmodium species, and produces 
thousands of daughter merozoites from a single sporozoite. The merozoites, still bound within 
the dead hepatocyte membrane, are released into the bloodstream where they may remain intact 
for more than an hour. The death of the host hepatocyte is achieved in a controlled manner and 
active accumulation of Ca2+ by the merozoites inhibits exposure of phosphatidylserine molecules 
on the outer surface of what is now little more than a membrane-bound sac of merozoites, 
thereby avoiding detection of the dying cell by phagocytes (38). This manipulation of the 
sequence of events during host cell death allows the merozoites to remain camouflaged within 
the liver cell membrane, minimizes their exposure to host immune defenses, and likely enhances 
the efficiency of progression from liver to blood-stage infection. As soon as the free merozoites 
are released from the ghost hepatocyte, they are vulnerable to detection and attack by the host 
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immune system. Rapid contact with and entry into RBCs, in which the parasites continue their 
life cycle, is therefore crucial. 
  
The blood. Free merozoites spend only a few minutes in the blood stream before attaching to 
RBCs, reorienting themselves so that their invasion machinery is poised on the RBC surface, and 
actively invading the RBC. As with hepatocyte invasion, RBC invasion is an active process 
through a tight junction formed between the merozoite and the RBC. In the process of RBC 
invasion, the merozoite’s own plasma membrane becomes surrounded by the RBC membrane to 
form another PVM, reminiscent of that surrounding liver-stage parasites. Plasmodium parasites 
in RBCs can follow one of two developmental routes. The majority replicate asexually, going 
through repeated cycles of asexual multiplication to produce daughter merozoites, RBC rupture 
with merozoite release, and finally reinvasion of further RBCs (figure 1.6). It is these cycles of 
RBC rupture and reinvasion that are thought to cause the cyclical fevers that are a hallmark of 
malaria (39). This asexual replication in RBCs continues indefinitely until the host dies or the 
infection is cleared, either by the host’s own immune system or by pharmaceutical intervention. 
Survival of Plasmodium, nor of any pathogen, as a species clearly cannot be sustained in a single 
host and the parasites must therefore employ some strategy by which they can be transmitted to a 
new host. To this end a subset of RBC parasites commit to sexual differentiation and become 
either a male or a female gametocyte, in a process known as gametocytogenesis (40). The 
proportion of parasites committing to a gametocyte fate depends on a complex set of poorly 
understood factors, but it is generally postulated that gametocyte fate determination depends in 
part on the prospects of maintaining a healthy (for the parasite) infection in its current host. Only 
very small numbers of gametocytes are found in blood-stage parasite populations cultured under 
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optimal conditions (41). When a mosquito takes a blood meal, the gametocytes that are ingested 
undergo final maturation in the mosquito midgut to become mature gametes. It was this final step 
of male gametocyte development, known as exflagellation, that was the first plasmodial life-
cycle stage observed by Alphonse Laveran. Mature gametes in the mosquito midgut then fuse to 
form a diploid zygote. The zygote further morphs into a motile ookinete, embeds itself in the 
wall of the mosquito’s midgut, and becomes the oocyst in which sporozoites develop. From one 
oocyst several thousand sporozoites will emerge and migrate to the mosquito’s salivary glands, 
ready to be deposited in the skin of the next feeding target. 
 
CLINICAL MALARIA 
The classical intermittent fevers associated with malaria were noted in 1886 by Camilo Golgi to 
coincide with the synchronized rupture of infected RBCs and indeed all clinically evident 













Figure 1.6 The asexual red blood 
cell cycle of Plasmodium. 
Reproduced from Bannister, L. & 
Mitchell, G., Trends in Parasitology 




asymptomatic, uncomplicated (symptomatic but with no evidence of severe malaria syndromes 
or vital organ dysfunction), or severe, with severe malaria encompassing a range of syndromes 
including cerebral malaria, severe malarial anemia, metabolic acidosis, or multiple organ failure, 
the last being more common in adults (42). Asymptomatic infections, although posing no 
imminent risk to the individual host, represent a substantial reservoir of infection: even when 
using the relatively insensitive method of microscopy as the means of detection, the prevalence 
of parasite carriage in apparently healthy volunteer blood donors in the Democratic Republic of 
Congo was found to be 28.3% overall, or 49.0% in 18-27 year olds (43). These asymptomatic 
cases can constitute the vast majority of all infections as evidenced by a study of 3640 Gambian 
school children in which, of the 1.9% found to be positive by microscopy, 97% were 
asymptomatic (44). 
 
The symptoms of uncomplicated malaria are broad, including headache, reduced energy, 
abdominal pain, muscle and joint aches, fever, chills, sweating, and other signs, and are not 
specific for malaria. Fevers are not always intermittent. Overdiagnosis is therefore common in 
malaria endemic regions and in some sites contributes to poorer outcomes for diseases 
misdiagnosed as malaria (45-47). Overdiagnosis is not confined to uncomplicated malaria and 
also contributes to inappropriate case management of diseases with neurological presentation 
that are falsely attributed to cerebral malaria (48). The fevers are thought to be induced by a pro-
inflammatory response (involving TNF-α, IFN-α, IL-12, MCP-1, and IL-6) to 
glycosylphosphatidylinositol, hemozoin, and other products of blood-stage parasite maturation 
released upon schizont rupture (figure 1.6), although there is some disagreement as to whether 
hemozoin alone is pro-inflammatory or must be presenting parasite DNA (49-52). 
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Uncomplicated malaria can rapidly devolve into severe malaria syndromes, which are mostly 
fatal if untreated, and which may present in isolation or in combination. Children suffering from 
cerebral involvement together with anemia and metabolic acidosis have in-hospital fatality rates 
of 25 to 50% (53-55), a figure which can rise to 100% in adults suffering from severe malaria 
(56). The pathogenesis of these syndromes is only poorly understood but many mechanisms have 
been proposed (57). For severe malarial anemia the loss of RBCs due to schizont rupture is 
apparently compounded by increased phagocytic destruction and splenic clearance of uninfected 
RBCs (58) as well as reduced RBC production (59). Metabolic acidosis is the strongest 
independent indicator of poor outcome and has numerous proposed etiologies (60). It is 
associated with severe anemia, reduced glucose, and increased TNF-α and IL-1α, with more 
extreme hyperlactatemia increasing fatality (61). Cerebral malaria is probably the most studied 
of the severe malaria syndromes, yet both understanding of its causes and therapeutic 
interventions remain elusive. Excessive pro-inflammatory cytokine production, especially of 
TNF-α (62), platelet clumping and accumulation in brain microvessels (63, 64), and 
sequestration of parasitized RBCs in brain microvessels (65) have all been implicated. The 
defining clinical characteristic of cerebral malaria, alongside blood-stage parasitemia, is coma 
(42). However, definitive diagnosis post mortem also includes the presence of parasitized RBCs 
sequestered in brain vessels (66). Retinopathy, noted as whitening and vascular color changes, 
can be detected while patients are still alive and has been found to correlate strongly with 
cerebral parasite sequestration. It has therefore been suggested that retinal exams should be 
included when assessing whether a patient has cerebral malaria in order to improve the 
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specificity of diagnosis (67). There is evidence for three main modes by which sequestration can 
contribute to the morbidity and sequelae of cerebral malaria: 
1) Vessel occlusion, causing ischemia: damage to axons and myelin is seen associated 
with areas of intense sequestration (68). 
2) Secondary injury caused by the host immune response: post mortem staining shows 
TGF-β, IL-1β, and TNF-α staining in brains of cerebral malaria or meningitis patients 
but not in non-cerebral malaria (69). 
3) Loss of integrity of the blood-brain barrier as a consequence of endothelial cell 
activation, upregulation of cell adhesion molecules, and reduction in cell junction 
proteins (70, 71). 
There is interplay between these three modes of brain damage and directly determining their 
relative contributions to morbidity and mortality of cerebral malaria is not possible in living 
patients. However, as we will discuss later, MRI studies are now allowing visualization of brain 
abnormalities in living patients and thus aiding inferences as what pathologies carry the greatest 
mortality risk and therefore should be prioritized in developing therapies targeted to managing 
symptoms. 
 
MALARIA TREATMENT TODAY 
As with most microbial diseases, anti-plasmodial drug development efforts are in a constant 
struggle to stay ahead of emerging drug resistance. The early-to-mid 2000s saw an almost 
complete shift from chloroquine (CQ) or sulfadoxine-pyrimethamine (SP) to artemisinin-based 
combination therapies (ACTs) as first line antimalarials due to the emergence and spread of CQ 
and SP-resistant parasites from South-East Asia across the globe (72). ACTs combine fast-
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acting, short half-life artemisinin derivatives, which kill the majority of the parasites, with longer 
half-life partner drugs to ensure complete clearance of the Plasmodium infection. Although 
treatment failures have rarely been reported, the emergence of infections with a longer parasite 
clearance time upon ACT treatment in South-East Asia suggests that the useful lifetime of ACTs 
is limited (73). Treatment failures appear to be increasing now with the ACT combination of 
dihydroartemisinin plus piperaquine (74, 75). While there are currently no clinically registered 
drugs ready to replace ACTs, intense efforts are underway to identify and develop new 
antimalarial medicines (76). 
 
A NOTE ON IMAGING AND MALARIA 
Malaria research has benefitted immensely from great strides made in imaging technology since 
the first watercolor and line drawings of blood-stage parasites produced by Alphonse Laveran 
125 years ago. We can now see minute structures within the parasite, visualize live Plasmodium 
development through all stages of the life cycle, follow the parasite’s movements through a 
living host, and assess cerebral pathology in human patients. This capability has contributed to 
advances in our understanding of parasite development, host-pathogen interactions, and 
pathogenesis of disease. The work presented in this thesis has benefitted directly from improved 
visualization techniques: an in vivo imaging system (IVIS), coupled with genetic engineering 
strategies that create luciferase-expressing parasites, allows us to follow progression of 
Plasmodium through liver-stage development in live mice. This avoids the cumbersome process 
of animal dissection and RNA extraction to eventually yield an indirect measure of parasite 
burden based on the relative abundance of mouse and Plasmodium RNA transcripts. Not only is 
the in vivo imaging approach much more efficient and less prone to error and contamination, but 
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the non-invasive procedure allows us to assess multiple timepoints in each mouse (figure 1.7). 
This latter point is of great advantage in allowing us to gauge how the impact of a particular 
intervention varies over the course of Plasmodium infection within a single mouse.  
 
The expansion of our knowledge regarding Plasmodium biology and malarial disease that has 
been gained using advanced imaging techniques also helps in guiding hypotheses and 
interpretation of existing data. Two examples that help to illustrate this point and highlight the 
power of modern imaging are 1) MRI studies of human cerebral malaria, and 2) confocal 
microscopy to image sporozoite traversal from the point of mosquito injection (77) to terminal 
infection of a hepatocyte (78). 
 
 
MRI scanning of children suffering from cerebral malaria. Our ongoing paucity of 




































Figure 1.7 An in vivo imaging system (IVIS) allows 
non-invasive determination of parasite burden in 
liver and blood-stage Plasmodium infection. Mice 
were infected with 10,000 P. berghei sporozoites. The 
same five mice were imaged in early liver stage (24 
hrs post infection; top), late liver stage (48 hrs; 
middle), and early blood stage (72 hrs; bottom). Color 
scales show average radiance (photons per second per 
cm
2
 per steradian). Radiance is proportional to 
parasite burden. Note the lower scale on the top image 
and slightly lower scale on the bottom image, such 
that the strength of the apparent signal in these images 
is amplified compared to that in the middle. Imaged 
produced by Rebecca Lewis. 
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fatality rate is high, but also because of the persistent neurological sequelae that are frequently 
associated with this severe manifestation of plasmodial infection. These sequelae include 
temporary working memory and tactile learning deficits, and long-lasting attention deficit (79, 
80); impairments in speech and language, motor function, memory and attention, and non-verbal 
function (81); and epilepsy and disruptive behavioral disorders (82). A few distinct clinical 
features of cerebral malaria have been associated with persistence of specific neurological 
deficits (80, 81). However, current treatment guidelines for cerebral malaria are still limited to 
parenteral administration of antimalarials (preferably artesunate), anticonvulsant therapy where 
appropriate, and management of non-neurological symptoms such as hypoglycemia and severe 
anemia (42). More precise knowledge of the anatomic, metabolic, biochemical and functional 
features of cerebral malaria, gathered by studying the brains of living patients, has the potential 
not only to further our understanding of the pathogenesis of cerebral malaria but also to suggest 
medical interventions for tackling specific features of the syndrome (83). MRI scanning makes 
non-invasive assessment of neurological disease possible and has been in use in human patients 
since the early 1980s. However, the US$1.4 million cost of a machine has largely precluded its 
application in the resource-poor settings of Sub-Saharan Africa. Now, in pursuit of generating 
the knowledge that such a machine would allow, a multi-center-funded MRI facility has been in 
operation since 2008 in Blantyre, Malawi (84). Studies conducted in this facility have presumed 
that patients who present with coma and meet the clinical definition of cerebral malaria but do 
not exhibit retinopathy in fact have a non-malarial cause of coma. Comparisons between MRI 
images of this retinopathy-negative group and a retinopathy-positive group of cerebral malaria 
patients have shown T2 signal abnormalities (indicative of edema and/or inflammation or white 
matter lesions) in almost all brain regions tested, including the brain stem (85). MRI imaging has 
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also brought to light associations between specific clinical characteristics seen in acute 
presentation of cerebral malaria and ongoing abnormalities seen by MRI (86). Additionally, a 
study published this year showed that mortality among cerebral malaria cases is strongly 
associated with severely increased brain volume (87) (figure 1.8) with 21 of 25 fatal cases, 
compared with 39 of 143 survivors, exhibiting this pathology. MRI studies have thus thrown 
light on numerous brain pathologies that were previously only seen, or indirectly implied, in 
post-mortem examination. The ability to observe these pathologies in vivo allows prevalence and 
intensity of such abnormalities to be compared between fatal and non-fatal cases, and allows 
analysis of which brain changes correlate with lasting sequelae. Studies using MRI have 
therefore identified pathologies that could be targeted in development of therapies to improve 
outcome in cerebral malaria. 
 
 
In vivo imaging of sporozoites in the skin and liver. The MRI studies discussed are helping to 
elucidate ultrastructural pathological changes in the host. Meanwhile, high speed and high-
resolution microscopy techniques are being used to describe in precise detail the activity of 
individual parasites during the very first stages of infection in the mammalian host, in three 
dimensions and over time (29, 77, 78). As with the IVIS technique shown above, these protocols 
make use of genetically engineered parasites, this time expressing constitutive fluorescent 
Figure 1.8 Brain swelling in a case of non-
fatal cerebral malaria. A: scan of a normal 
brain. B: severe brain swelling. Brain 
swelling is causing compression in image B 
of the 4th ventricle, indicated in both images 
with a curved arrow. Increased pressure due 
to swelling in image B is causing downward 
herniation of the cerebellar tonsils (circle), in 
turn placing pressure on the brain stem. 
Image reproduced from Seydel, K.B., et al., 
New England Journal of Medicine 372:1126-
1137 (March 2015). 
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reporters that allow for their detection by fluorescence microscopy. High speed, high-resolution 
microscopy techniques that can image through a range of focal depths allow these reporter 
parasites to followed in vivo in real time. This avoids the need for the sectioning, fixation and 
staining that would otherwise be required to detect host-parasite interactions in intact tissue and 
therefore allows for much more direct and definitive interpretations of parasite behavior. In vitro 
culture experiments can demonstrate viable routes for an infecting sporozoite across extracellular 
substrates, or through specific cell types, and the ability to conduct such experiments in 
monolayer cultures does allow for live imaging. However, in vitro cultures are limited in their 
ability to show the preferred, as opposed to viable, routes that a parasite would take in vivo. The 
cell populations and molecular factors that are present in the intact host cannot be fully 
recapitulated in vitro, and the altered properties of cell lines and primary culture cells fail to 
exactly match intact tissue. Using spinning-disc confocal microscopy Tavares et al. (30) were 
able to show that sporozoites entering the liver can take a variety of routes from the liver 
sinusoid into the parenchyma, and do so even when not forced to by the culture conditions 
imposed upon them. Invasion through the sinusoidal endothelium, through Kupffer cells, and via 
cell-free mechanisms were all observed. Significantly, in vitro models are also limited in their 
ability to demonstrate the host defense mechanisms that the invading parasite must contend with. 
Amino et al. (88) were able to show, again using spinning-disc confocal microscopy, the in vivo 
recruitment of leukocytes to the site of infectious mosquito bite. All the associated pitfalls of 
attempting these investigations in vitro are exacerbated by the fact that we do not completely 
understand the processes involved in sporozoite traversal through host skin or liver and therefore 
could not faithfully recreate these environments in vitro even if it were practical to do so.  
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IMMUNE DEFENSES OF THE VERTEBRATE HOST 
Despite the subterfuge committed by Plasmodium in the vertebrate host, infection does elicit 
innate immune defense mechanisms and labile naturally acquired immunity (89-91). In high-
transmission malaria-endemic areas partial immunity is acquired early in life, explaining why 
young children, who have not yet acquired any protective immunity, vastly predominate amongst 
those dying from malaria. In lower transmission settings, partial immunity takes longer to spread 
through the population, and the mean age of people suffering from cerebral malaria increases 
(92). This naturally acquired immunity is easily lost and people who have lived away from 
endemic areas for extended periods have heightened susceptibility to developing clinical disease 
compared to recent emigrants from the same origin (93). Whole populations are at risk from this 
renewed susceptibility in areas where malaria control efforts initially work and then fail, 
allowing resurgence of transmission in a population that has not had regular recent exposure (94, 
95). Massive efforts have been made to understand the immune mechanisms that protect against 
either infection or progression of disease, and the ways the parasite evades these mechanisms, as 
a means to guide vaccine development. There have also been attempts to develop immune-
modulating therapies, inspired by rodent models of infection in which experimental cerebral 
malaria appears to be mainly a result of an inappropriate immune response (96-98). Although 
several such therapies have been successful in mice, none have shown any benefit in humans 
(99). Immune defenses against Plasmodium-infected hepatocytes have been an especial point of 
interest for vaccine development: although clinically silent, liver-stage Plasmodium development 
is by no means immunologically silent, rather it is vulnerable to both innate defenses and 
acquired immunity.  
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PRO-INFLAMMATORY CYTOKINES TARGETING LIVER-STAGE PLASMODIUM. 
A number of pro-inflammatory cytokines have been shown to inhibit intrahepatocytic plasmodial 
development in murine, human, or simian hosts, including IL-12 (100, 101), IFN-γ (102-104), 
IL-1 and IL-6 (103), TNF-α (105, 106), and Type I IFN (89).  
 
IL-12 and IFN-γ . Administration of recombinant mouse (rm) IL-12 starting one or two days 
before P. yoelii sporozoite injection completely protects BALB/C mice from developing blood-
stage parasitemia (101). This protection is dependent on IFN-γ and is lost if mice are treated with 
anti-IFN-γ neutralizing antibody. Likewise, recombinant human (rh) IL-12 can prevent monkeys 
infected with P. cynomolgi sporozoites from developing blood-stage parasitemia (100). Although 
this latter study did not treat with neutralizing antibody to IFN-γ it was noted that IL-12-treated 
monkeys show elevated plasma IFN-γ, supporting its likely role in protection. Studies covering 
multiple model systems have directly shown that IFN-γ treatment has a detrimental effect on 
development of liver stage Plasmodium parasites (102-104). This applies to rodent Plasmodium 
strains both in vivo and in vitro as well as P. falciparum in hepatocyte culture and P. cynomolgi 
in monkeys. In vitro IFN-γ-dependent inhibition of liver-stage development is only achieved, 
however, if IFN-γ treatment is started after sporozoite infection or, if started before infection, is 
maintained until after sporozoites are added to the culture. This inhibition is thus likely to depend 
on a transient hepatocyte response to the cytokine (104). In support of an inhibitory role for IFN-
γ in liver-stage development, in vivo pre-treatment of mice with IFN-γ was shown to increase the 
delay between sporozoite infection and detection of parasites in the blood, although 100% of 
mice did eventually develop blood-stage parasitemia. Treatment of mice with IFN-γ 20 hours 
after inoculation with sporozoites also directly reduces the liver parasite burden, and similar 
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results are found in chimpanzees and human hepatocyte cell lines (102). IFN-γ is of especial 
interest in the context of vaccine development efforts as it is likely to be a major effector of anti-
plasmodial adaptive immunity in humans (107). Although naturally acquired immunity is labile, 
complete sterilizing immunity can be induced in humans following P. falciparum infection via 
repeated infectious mosquito bites in the presence of chloroquine prophylaxis (to selectively 
eliminate blood-stage parasites) (108). Although such immunity is most efficient when subjects 
are rechallenged with the identical parasite strain, a fraction of human volunteers immunized 
under chloroquine prophylaxis and then rechallenged with a different strain of P. falciparum 
were completely protected against progression to blood-stage disease. In this heterologous 
challenge model even those volunteers who did develop blood-stage parasite infection show 
delayed progression to this phase (109). The strength of protection in volunteers was seen to 
correlate with the percent of IFN-γ-producing lymphocytes in the blood, hence the supposition 
that this cytokine is a substantial player in the protection of individuals with acquired immunity.  
 
IL-1 and IL-6. IL-1 and IL-6 inhibit human and murine intrahepatic parasite development (103), 
with IL-1 inhibiting hepatic stages of the rodent species P. yoelii in a partially IL-6-dependent 
manner. Pre-treatment of P. yoelii-infected hepatocytes with either rh-IL-1 or rh-IL-6 inhibits 
parasite development whereas treatment with IL-1 given simultaneously with anti-IL-6 
neutralizing antibody showed much-reduced inhibition (110).  
 
Type I IFN. Recently it has been demonstrated that type I IFN responses help control liver-stage 
infection with another rodent species, P. berghei (89). This Plasmodium-inhibitory activity of 
type I IFN signaling can be induced by liver-stage P. berghei infection itself, as well as by 
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Hepatitis C viral infection, exemplifying how co-infection with diverse pathogens can alter the 
suitability of the host environment for incoming infections. Knocking out the IFN-α Receptor 1 
(IFNAR1) specifically on hepatocytes reduced this protection, leading to increased liver and 
subsequent blood-stage parasite burden (89).  
 
TNF-α . Intravenous delivery of rm-TNF-α can protect nearly 80% of P. yoelii sporozoite-
infected mice from developing blood-stage parasitemia (106). Inhibition also occurs in vitro 
although – in contrast to treatments with IFN-γ, IL-1 or IL-6, – TNF-α has no effect in 
hepatocyte cultures unless non-parenchymal cells are also present (106). Inhibition by TNF-α is 
similar to that achieved by IFN-γ and IL-1, however, in being dependent on IL-6. Notably, anti-
IL-6 neutralizing antibody only abrogates the inhibitory effect of TNF-α if both the neutralizing 
antibody and the cytokine are administered at the same time, 24 hours before sporozoite 
infection. If anti-IL-6 treatment is delayed until 30 minutes before infection the level of 
inhibition is almost identical to that achieved without anti-IL-6. This implies that the 
Plasmodium-inhibitory change in hepatocytes induced by TNF-α does not depend on maintained 
IL-6 availability. As well as inhibition of rodent Plasmodium species TNF-α has been shown to 
hamper development of P. falciparum in human hepatocyte culture. This inhibition of liver-stage 
P. falciparum growth can be achieved without any direct exposure of the infected hepatocytes to 
TNF-α, instead using conditioned medium taken from uninfected TNF-α-treated hepatocytes 
(105).  
 
IL-10. As well as the pro-inflammatory cytokines that impact Plasmodium liver-stage growth, 
higher levels of the anti-inflammatory cytokine IL-10 have been implicated in helping to protect 
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against the development of severe blood-stage malarial disease in both humans and mice (111, 
112). Additionally, BALB/c mice co-infected with the filarial parasite Litomosoides sigmodontis 
show IL-10-dependent protection against developing blood-stage parasitemia following P. 
berghei sporozoite challenge (113). The implication of this is that IL-10 is likely protective 
against P. berghei liver stages. One could speculate that this inhibition early in a mammalian 
host’s exposure to Plasmodium may contribute to protection against severe pathology during 
blood-stage disease. 
 
CYTOSOLIC DEFENSE IN THE PLASMODIUM-INFECTED HEPATOCYTE 
Long-term imaging of primary mouse hepatocytes has recently allowed the detection of selective 
autophagy directed against the invading parasite (114). Selective autophagy in uninfected cells is 
used to recycle damaged or obsolete organelles and clear large protein complexes (115). The 
diversion of this response towards clearing intracellular pathogens has been shown to have a 
critical role in defense against Toxoplasma gondii (116) and a number of intracellular bacteria, 
including Salmonella Typhimurium (117, 118). In the case of Plasmodium-infected hepatocytes, 
early stages of parasite development are seen to recruit the autophagy-related protein LC3 to 
membranous structures around the parasite. LC3 then recruits further effectors of the selective 
autophagic pathway, in some cases managing to eliminate the parasite. In spite of the parasites’ 
vulnerability to selective autophagy, starvation-induced autophagy, which tends to lead to the 
destruction of the entire cell, appears to promote Plasmodium growth in the liver (114). 
 
Given the array of host factors that have profound effects on Plasmodium development, it 
becomes difficult to imagine that any intervention that changes the environment within the 
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vertebrate host could leave parasite development unaltered. Almost all of the examples above 
were demonstrated using artificially isolated and administered immune modulators. However, 
infections with two non-plasmodial pathogens, Hepatitis C and filaria, were also mentioned as 
interventions that inhibit Plasmodium growth. Experimental co-infections such as these are not 
simply of academic curiosity, but reflect a reality that people living in malaria-endemic countries 
must contend with. This thesis presents work examining another such co-infection that has 
gained recognition, that of Plasmodium and invasive non-typhoidal Salmonella (NTS).  
 
PLASMODIUM-NTS CO-INFECTION IN HUMANS 
George Giglioli was an Italian malariologist who was credited with discovering the source of a 
malaria resurgence in Guyana, thereby allowing the resurgence to be beaten back and averting 
what could have been, due to the loss of anti-plasmodial immunity in the population, a public 
health disaster. Giglioli is also pertinent to our discussion of Plasmodium-Salmonella co-
infections as having been the first to report, in 1929, an association between outbreaks of malaria 
and increased incidence and virulence of paratyphoid C (a Salmonella species causing 
paratyphoid fever and distinct from NTS) (119). Since this observation, more recent field studies 
have demonstrated that Plasmodium infections indeed cause increased susceptibility to invasive 
NTS. Mabey et al. (120) noted in the Gambia that, in the absence of any strong correlation 
between incidence of malaria and prevalence of NTS in stool samples, there was a strong 
correlation between the incidence of malaria and of NTS septicemia. From this study the authors 
concluded that malarial infection predisposes individuals towards invasive NTS infection in spite 
of unchanged exposure levels. Scott et al. (121) came to the same conclusion in a study carried 
out in Kilifi, Kenya, where malaria is endemic. Their study followed the change in relative risk 
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of acquiring NTS bacteremia for carriers of the sickle cell trait (with the HbAS genotype) 
compared to homozygous wild type individuals (HbAA) over a period of steadily declining 
malaria incidence. The protective effect of the sickle cell trait against malaria is well-established 
(17, 18) and at the beginning of the study period HbAS children were at lower risk of either 
malaria or invasive bacterial disease than HbAA children. It was hypothesized that the observed 
protection from invasive bacterial diseases, including NTS, might be an indirect one thanks to 
the reduced susceptibility to malaria of HbAS individuals; in other words that malaria infection 
increases the risk of invasive bacterial disease. This hypothesis was indeed supported by the 
finding that as malarial incidence decreased, so did the difference between HbAS and HbAA 
individuals in terms of the risk of developing invasive bacterial diseases, including NTS. This 
result is perhaps all the more striking in light of the fact that homozygous sufferers of sickle cell 
disease, with the HbSS genotype, are at much greater risk of becoming bacteremic than HbAA 
individuals, as shown previously in the same district (122). 
 
The prevalence of invasive NTS in children with malaria is most significantly increased above 
that in malaria-free children in cases of severe malarial anemia (SMA). Patients exhibiting 
symptoms of both cerebral malaria and SMA have a moderately elevated risk of sepsis, while 
patients with cerebral malaria but no SMA show a prevalence of invasive NTS that is barely 
higher than that in the general population (123). It is unclear whether these differences in the 
prevalence of NTS bacteremia between severe malaria syndromes is due to increased 
susceptibility of patients with SMA to invasive NTS, compared to patients with cerebral malaria, 
or rather that NTS infection reduces the risk of developing cerebral malaria. Given the unequal 
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prevalence of co-infection between patients with cerebral malaria plus SMA and patients with 
only SMA, the latter explanation may make more sense. 
 
PLASMODIUM-NTS CO-INFECTION IN MICE 
The increased susceptibility to invasive NTS of malaria-infected humans has been replicated in 
mouse models of co-infection. These mice, infected with both P. yoelii and S. Typhimurium (a 
common NTS serovar), have been used to tease out some of the mechanisms responsible for the 
increased susceptibility (124, 125). Roux et al. (124) identified hemolytic anemia (caused by 
rupture of parasitized red blood cells) and a dampened IL-12 response to invasive NTS as 
contributing factors. Cunnington et al. (125) showed that malaria hampered the host’s immune 
response to Salmonella by causing premature release of granulocytes from the bone marrow, 
before they had matured sufficiently to produce the oxidative burst necessary to kill intracellular 
Salmonella. 
 
Multiple human and mouse studies provide convincing evidence that an existing Plasmodium 
infection hampers the host’s ability to resist invasive NTS infection but what of the inverse 
relationship? The incidence of malaria varies widely throughout Sub-Saharan Africa (126), and 
in areas of moderate transmission it is entirely possible that Salmonella infection might precede 
malaria infection. In a study conducted in Malawi in 2003-2004, the prevalence of anti-
Salmonella antibodies in healthy children older than 16 months, with no known history of 
Salmonella infection or vaccination, was found to be 100% (127). This indicates a high 
frequency of Salmonella exposure. Such high exposure levels, which are likely not unique to 
Malawi, support the supposition that instances of co-infection in which acquisition of the 
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invasive NTS infection precedes acquisition of Plasmodium parasites may be common. In spite 
of this possibility there are no existing studies focusing on the impact of Salmonella infection on 
subsequent malaria infection. However, a few field studies have made intriguing observations 
that hint at how Salmonella bacteremia might influence the Plasmodium population with which it 
coexists, namely that presence of bacteremia associates strongly with a much reduced parasite 
load (123, 128, 129) and, as noted above, bacteremia is more commonly seen in patients with 
SMA than in those with cerebral malaria (123). Associations have also been noted in malaria 
patients between the presence of bacteremia and a slightly but significantly reduced hemoglobin, 
packed cell volume, and weight-for-age Z-score, as well as increased blood glucose (123, 128, 
129). It is not clear what the cause and effect relationships are between these host parameters and 
susceptibility to each of the invading pathogens. As the Plasmodium life cycle is intimately 
entwined with host red blood cells it would not be surprising for any preceding pathogen that 
alters the host’s blood parameters to change the course of malarial infection.  
 
MODELING PLASMODIUM-NTS CO-INFECTIONS 
This thesis project was undertaken to investigate how invasive Salmonella infection impacts 
Plasmodium populations in the liver and blood stages of malarial disease. With no single 
prediction of whether the two pathogens might interact directly, or via modulation of host 
responses, or what those specific interactions or responses might be, this enterprise required the 
use of an animal model. Fortunately, both invasive non-typhoidal Salmonella infections and 
malaria can be modeled in mice. However, we must remain aware of the caveats involved in 
relating our findings to human co-infection and disease.  
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There is no overlap between the Plasmodium species that can infect rodents and those that can 
infect humans, although both host groups are susceptible to a number of species with varied 
characteristics. No rodent malaria species accurately models all aspects of P. falciparum 
infection, which is the species involved in the vast majority of human Plasmodium-NTS co-
infections in Sub-Saharan Africa. Our goal in co-infection studies is to determine not only what 
impact each infection has on the host, but also what impact alteration of the host environment by 
one pathogen has on progression of infection and associated pathology of the other. In choosing 
a rodent Plasmodium model it is therefore important to consider both 1) how the pathogenicity of 
different rodent Plasmodium infections correlates with P. falciparum infections in humans and 2) 
aspects of Plasmodium biology that confer different sensitivities to potential co-infection-
induced alterations in the host environment. An example of the second consideration that is 
pertinent to this discussion is the differing host cell tropism between Plasmodium species for 
RBCs of different maturities. Of the globally predominant human malaria species, P. falciparum 
readily infects reticulocytes and mature red blood cells, with a slight preference for reticulocytes 
(130), while P. vivax infects only reticulocytes (131). For P. vivax infections it is therefore likely 
that if invasive NTS infection causes an increased reticulocyte count then parasite replication 
might also be increased, raising the potential for high parasite loads and more severe disease; the 
inverse might be true if invasive NTS infection causes a reduction in reticulocyte availability. 
However, P. vivax infections are uncommon in Sub-Saharan Africa and co-infections between P. 
vivax and NTS are rarely observed, so a rodent Plasmodium model that most accurately reflects 
the host cell tropism of P. falciparum is preferred. The rodent-infecting species P. berghei has a 
similar slight preference for reticulocytes (132) and is therefore a reasonable model for 
examining the effect of invasive NTS infection on parasite burden. Relative proportions of RBCs 
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of different ages not only may impact Plasmodium burden but also may affect the rate of 
gametocyte production. Indeed, although P. falciparum can infect both mature and immature red 
blood cells, alterations in the proportions of potential host cells do impact gametocyte production. 
In vitro cultures of P. falciparum in blood with high reticulocyte counts have an increased rate of 
commitment to gametocytogenesis (133). The viability of these P. falciparum gametocytes was 
not assessed but the pattern of increased gametocytogenesis in the presence of increased 
proportions of reticulocytes matched a previous study by Gautret et al. (134). In this study P. 
chabaudi-infected mice that had been pretreated with phenylhydrazine to induce reticulocytosis 
were found to be more infective to mosquitoes and to harbor more gametocytes, even at lower 
total parasitemia, than mice that didn’t receive phenylhydrazine. Similarly, it is recommended to 
pretreat mice with phenylhydrazine before infection with P. berghei to promote 
gametocytogenesis (135). P. berghei thus provides a reasonable model for investigating the 
impact of co-infection not only on parasite burden but also on gametocyte production.  
 
As well as hematological changes there are likely to be altered levels of immune response 
regulators in invasive NTS-infected mice that could influence progression of subsequent malarial 
infection. Both immune responses and hematological changes may take a few days to develop 
after invasive NTS infection. Any impact such effects have on plasmodial infection are therefore 
likely to have been missed in prior investigations of co-infection in mice as those studies either 
infected simultaneously with both pathogens or introduced the malaria parasites prior to 
challenge with Salmonella bacteria (112, 124, 125). Importantly, hematological or 
immunological changes may exert their influence even after bacteria have been cleared by 
antibiotic or other treatment, for example due to a delay in recovery of red blood cell populations. 
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Malarial disease is not only dependent on parasite burden but also on how the parasite and host 
interact. Commonly fatal manifestations of P. falciparum infection include severe malarial 
anemia, cerebral malaria, and acute respiratory distress, all resulting from complex pathogenic 
mechanisms that are far from being completely understood. The ethical impossibilities of 
inducing these manifestations in humans in order to study their pathogenesis require that animal 
models be used instead. However, animal models of severe malaria syndromes are controversial 
thanks to differences in the pathogenesis of these syndromes compared to their equivalents in 
humans. The need to understand the pathogenesis of severe malaria in humans in order to reduce 
morbidity and mortality is such that it has inspired the malaria community to convene at least 
one meeting specifically to discuss the current state of animal models and how best to apply 
them (136). As the most tractable organism in terms of being able to test the effects of a variety 
of interventions and genetic variations on susceptibility to severe disease, mice are the 
predominant model host. However, it is misleading to refer to mice as a single model in this 
context: the strain of mouse, the species (and even specifc strain) of Plasmodium, and the precise 
combination of murine host with Plasmodium parasite all affect what pathology can be 
reasonably modeled. As with human Plasmodium species, the course of infection with rodent 
Plasmodia varies depending on both the parasite and the genetic makeup of the host. It is 
therefore important to choose carefully a host-parasite combination that mimics the human 
pathologies most relevant to the specific investigation. The four predominant rodent models are 
P. yoelii, P. chabaudi, P. vinckei and P. berghei. All four have a blood-stage generation time of 
roughly a day but whereas P. berghei and P. yoelii prefer to infect erythrocytes and are relatively 
asynchronous, P. chabaudi and P. vinckei prefer to infect mature reticulocytes and are 
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synchronous (137). Additionally lethal P. berghei and P. vinckei strains kill C57BL/6 mice 
roughly one week after introduction of blood-stage parasites, while non-lethal P. chabaudi AS 
and P. yoelii 17XNL infections will be cleared by C57BL/6 mice within 2 weeks and 4 weeks 
respectively (138). Even between lethal species the responsible pathologies are starkly different, 
with P. berghei-infected mice succumbing to cerebral symptoms, including convulsions, 
paralysis, and coma, at 10-30% parasitemia and P. vinckei-infected mice succumbing instead to 
liver injury and hypoglycemia under explosive blood-stage parasite growth rates, which may 
achieve 80% parasitemia within 6 days of infection (139, 140). Just as the parasite species can 
have profound effects on the progression of disease, so can the host mouse strain. In contrast to 
the 10-day survival of C57BL/6 mice infected with P. berghei ANKA, BALB/c mice receiving 
the same parasites will survive almost 4 weeks, tolerating parasitemias four times as high as 
C57BL/6 mice and eventually dying of anemia caused by overwhelming parasitemia as opposed 
to any evident cerebral involvement (141). 
 
Although aspects of severe malaria can be superficially recapitulated in mouse models, the 
underlying mechanisms may be starkly different. For example, although P. berghei infections in 
C57BL/6 mice almost invariably induce the cerebral symptoms mentioned, reminiscent of 
human cerebral malaria and referred to as experimental cerebral malaria (ECM) (142), the 
pathogenesis of ECM and human cerebral malaria may be very different. Most human patients 
with cerebral malaria show sequestration of parasites in brain blood microvessels; both the 
number of vessels with sequestered parasites and the density of sequestered parasites within 
those vessels is greater in those dying with cerebral malaria than in those dying with non-
cerebral malaria (68, 143, 144). Higher intensity of sequestration has also been associated with 
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deeper coma and shorter time to death (145). The existence of a subset of fatal cerebral malaria 
cases in which sequestration occurs but is not accompanied by any intravascular or perivascular 
pathology (ring hemorrhages, blood brain barrier leakage, axonal lesions, and myelin damage) 
(68), indicates that parasite sequestration may be capable of causing coma and death solely 
through obstruction of cerebral blood flow. Although parasite sequestration in the brain is also 
seen in ECM, and adhesion to endothelial cells in vitro is correlated specifically with murine 
Plasmodium strains that cause ECM rather than those that do not (146, 147), this sequestration is 
prominently accompanied by leukocyte sequestration (148), a feature that is seen to a much 
lesser degree in human cerebral malaria (144, 149). 
 
Opinions are polarized on the relative contributions of inflammatory processes and parasite 
sequestration in human cerebral malaria versus ECM, and therefore on the validity of mouse 
models (99, 150, 151). A further challenge to the validity of ECM as a model for human cerebral 
malaria comes from the discrepancy between interventions that protect against ECM and those 
that are beneficial in human cerebral malaria. Given the imperfections of mouse models of 
severe malaria and the open nature of our investigation, it was prudent to use a well-
characterized mouse/Plasmodium combination. Such a choice of host/parasite combination 
allows us to interpret data in light of known caveats and to make reasonable deductions about 
relevance to human disease. P. berghei infections in C57BL/6 mice offer such a model, with the 




Our discussion of modeling Plasmodium infection in mice has so far concentrated on the 
correlations between humans and mice in blood-stage infection. However, invasive NTS 
infection might also impact development of malaria parasites through the liver stages. The 
validity of mice as models for liver-stage Plasmodium infections is much less controversial, 
though we note that, while experimental human infections in vaccine studies have been carried 
out since 1975 (152, 153) the ethical impediments to taking liver biopsies from healthy people in 
order to refute findings from mouse studies may have protected the reputation of said mouse 
models. Although the exact environment of liver-stage parasites in humans cannot be examined, 
systemic responses can and mouse and human Plasmodium vaccination studies have both shown 
induction of IFN-γ, TNF-α, and IL-2 responses, although there is some question whether these 
are mediated by CD4+ or CD8+ T cells (153-155) (153-155). As we have already discussed, a 
number of pro-inflammatory cytokines and acquired immune defense mechanisms can inhibit 
growth of liver-stage Plasmodium parasites. In addition, Portugal et al. (156) demonstrated that 
existing blood-stage P. berghei infection inhibits progression of newly introduced parasites 
through the liver stages by inducing upregulation of hepcidin. Hepcidin expression (to be 
discussed in more detail in chapter 3) is increased in response to inflammation and is therefore a 
feature of many infections, including invasive NTS (157-159).  
 
INVASIVE NTS TRANSMISSION CYCLE 
We have given an overview of some of the ways in which the host environment impacts 
progression of Plasmodium infection, and we have commented on some points at which invasive 
NTS co-infection might tweak this environment. We will now review the journey invasive 
Salmonellae take through the host from initial infection to transmission back into the 
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environment. The burden of disease that invasive NTS imposes on people in malaria-endemic 
regions will be discussed in Chapter 3. 
 
In contrast to Plasmodium, Salmonella species are not transmitted via a vector, but most 
commonly through ingestion of contaminated food or water and also through person-to-person 
contact. Studies in The Gambia and Kenya reported that clonally related infections are 
commonly found between people living in close contact, whilst domestic animals also living in 
close contact with those people carry Salmonella infections that are phenotypically and 
genotypically distinct or of different serovars (160-162). The authors of these studies therefore 
inferred that human-to-human transmission is the predominant mode in these settings. This is in 
contrast to the United States, where more than 95% of cases are acquired from contaminated 
food (163). Regardless of whether the infection is acquired from food or from another person, 
the route of infection within the person is through the gut. According to the World Health 
Organization fact sheet on NTS (Fact sheet Nº139), enteric infection is usually self-limiting and 
causes symptoms of gastroenteritis (fever, abdominal pain, diarrhea, nausea, and sometimes 
vomiting) lasting up to a week. Mice are naturally resistant to this stage of infection, instead 
progressing directly to invasive disease. In order to model gastroenteritis in mice the animals 
must first be pretreated with streptomycin to clear the gut microbiota (164). In this model 
intestinal infection is associated with submucosal edema, loss of goblet cells, erosion or 
ulceration of the epithelial cell layer, and massive infiltration, mainly by neutrophils, into the 
lumen of the gut (164). Invasive Salmonella infections in humans also commonly occur without 
any symptoms associated with enteric disease (165). In the case of some more invasive S. 
Typhimurium serotypes such as ST313 this may be due to substantial genome degradation, 
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which has led to reduced expression of genes encoded on the Salmonella pathogenicity island 1 
compared to serotypes associated with gastroenteritis such as ST19 (166, 167). When compared 
with ST19, ST313 is associated with lesser activation of the host inflammasome and subsequent 
cytokine release and macrophage death (167). In Sub-Saharan Africa the risk of developing an 
invasive infection is higher due to both the predominance of ST313 (168), and the prevalence of 
malnutrition, HIV, malaria, and sickle cell anemia (120, 122, 123, 169, 170). Invasive infections 
occur when Salmonellae in the gut breach the gut wall and spread via the blood or lymph to other 
sites in the body. The preferred route for Salmonellae out of the gut lumen is through M cells, 
specialized cells interspersed amongst the absorptive enterocytes that line the gut. M cells are 
antigen sampling cells that sit atop domes rich in macrophages, T cells, B cells, and dendritic 
cells known as Peyer’s patches (171). Their curious shape, with a pocket on their basal side 
within which macrophages and lymphocytes sit and sample antigens that pass through the M cell 
from the gut (172), allows for efficient recognition of and response to enteric pathogens. 
However, M cells are also exploited as invasion routes by bacteria such as Salmonella (173). 
Salmonella invade M cells by inducing actin polymerization, thus causing membrane ruffling 
(173, 174). M cells that have been invaded by S. Typhimurium are destroyed by the intrusion 
(174) and their disintegration leaves a hole in the gut endothelium that allows Salmonella 
remaining in the lumen even more efficient access to the underlying cells. Salmonella can also 
breach the gut wall independently of M cells when taken up by dendritic cells and possibly also 
macrophages sampling the gut lumen (175, 176). Salmonellae are thus phagocytosed by 
macrophages or dendritic cells either in the Peyer’s patch, or directly from the gut lumen. This 
latter M cell-independent invasion allows Salmonella that are deficient in the virulence factors 
required for M cell destruction to establish systemic infection, as further colonization of the host 
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relies on separate virulence factors (177, 178). Salmonella-infected dendritic cells and 
macrophages are probably responsible for then disseminating the bacteria to the mesenteric 
lymph nodes from where they can further spread to the liver, spleen, and gall bladder (179-181). 
Salmonellae are not entirely passive in the process of dissemination, even once within 
phagocytes. In fact Salmonella-infected macrophages and dendritic cells display increased 
motility in vitro and dissemination in vivo, dependent on expression of the bacterial type III 
secretion system effector SrfH (182). Within the liver and spleen Salmonellae replicate mainly 
within macrophages (183, 184), around which inflammatory foci develop. Initially these foci 
consist largely of neutrophils but macrophages later come to predominate (183). Systemic 
Salmonella infection is associated with broad cytokine upregulation including IFN-γ, IL-1β, IL-
18, TNF-α, IL-12, IL-2, and IL-6 (185-189). Transmission from a Salmonella-infected host back 
into the environment is thought to occur primarily via the gall bladder, which becomes colonized 
as bacteria are carried from the liver to the gall bladder in the bile. Gallstones support formation 
of Salmonella biofilms, from which bacteria are discharged into the small intestine via bile. 
Following this re-seeding of the intestines Salmonella are shed in the feces into the environment, 
from where transmission to a new host can occur (190).  
 
RESEARCH GOALS 
Invasive Salmonella infection occupies a variety of different niches. Host responses are elicited 
at each stage of infection and may alter the favorability of the host environment for incoming 
Plasmodium parasites in a number of ways. In this thesis we will present the results of our 
investigations regarding the impact of invasive Salmonella infection on Plasmodium infection 
and disease in the murine host, and discuss what mechanisms may be at play. 
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CHAPTER 2 - EXPERIMENTAL PROCEDURES 
 
MICE 
Mice were housed in the facilities at Columbia University Medical Center under BSL2 
conditions. 5-8 week old, female C57BL/6J mice, IFN-γ-/- mice on a C57BL/6 
background, and 129S1/SvImJ mice, were purchased from Jackson Laboratories (stock 
numbers 000664, 002287, and 002448 respectively, Jackson Labs, Bar Harbor, ME, 
USA). IFNαR1-/- mice on a C57BL/6 background were a kind gift of Dr. Alice Prince. 
STAT1/STAT2 double knockout mice on a C57BL/6 background were a kind gift of Dr. 
Christian Schindler. IFN-γ-/- mouse genotypes were confirmed by PCR, performed on 
genomic DNA extracted from tail samples of 2 mm. Primer sequences were 5’-
CCTTCTATCGCCTTCTTGACG-3’, 5’-AGAAGTAAGTGGAAGGGCCCAGAAG-3’, 
and 5’-AGGGAAACTGGGAGAGGAGAAATAT-3’ as provided on the Jackson Lab 
website. Using these primers, a ~500 bp band is amplified from IFN-γ-/- mouse gDNA 
and a ~210 bp band is amplified from wild-type mouse gDNA. All experiments were 
approved by the Columbia University Institutional Animal Care and Use Committee and 
complied with guidelines by the National Institutes of Health for the humane use of 
laboratory animals. 
 
LIVE AND HEAT-KILLED SALMONELLA PREPARATION, TREATMENT, AND ORGAN BURDEN 
DETERMINATION. 
Salmonella dilution titration. All bacterial infections were performed using Salmonella 
enterica serovar Typhimurium strain LT2 (S. Typhimurium, ATCC # 19585, provided as 
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a kind gift by Dr Steven Spitalnik). To determine the OD of Salmonella suspension to use 
for dilution before infecting experimental mice, we created titration curves. Salmonella 
was cultured from frozen stock in 7.5 ml Lennox LB broth (BD DifcoTM, Sparks, MD, 
USA) for 4.5 hours, shaking at 37 ºC. Care was taken to avoid overgrowth of the culture, 
which would lead to substantial numbers of dead bacteria in the culture increasing the 
measured OD. Bacteria were pelleted by centrifugation at 230 rcf for 16 minutes and 
washed three times with sterile PBS (further centrifugation steps were at 2500 rcf for 10 
minutes). Dilutions of the washed culture were made to between OD600 0.1 and 1. 
Further dilutions at 1/20,000 were then made and 50 µl of each final suspension was 
plated on Salmonella Shigella agar (SS agar, BD BBLTM, Sparks, MD, USA). Colonies 
were counted after overnight incubation at 37 ºC and a linear regression line was found to 
determine the OD600 for which a 1/20,000 dilution contained 75 CFU per 50 µl (300 
CFU per 200 µl). This gave us an OD600 of 0.6. 
 
Live Salmonella infections. Live Salmonella infections were initiated by intraperitoneal 
(i.p.) injection of 300 colony forming units (CFU), unless otherwise stated. Salmonella 
was cultured and washed as described above and diluted to an OD600 of 0.6. A 1/20,000 
dilution of this suspension was made in sterile PBS, and 200 µl (~ 300 CFU) was injected 
per mouse. Control mice were sham-treated by i.p. injection of 200 µl sterile PBS. Once 
infected, mice were monitored twice daily for signs of morbidity and euthanized if 
necessary according to the clinical scoring scale shown in table 2.1. S. Typhimurium 
dosage was confirmed by plating 50 µl of the final dilution on SS agar and counting 




0 1 2 3 
Body weight 
changes 
normal < 10% weight loss 10-20% weight loss > 20% weight loss 
Physical 
appearance 
normal lack of grooming rough coat, nasal/ocular 
discharge 
very rough coat, 
abnormal/hunched 
posture or recumbency 
Respiratory normal minor increase in 
rate or effort 










mutilation, either very 








violent reactions, or 
comatose 
 
Table 2.1 Clinical scoring scale for determining survival endpoint of infected mice. Any mouse 
scoring 9 or above, or 3 in any single category, was immediately euthanized. Any mouse scoring 7 or 8 
had monitoring increased to 3 times daily. 
 
Preparation of heat-killed Salmonella. Heat-killed S. Typhimurium (HKSTm) stock 
was prepared from the same strain as was used in live S. Typhimurium infections. Live 
cultures were grown from frozen stock to mid log-phase in Lennox LB broth. Bacteria 
were then washed 3 times and resuspended in sterile PBS before heating for 30 minutes 
at 60 ºC. These heat-killing conditions were chosen as the gentlest conditions that 
resulted in complete death of the Salmonella cultures. Initial conditions tested were 
heating in either PBS or distilled water at 60ºC for 30 minutes, 72ºC for 30 or 60 minutes, 
80ºC for 60 minutes, against a control kept at 4ºC for 60 minutes. All these conditions 
achieved complete killing. Further testing therefore included, again in either PBS or 
distilled water, 50ºC for 30 minutes or 60 minutes, 60ºC for 30 minutes, 70ºC for 30 
minutes. These alternatives were retested twice further. The gentlest conditions that 
reliably killed all bacteria were 60ºC for 30 minutes in PBS and were used to prepare all 
heat-killed Salmonella used to treat mice. All subsequent preparations of heat-killed 
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bacteria stock were plated on SS agar to confirm complete killing. The concentration of 
HKSTm stock was determined by plating 50 µl of a 1/400,000 dilution on SS agar before 
heat treatment. Colonies were counted after overnight incubation at 37 ºC. A further 
sample was plated on SS agar after heat treatment to confirm complete killing of the 
culture. HKSTm stock was stored at -20 ºC and was not refrozen once thawed. Treatment 
with HKSTm prior to sporozoite infection consisted of two intravenous (i.v.) injections 
into the lateral tail vein of 1-3.25 × 108 heat-killed bacteria unless otherwise stated, 
diluted to a total volume of 200 µl in sterile PBS. These injections were delivered 3 days 
and 2 days prior to introduction of P. berghei sporozoites. Control mice received i.v. 
injections of 200 µl sterile PBS into the lateral tail vein at the same timepoints. Treatment 
with HKSTm prior to blood-stage Plasmodium infection consisted of either a) i.p. 
injection of 103, 105, or 107 HKSTm, or b) i.v. injection of 108 HKSTm, 3 days and 2 
days before i.p. injection of 106 infected red blood cells (iRBCs). 
 
Determination of organ bacterial burden. Mice were euthanized with 100 mg/kg 
ketamine and 10 mg/kg xylazine, injected i.p. The entire spleen, and the right median 
lobe of the liver were harvested at the stated time points and weighed before 
homogenization of each organ separately in 1X PBS. Homogenization was achieved 
either with a Kinematica Polytron PT® 10-35 tissue homogenizer (Kinematica, Bohemia, 
NY, USA) or by manual grinding with a disposable pellet pestle (FisherbrandTM, 
Pittsburgh, PA, USA). Serial dilutions were made in 1X PBS and plated on SS agar 
before incubation overnight to determine CFU per gram of tissue. 
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PARASITE INFECTIONS AND PARASITE LOAD DETERMINATION 
Parasites. P. berghei ANKA strain MRA-868 was used for all parasite infections (191). 
P. berghei ANKA produces robust infection leading to experimental cerebral malaria in 
C57BL/6J mice (192). Strain MRA-868 carries a constitutive GFP-luciferase fusion gene, 
allowing for non-invasive in vivo imaging of the parasite in both liver and blood stages of 
the life cycle (193). MRA-868 iRBCs were purchased from the Malaria Research and 
Reference Reagent Resource Center (MRA-868, ANKA 676m1cl1, deposited by C.J. 
Janse and A.P. Waters). Infected Anopheles stephensi mosquitoes were purchased from 
the Insectary Core Facility at New York University Langone Medical Center. Parasite 
infections were introduced three days after live S. Typhimurium infection or the first 
HKSTm injection, regardless of the mode of infection, unless otherwise stated.  
 
Isolated sporozoite infections. Sporozoites were isolated from salivary glands of A. 
stephensi mosquitoes 18-23 days after feeding on P. berghei-infected mice. Mosquitoes 
were anesthetized by cooling to 4ºC and then dissected in RPMI 1640 (Gibco, Life 
Technologies, Carlsbad, CA, USA). Salivary glands were removed and homogenized in 
RPMI 1640 by manual grinding with a disposable pellet pestle (FisherbrandTM, Pittsburgh, 
PA, USA) to release individual sporozoites. Sporozoites were counted in a 
hemocytometer under a 40 × objective at a low condenser diaphragm aperture. 
Sporozoites were further diluted in RPMI 1640 to 50,000 sporozoites per ml and 200 µl 
(10,000 sporozoites) were injected i.v. into the lateral tail vein of each mouse.  
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Infectious mosquito feed. Mosquitoes were sorted to cages of 10 mosquitoes per cage 
18-23 days after feeding on P. berghei-infected donor mice. Mosquitoes were starved for 
at least 4 hours before feeding on mice. Salmonella-infected and uninfected mice were 
anesthetized with 65 and 80 mg/kg ketamine (Ketaset (Ketamine Hydrochloride), Butler 
Schein, Dublin, OH, USA) respectively and 10 mg/kg xylazine (AnaSed Injection, 20 
mg/ml xylazine, Butler Schein). Mice were then laid over the mosquito net coverings, 
ventral side down, one mouse per cage, for a 10 minute exposure to infectious 
mosquitoes. Mosquitoes were checked for successful blood feeding and any mouse on 
which no mosquito fed was removed from analysis. 
 
Mouse to mosquito transmission. To investigate the effect of invasive Salmonella 
infection on parasite transmission from mouse to mosquito we fed uninfected mosquitoes 
on P. berghei MRA-868-infected 129S1/SvImJ mice 4-5 days after inoculation with 
parasitized red bloods cells. Feeds were as described above for infectious mosquito feeds. 
Blood-fed mosquitoes were then maintained in a humidified incubator at 70-80% 
humidity and 21ºC, in which they were fed from cotton balls soaked with 10% sucrose. 
The sucrose-soaked cotton balls were replaced at least once every two days. 13 days after 
blood feeding, mosquitoes were dissected to remove the midgut, which was mounted 
under a coverslip. P. berghei ANKA strain MRA-868 expresses GFP constitutively and 
GFP+ oocysts were visualized on an Eclipse Ti inverted microscope (Nikon Instruments, 
Melville, NY, USA). The number of oocysts per mosquito midgut was recorded 
separately for each mouse. 
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Blood-stage P. berghei infections. For iRBC infections, C57BL/6J donor mice were 
infected from frozen stock of iRBCs. 400 µl of frozen stock was thawed and diluted to 
600 µl with 0.9% NaCl/0.2% dextrose. 200 µl was injected into each donor mouse. 
Donors were euthanized with 100 mg/kg ketamine and blood was harvested by cardiac 
puncture at 2-4% parasitemia using a 26-gauge needle to avoid damaging RBCs. The 
dead space of syringes was prefilled with heparin (27602, Fresenius Kabi, Lake Zurich, 
IL, USA) to prevent coagulation. Blood was diluted in P. falciparum culture medium 
(194) to 5 × 106 iRBC per ml. 200 µl (106 iRBC) was injected i.p. into each mouse, again 
using a 26-gauge needle to avoid damaging RBCs.  
 
In vivo bioluminescence imaging. In vivo imaging was used to determine liver-stage 
and early blood-stage parasite load in mice infected with isolated sporozoites or via 
infectious mosquito bite. Imaging was performed in a Xenogen IVIS® Spectrum Optical 
Imaging System (Caliper Life Sciences) in the animal facility at Columbia University 
Medical Center. Prior to imaging the ventral abdomen of the mice was depilated by first 
shaving and then treating with hair removal lotion (Nair, Church & Dwight Co., Inc., 
Ewing, NJ). Hair removal lotion was applied for no more than 90 seconds and was 
cleaned off thoroughly using a PBS-soaked gauze sponge. Mice were anesthetized by 
inhalational isoflurane (2%) for purposes of restraint during imaging. 3 mg luciferin (D-
luciferin - K+ salt bioluminescent substrate, PerkinElmer, Waltham, MA, USA) 
dissolved in 200 µl saline dextrose (0.9% NaCl, 0.2% dextrose) was injected either i.p. or 
subcutaneously (s.c.) into the back of the neck. The route of injection was changed from 
i.p. to s.c. as we suspected that the former may introduce greater variability in luciferase 
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signal. The optimal time lag between s.c. luciferin injection and image acquisition was 
determined: multiple images acquired between 4 and 23 minutes after luciferin injection 
showed peak luciferase signal 10 minutes after injection, decaying slowly over the 
following 13 minutes (figure 2.1). Luciferin was therefore allowed to distribute for 10 
minutes before images were acquired. Mice were imaged on their backs to allow 
detection of luciferase signal through the depilated area of skin. Luminescence was 
measured as photon emission from the region of interest (ROI) in 
photons/second/cm2/steradian (radiance). These units correct for differences in exposure 
and sensitivity settings between images. The size of the ROI was kept constant between 
all animals. In images taken at 24 or 48 hours post-sporozoite infection, i.e. during liver 
stages of infection, the ROI was centered over the liver. In images taken 72 hours post-
sporozoite infection, by which time a blood-stage infection has developed, the ROI was 
placed at the base of the tail to obtain the most reproducible measurements. 
 
P. berghei synchronization attempts. Synchronization was attempted for initial 
experiments investigating gametocyte production in order to reduce variability, as 
advised by Dr. Shahid Khan (personal communication). These attempts resulted in poor 


























survival of parasites and failure to establish infection in some recipient mice. The 
following protocol therefore requires further optimization. Briefly, synchronization was 
attempted by harvesting whole blood from donor mice at 2-4% parasitemia. 400 µl blood 
was diluted in 6 ml P. falciparum culture medium (194) and incubated overnight at 37ºC 
on a shaker in a humidified chamber (Billups-Rothenberg, Del Mar, CA, USA), gassed 
with 5%CO2/5%O2/90%N2. As P. berghei will not egress from red blood cells ex vivo 
this incubation synchronizes the parasites by stalling development at the late schizont 
stage, just prior to RBC egress. 
 
Peripheral parasitemia measurements. Ongoing blood-stage parasite load was assessed 
daily either by flow cytometry on a BD Accuri C6 flow cytometer, equipped with a 96-
well plate reader, or from Giemsa-stained blood smears. Parasitemia was monitored 
starting at 3 days post-sporozoite injection or infectious mosquito feed or at one day post-
iRBC infection. 1 µl blood was collected by pricking the lateral tail vein with a 27 gauge 
needle and was diluted in 40 µl staining mix (P. falciparum culture medium (194), 1.4:10 
citrate-phosphate-dextrose (CPD, Sigma Aldrich, St. Louis, MO, USA), 3 × SYBR Green 
(SYBRG, Life Technologies, Eugene, OR, USA), and 1/3000 of a 0.5 M stock of 
MitoTracker Deep Red (MTDR, Life Technologies, Eugene, OR, USA)) in a round-
bottomed 96-well plate. Samples were incubated in staining mix for 30 minutes at room 
temperature. Samples were then diluted 16 × in sterile PBS before collecting events by 
flow cytometry. At least 1000 events were collected per well. Debris and doublet events 
were excluded by gating in FSC and SSC and parasites were gated as the FL-1A-hi:FL-
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4A-hi population. Mice were monitored twice daily once infected with P. berghei and 
euthanized if necessary, according to the clinical scoring scale shown in Table 2.1. 
 
RETICULOCYTE MEASUREMENTS 
Initial observations of an altered percentage of reticulocytes among red blood cells were 
noted in Giemsa-stained smears of tail blood, and in FACS plots of SYBRG/MTDR-
stained cells. To obtain more specific measurements of reticulocyte percentages, we 
stained blood samples with an antibody panel to identify immature red blood cells. The 
antibodies used were PE-conjugated anti-TER119, FITC-conjugated anti-CD71, and PE-
Cy7-conjugated anti-CD45 (BD, Franklin Lakes, NJ, USA) all at a final concentration of 
1:100. 1 µl blood was collected from the lateral tail vein into 40 µl P. falciparum culture 
medium with 1.4:10 CPD. 4 µl of this RBC suspension was removed into 26 µl Fc 
receptor block (CD16 + CD32 antibody, Invitrogen, Camarillo, CA, USA) diluted 1:100 
in staining buffer (1X PBS; 0.2% BSA; 5 mM glucose. Staining buffer was freshly 
filtered to avoid clogging the flow cytometer) and incubated for 20 minutes on ice. 30 µl 
of staining buffer containing all three antibodies, each at a 1:50 dilution, was added and 
incubated for a further 20 minutes on ice. The total sample volume was then brought up 
to 150 µl with PBS before collecting at least 1000 events on a BD AccuriTM C6 flow 
cytometer for analysis. 
 
LIVER EXPRESSION ANALYSES 
Mice were euthanized at the stated timepoint by i.p. injection of 100 mg/kg ketamine and 
10 mg/kg xylazine. A 20 mm3 segment of the median lobe of the liver was harvested into 
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RNAlater (Qiagen) and stored at -20ºC before RNA extraction and qPCR analysis. qPCR 
analyses for cytokine signaling were performed by Dr. Vanessa Zuzarte Luìs in the lab of 
Dr. Maria Mota. The following description of procedures is reproduced from (89). For 
mouse liver RNA extraction, whole livers were homogenized in 3 ml denaturing solution 
(4 M guanidine thiocyanate; 25 mM sodium citrate pH 7, 0.5% N-lauroylsarcosine and, 
0.7% β mercaptoethanol in DEPC-treated water). RNA was extracted using RNeasy Mini 
kit (Qiagen). Complementary DNA was synthesized using Transcriptor First Strand 
cDNA Synthesis kit (Roche). Gene expression analysis was performed using kits from 
Applied Biosystems. For analysis, the expression levels of all target genes were 
normalized against hypoxanthine guanine phosphoribosyltransferase (Hprt) housekeeping 
gene (ΔCt). Gene expression values were then calculated based on the ΔΔCt method. 
Primer pairs used to detect target gene transcripts are listed in Table 2.2.  
Mus musculus  




Forward Primer Reverse Primer 
Hprt (15452) 5'-CAT TAT GCC GAG GAT TTG GA 5'-AAT CCA GCA GGT CAG CAA AG 
Ifi44 (99899) 5'-TCG ATT CCA TGA AAC CAA TCA C 5'-CAA ATG CAG AAT GCC ATG TTT T 
Ifit1 (15957) 5'-CCT TTA CAG CAA CCA TGG GAG A 5'-GCA GCT TCC ATG TGA AGT GAC 
Irf7 (54123) 5'-CTT CAG CAC TTT CTT CCG AGA 5'-TGT AGT GTG GTG ACC CTT GC 
Usp18 (24110) 5'-CGT GCT TGA GAG GGT CAT TTG 5'-GGT CGG GAG TCC ACA ACT TC 
Ifit2 (15958) 5'-AGA GGA AGA GGT TGC CTG GA 5'-CTC GTT GTA CTC ATG ACT GCT G 
Ifit3 (15959) 5'-CTG AAC TGC TCA GCC CAC AC 5'-TGG ACA TAC TTC CTT CCC TGA 
Lgp2 (80861) 5'-TCA TCT GTA CGG CAG AGT TGT 5'-TGT TGT AGA CGG TGT CTT TGT 
Mx2 (17858) 5'-AGA CAA AGC ATG GCA CTT CC 5'-ACT GGA TGA TCA AGG GAA CG 
Ifn-γ (15978) 5'-CAC ACT GCA TCT TGG CTT TG 5'-TCT GGC TCT GCA GGA TTT TC 
Il-6 (16193) 5'-TTC CAT CCA GTT GCC TTC TT 5'-CAG AAT TGC CAT TGC ACA AC 
Tnf-α (21926) 5'-AAT GGC CTC CCT CTC ATC AGT T 5'-CCA CTT GGT GGT TTG CTA CGA 
 
Table 2.2 Primers used in liver cytokine and cytokine signaling expression analyses 
qPCR analyses of hepcidin (encoded by the Hamp1 gene) expression were performed by 
Dr. Natasha Spottiswoode in the lab of Dr. Patrick Duffy. The following description of 
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these procedures is reproduced from (195). Liver samples were homogenized using a 
TissueRuptor in 600 µl RLT Buffer, then 350 µl of the resulting mixture used for further 
extraction. RNA was extracted using the Qiagen RNeasy Mini Kit, Animal Cells Spin 
Protocol, according to kit instructions. RNA was reverse transcribed to cDNA using the 
High Capacity RNA-to-cDNA kit (Applied Biosystems) according to the manufacturer’s 
instructions. qRT-PCR reactions were performed on an Applied Biosciences 7500 Fast 
Real-Time PCR System machine with cDNA at a final concentration of 1-5 ng/µl, using 
Taqman Gene Expression Mastermix and inventoried Taqman Gene Expression Assays 
(all Applied Biosystems). All qRT-PCR reactions were run in technical duplicate. qRT-
PCR values were analyzed relative to Hprt using the 2ΔCt method and technical duplicates 
were averaged. The probes used were Mm04231240_s1 for Hamp1 and 
Mm03024075_m1 for Hprt (Life Technologies, Grand Island, NY, USA). 
 
PLASMA CYTOKINE MEASUREMENTS 
Blood was sampled either from the saphenous vein (60 µl blood taken) into a K2EDTA-
coated blood collection tube to prevent coagulation (BD, Franklin Lakes, NJ, USA), or 
by cardiac puncture (400 µl blood taken). Blood was kept at 4ºC during processing. Cells 
were pelleted by centrifugation at 2000 rcf for 15 minutes and the resulting supernatant 
was collected into a fresh tube and stored at -20ºC. Freeze-thaw cycles were avoided. For 
determination of cytokine levels in these samples we used a BDTM cytokine bead array 
(CBA) Flex Set, comprising beads and detection reagents specific to IFN-γ (bead A4), 
IL-6 (bead B4), TNF (bead C8), IL-12p70 (bead D7), IL-2 (bead A5), IL-10 (bead C4), 
and IL-1β (bead E5). The use of these capture beads, each type coated with specific 
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antibody and having unique coordinates on a FL3-A:FL4-A fluorescence plot, allows for 
all seven cytokines to be assayed in a single sample. PE-conjugated detection antibodies 
bind to analytes on capture beads, such that the magnitude of the PE fluorescence signal 
is proportional to the concentration of analyte in the sample. The assay was conducted as 
directed in the product manual: a set of 10 standards was prepared by 2-fold serial 
dilution of a 2,500 pg/ml standard down to 9.77 pg/ml, plus a 0 pg/ml blank. Plasma 
samples were diluted at least 5 ×. Each standard and diluted plasma sample was 
incubated with capture beads for one hour at room temperature. Mixed PE-conjugated 
detection antibodies were then added for a further one hour incubation at room 
temperature. Bead-analyte-detection reagent conjugates were centrifuged at 200 rcf for 5 
minutes and resuspended in wash buffer twice to remove unbound analytes and detection 
reagents before collecting at least 4000 bead events per sample on a BD AccuriTM C6 
flow cytometer. Median fluorescence intensity (MFI) of the PE detection reagent for each 
bead in each sample was determined in FlowJo. A polynomial (order 2) line of best fit 
was constructed using a scatter plot of PE MFI against concentration of the known 
standards. The equation of this line was used to calculate the concentration of each 
analyte.  
 
NEUTRALIZING ANTIBODY TREATMENTS 
150 or 250 mg anti-IFNαR1 as noted (clone MAR1-5A3, BioXCell, West Lebanon, NH, 
USA), 50 mg anti-TNF-α (soluble TNF receptor 1, PEG-rmethu-sTFN-R1, kind gift of 
Dr. Grégoire Lauvau), or 250 mg non-specific IgG control (clone MOPC-21, BioXCell), 
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were injected i.p. on days 0, 2, and 3 of S. Typhimurium infection, diluted to a total 
volume of 200 µl in filter-sterilized PBS. 
 
LIVER AND SPLEEN LEUKOCYTE ISOLATION AND ANALYSIS 
Mice were euthanized with ketamine/xylazine as described above. To flush out red blood 
cells the liver was perfused with heparinized PBS (10 units heparin per 1 ml PBS). 
Perfusion was done using a 27-gauge 1/2” needle inserted into the portal vein before its 
branch point in order to perfuse both sides of the liver. The left and right superior vena 
cava and the aortic arch were cut to allow perfusion. The entire liver was then removed to 
a 6-well plate containing 6 ml HBSS (+Ca/+Mg, Life Technologies, Grand Island, NY, 
USA). The entire spleen was removed to a separate well, containing 3 ml HBSS. Once 
removed from the mouse both spleen and liver were kept on ice for the duration of 
preparation for FACS analysis unless otherwise stated. The organs were homogenized by 
forcing through a 100 µm filter. 0.01% Collagenase I and 0.002% DNAse I were added 
to the homogenized organs and incubated at 37 ºC for 30 minutes. Further RBC removal 
from both organs was achieved using RBC lysis buffer (0.83% NH4Cl). RBC lysis buffer 
was added at a ratio of 1:1 to the homogenate in HBSS and the mixture was immediately 
refiltered through a 100 µm filter. The sample was then incubated at room temperature 
for 15 minutes. Lysed RBCs were removed by centrifugation at 420 rcf for 5 minutes at 
4ºC.  The supernatant was discarded and spleen cells were resuspended in FACS buffer 
(1X PBS; 1% fetal calf serum; 0.02% sodium azide; 2mM EDTA). Liver cells were 
resuspended in 33% Percoll (GE Healthcare Life Sciences, Pittsburgh, PA, USA) to 
separate leukocytes from parenchymal cells by density gradient centrifugation. Liver 
 54 
samples resuspended in 33% Percoll were spun at 690 rcf for 15 min at room temperature 
with no brake. This pellets leukocytes while parenchymal cells remain layered on top of 
the Percoll. The Percoll, including the parenchymal cell layer, was removed and the 
leukocytes were washed in FACS buffer. Wash centrifugation was performed at 690 rcf 
for 5 minutes at 4ºC with maximum acceleration and brake. After washing, liver and 
spleen cells were transferred to a 96-well plate (not more than 1 × 107 cells per well). 
Cells were then spun at 890 rcf for 3 minutes at 4ºC and resuspended in Fc receptor block 
(supernatant from hybridoma clone 24G2, diluted 1:1 in FACS buffer, gift of Dr Grégoire 
Lauvau). Samples were incubated with Fc block for 15 minutes at 4ºC and then spun 
down at 890 rcf for 3 minutes at 4ºC. Cells were resuspended in 50 µl primary antibody 
mix (table 2.3) and incubated in the dark for at least 30 minutes at 4ºC. All primary 
antibodies were fluorochrome conjugated as noted in table 2.3 








Table 2.3 Antibodies used in liver and spleen leukocyte profiling 
 
Cells were washed in excess FACS buffer and refiltered through a 100 µm filter 
immediately before FACS analysis. Analysis was performed on a FACSAria™ III cell 




Prism 6 for Mac OS X was used for all graphing and statistical analyses.  
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CHAPTER 3 - DETERMINING THE IMPACT OF INVASIVE SALMONELLA TYPHIMURIUM INFECTION 
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 57 
ABSTRACT 
Upon injection by the mosquito into the vertebrate host, Plasmodium parasites must migrate to 
the liver and invade hepatocytes, within which they will develop to produce the life cycle forms 
that are infectious to red blood cells. Intrahepatic development has substantial metabolic 
requirements and is also vulnerable to host defense mechanisms. Liver-stage parasites are 
therefore susceptible to perturbations in the host environment that lead to either restricted 
metabolite availability or enhanced defense. One such perturbation that human Plasmodium 
parasites are exposed to naturally is co-infection of the vertebrate host with invasive NTS. 
 
In this chapter we use a mouse model of invasive NTS-Plasmodium co-infection to examine how 
existing invasive NTS infection impacts progression through Plasmodium liver-stage 
development. We show that invasive NTS infection robustly inhibits liver-stage development, 
and that this inhibition can be replicated by treatment with heat-killed NTS, indicating that 
suppression of liver-stage parasite growth is a result of a host response rather than direct 
competition between the two pathogens. We confirmed that invasive NTS induces a pro-
inflammatory environment in our model, but did not find evidence for Type I IFN, IFN-γ, or 
TNF-α signaling being required for NTS-induced inhibition of Plasmodium liver-stage growth.  
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INTRODUCTION 
Both Plasmodium and non-typhoidal Salmonella species impose a substantial burden of disease 
on peoples in Sub-Saharan Africa, where the distributions of these two diseases overlap both 
geographically and demographically. The estimated 163 million cases of malaria in Africa in 
2013 caused an estimated 528,000 deaths, 83% of which were in children under the age of five 
(1). Invasive non-typhoidal Salmonella is also endemic in many parts of the continent and also 
disproportionately affects young children, with the majority of cases found in children under the 
age of three (162, 196). In contrast to the public health burden imposed by malaria, invasive non-
typhoidal Salmonella is a much less recognized, though real, concern in Sub-Saharan Africa. 
Estimates of the incidence of non-typhoidal Salmonella infections that progress to bacteremia 
range from 0.2 to 0.7% in the most susceptible age groups (197-199). The burden of invasive 
non-typhoidal Salmonella infection not causing bacteremia is unknown but likely to be 
substantially higher. Exposure levels to non-typhoidal Salmonella species are high enough in 
some regions that 100% of study subjects with no known prior Salmonella infection or 
vaccination history carry antibodies to Salmonella antigens (127). The threat from invasive NTS 
infections in Sub-Saharan Africa is aggravated by the emergence of a highly virulent sequence 
type, ST313, which has been isolated from blood culture in at least seven sub-Saharan African 
countries (168). This sequence type has undergone substantial genomic degradation, which 
appears to have rendered it more akin to Salmonella Typhi in host tropism and pathogenesis than 
other NTS sequence types (166). Dispersal of the bacteria within an individual is not a direct 
route from initial acquisition (generally via ingestion of contaminated food or drink) to 
bloodstream infection. Rather, the bacteria first must invade the mucosal barriers of the gut 
before disseminating to and persisting in lymph nodes, spleen, liver and bone marrow (200). 
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Other than enteric infection, which is evidenced by the presence of bacteria in fecal samples, the 
stages of invasive NTS disease prior to occurrence of bacteremia cannot generally be detected by 
non-invasive means. The true incidence of invasive NTS is therefore unable to be determined 
and, given the high levels of exposure to these bacteria in Sub-Saharan African populations, 
there is likely to be a substantial unidentified pool of subclinical invasive NTS infections. The 
considerable and overlapping presence of Plasmodium and non-typhoidal Salmonella creates the 
risk of becoming co-infected with both pathogens. Such co-infections have been widely noted 
(120, 123, 128, 197, 201, 202) and blood-stage Plasmodium infection increases susceptibility to 
Salmonella infection, as demonstrated in both human studies and mouse models (112, 120, 121, 
124, 125). The influence of Salmonella infection on susceptibility to Plasmodium, however, has 
not been investigated.  
 
Our aim with this body of work was to investigate the impact of existing invasive non-typhoidal 
Salmonella infection on progression of Plasmodium parasites through the life cycle and 
development of the associated pathologies. In this chapter we will discuss the first stages of 
Plasmodium life cycle that occur in humans, the liver stages (figure 1.5). The natural mode of 
acquiring Plasmodium infection is via the bite of a female anophelene mosquito harboring 
Plasmodium sporozoites in her salivary glands. Whilst taking a blood meal the mosquito injects 
saliva, which enhances feeding efficiency thanks to antithrombotic (203, 204), vasodilatory (205), 
and anti-inflammatory proteins carried therein. The antithrombotic and vasodilatory components 
serve to maintain good blood flow whilst the anti-inflammatory components serve in part to 
reduce pain felt by the mosquito’s feeding target, thus avoiding disruption of feeding. 
Plasmodium sporozoites in the salivary glands are ideally placed for deposition in vertebrate 
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hosts, where the next stages of the life cycle will occur. As well as being in prime location, 
sporozoite presence in the salivary glands has been reported to increase the biting behavior of 
mosquitoes compared with those that are uninfected, both in terms of biting frequency (26), and 
biting perseverance (206). Sporozoites are highly motile and after injection by the mosquito can 
be seen by confocal microscopy gliding in the skin at speeds of up to 4 µm per second (77). 
When imaged in conjunction with red blood cells the sporozoites are eventually carried away at 
velocities equal to those of the red blood cells, signifying the parasites’ invasion into a blood 
vessel (28). From their initial point of entry into the blood stream sporozoites travel to the liver 
where they can again be imaged in vivo (29). This study demonstrated that upon arrival in the 
liver sinusoids, sporozoites adhere to the endothelial cell layer tightly enough to move either 
with or against blood flow until they encounter a Kupffer cell (a liver resident macrophage). 
Sporozoites enter the Space of Disse, which separates hepatocytes from the liver sinusoid 
endothelial cell layer, mostly traversing through Kupffer cells or endothelial cells (30). Once in 
the liver parenchyma sporozoites traverse multiple hepatocytes intracellularly before establishing 
infection in the last hepatocyte it invades (32) where it will develop for 2-15 days, depending on 
the species.  Massive replication occurs within this hepatocyte, with a single sporozoite 
producing thousands of merozoites (38). These merozoites are then released into the blood 
stream where they will infect red blood cells and undergo repeated rounds of asexual replication. 
From the time of mosquito bite to release of merozoites from hepatocytes into the blood stream 
parasites cause no overt pathology in the host. These life cycle stages are nonetheless vulnerable 
to attack by the vertebrate host’s immune system, both cell- and cytokine-mediated (89, 90, 114, 
207). In addition, with massive replication come substantial requirements for nutrients including 
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fatty acids (208) and iron (156). Liver-stage Plasmodium obtains some of these nutrients by 
diverting the host cell’s endocytic pathway. 
 
Salmonella Typhimurium follows an entirely different route of infection into the host, although it 
shares the liver with Plasmodium as a major site of replication (209). Although farm animals 
have been implicated as a major reservoir of non-typhoidal Salmonella in industrialized countries, 
studies in Kenya have suggested that person-to-person transmission may be a more likely event 
(161, 162). The presence of clonally matching infections between people living in close 
proximity to one another does not indicate whether multiple people acquired the infection in a 
single event, or whether one person passed the infection on to others. However, the lack of 
clonally related bacteria between animals and infected humans that live in close proximity 
indicates that zoonotic transmission in some regions is relatively rare (161). Upon entry into the 
human host, the establishment of an invasive infection depends on the bacteria traversing across 
the gut endothelium and disseminating via the lymph and blood (reviewed in (210) and (211)) 
Bacteria from heavily infected liver and spleen can also transfer between these two organs via 
the blood. Colonization of the gall bladder allows for reinfection of the gut and hence fecal 
shedding, returning bacteria to the environment where the infection can be acquired by a new 
host. 
 
Both enteric and invasive Salmonella infections induce a plethora of host immune responses, 
both cytokine and cell-mediated (212-217). As already mentioned pre-erythrocytic Plasmodium 
parasites, although clinically silent, are vulnerable to a number of host immune defense 
mechanisms. Overlap between the responses that are induced by Salmonella infection and 
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responses that inhibit Plasmodium hepatocyte invasion or growth within the liver might therefore 
lead to altered progression of Plasmodium infection in a Salmonella co-infected host. 
 
Salmonellae are facultative intracellular bacteria. Once past the barrier imposed by the gut 
endothelium, Salmonella preferentially infect macrophages, including Kupffer cells (218). 
Salmonella growth is dependent on iron availability and Salmonella-infected macrophages 
exploit the high iron demands of the bacteria as a means of defense. By increasing production of 
the cellular iron-exporter ferroportin, macrophages can reduce cytoplasmic ferrous iron 
availability and impede bacterial replication (219). Genetic modifications that inhibit glucose 
transport into Salmonella also impair bacterial replication, indicating the importance of 
exogenous glucose for Salmonella growth (220). Plasmodium liver-stage development is 
likewise strongly affected by glucose and iron availability (156, 221, 222) and competition for 
these or any other nutrients required by both pathogens has potential consequences for co-
infection. 
 
To determine the impact of invasive Salmonella infection on progression of liver-stage 
plasmodial development we used a mouse model of co-infection. We used Salmonella 
Typhimurium LT2 (ATCC # 19585, referred to in this chapter and chapter 4 simply as 
Salmonella) and Plasmodium berghei ANKA, strain MRA-868 (referred to in this chapter and 
chapter 4 as P. berghei). This strain of P. berghei carries a constitutively expressed GFP-
luciferase fusion reporter, allowing for non-invasive in vivo imaging in both liver and blood 
stages of the parasite life cycle (193). We initiated Salmonella infections via intraperitoneal 
injection, thus bypassing enteric disease and concentrating on disseminated invasive infection. In 
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this chapter Plasmodium infection was administered either by the natural mode of transmission 
(mosquito bite-delivered sporozoites) or by intravenous injection of sporozoites isolated from 
mosquito salivary glands. Both modes of Plasmodium infection allowed us to examine liver-
stage development, although the environments encountered by the parasites en route to the liver 
are slightly different. Through these studies we describe the impact of invasive Salmonella 
infection on Plasmodium liver-stage development. We have also tested several hypotheses 
regarding potential mechanisms to explain our findings and present the results here.  
 
RESULTS 
Invasive Salmonella infection inhibits development of liver-stage P. berghei following 
infectious mosquito bite or isolated sporozoite inoculation. To determine whether existing 
Salmonella infection alters P. berghei liver stage development we injected wild-type C57BL/6J 
mice intraperitonealy with 300 colony-forming units (CFU) Salmonella, or sterile PBS as control, 
and three days later administered P. berghei sporozoites. For investigating the impact of acute 
invasive salmonellosis on P. berghei, the timing of the two infections relative to each other was 
determined according to the practicability of using our co-infection model with parasitized red 
blood cell (RBC) rather than sporozoite infections (discussed in Chapter 4). The delay between 
infecting donor mice from frozen parasite stock and parasites becoming detectable in the blood 
stream is highly variable. Timing the Salmonella infection so that parasitized RBCs will be 
available at a specific timepoint is therefore difficult, unless Salmonella infection is delayed until 
parasitized RBCs are detectable in the bloodstream. In order to maintain a constant time interval 
between Salmonella and P. berghei-infected RBC infection we waited for donor mice to show 
detectable blood-stage parasitemia before introducing the Salmonella infection (or control 
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injections of PBS) into experimental mice. C57BL6 mice are highly susceptible to P. berghei 
and in our hands the infection is generally fatal within 4-6 days after blood-stage inoculation 
from donor mice. A three day delay between Salmonella and Plasmodium infection was chosen 
to allow time for mice to mount an early response to Salmonella infection, and to avoid 
Plasmodium donor mice dying before their blood could be harvested for transfer to experimental 
mice. In initial experiments sporozoites were delivered via infectious mosquito bite. P. berghei 
liver-stage development lasts up to 52 hours (223, 224) whilst the duration of the asexual blood-
stage cycle is 21-23 hours (132). We therefore used an in vivo imaging system to determine 
parasite load at 48 hours after infectious mosquito bite to capture the peak of liver-stage 
development. Mice infected with Salmonella consistently showed a significantly lower liver-
stage P. berghei burden 48 hours after infectious mosquito feed (the peak of P. berghei liver-






Mice were monitored for survival and development of peripheral parasitemia, from which we 
noted that Salmonella-induced inhibition was sufficient to completely block progression to 
blood-stage disease in a quarter of mice, whereas no PBS control mice failed to develop 
peripheral parasitemia (table 3.1). For those mice that did develop peripheral parasitemia, 
Salmonella infection delayed the appearance of blood-stage parasites following either isolated 
sporozoite injection or infectious mosquito feed (table 3.1) and reduced the peripheral parasite 
burden (figure 3.2). Survival rates were similar between Salmonella-infected and control mice 












































Figure 3.1 Salmonella infection inhibits development of 
Plasmodium liver stages following injection of sporozoites 
via infectious mosquito feed. Plasmodium-infected 
mosquitoes were allowed to feed on C57BL/6J mice 3 days 
after injection of 300 CFU Salmonella or PBS control. The 
peak of liver-stage burden was imaged in vivo 48 hours after 
infectious mosquito feed. Bars show mean + SD of 
independent repeats (the number of repeats is noted in 
brackets). *** p < 0.001. 
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control mice is likely to be due to experimental cerebral malaria. In contrast, the early death of 
Salmonella co-infected mice is more likely to be due to overwhelming bacterial infection due to 
the high susceptibility of Plasmodium-infected mice to invasive Salmonella. Late death of 
control mice is likely due to hyperparasitemia and resulting anemia. 
 
Table 3.1 
Salmonella infection impedes production of blood-stage parasites after sporozoite inoculation 
  Isolated sporozoite injection  Infectious mosquito bite 
Measurement 
 
PBS + P. b. S. Tm. + P. b.  PBS + P. b. S. Tm. + P. b. 
Days to 2% parasitemia§  
5.2 ± 0.6  
(n = 13) 
>6.5 ± 1.1**  
(n = 8)^  
6.2 ± 0.7  
(n = 15) 
>10.0 ± 1.4***  
(n = 6)^ 
Percent developing 
peripheral parasitemia  
100%  
(n = 13) 
100%  
(n = 13)  
100%  
(n = 19) 
< 73%  
(n = 10)† 
P. b. = Plasmodium berghei; S. Tm. = Salmonella Typhimurium 
§Mean ± standard deviation 
^Mice that died before reaching 2% parasitemia were omitted from the calculations (5 mice after sporozoite 
injection; 8 mice after mosquito bite) 
†Four mice that died without detectable blood-stage parasitemia but sooner than the longest prepatent period 
observed were omitted from the calculations 





Figure 3.2 Salmonella-infected C57BL/6J mice have reduced blood-stage Plasmodium burden following 
infectious mosquito feed but survival is not significantly altered. Plasmodium-infected mosquitoes were 
allowed to feed on mice 3 days after injection of 300 CFU Salmonella or PBS control. Parasitemia and survival 
were monitored daily from 3 days post mosquito feed. Bars show mean + SD of 15 PBS control mice and 14 
Salmonella-infected mice from 3 independent repeats. Significance measured by T-test with Welch’s correction: 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
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Differences in blood-stage parasite burden between Salmonella-infected and PBS control groups 
are lost when the majority of Salmonella-free mice die, which occurs 5 to 7 days post-sporozoite 
inoculation. Due to differences in Salmonella susceptibility and in the impact of Salmonella 
infection on the progression of blood-stage plasmodial infection in 129S1/SvImJ mice (which 
will be discussed in more detail in chapter 4), we conducted parallel experiments in this mouse 
strain. Although there was a trend towards lower liver stage parasite burden in Salmonella-
infected 129S1/SvImJ mice compared with PBS controls, the inhibition was less intense than in 
C57BL/6J mice  (possibly as a by-product of the greater resistance of 129Sv mice to Salmonella, 






We therefore focused further investigations in C57BL/6J mice in order to distinguish the 
phenotype more reliably. Delivering sporozoites via infectious mosquito bite has the advantage 



































48 hr IVIS grouped
Plasmodium only
Plasmodium + Salmonella
Figure 3.3 Salmonella infection has a 
mild effect on development of 
Plasmodium liver stages in 
129S1/SvImJ mice following infectious 
mosquito feed. Plasmodium-infected 
mosquitoes were allowed to feed on 
mice 3 days after injection of Salmonella 
or PBS control. The peak of liver-stage 
burden was imaged in vivo 48 hours 
after infectious mosquito feed. Bars 
show mean + SD of 5 mice per condition 
in each experiment. 
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environments as are traversed in field infections (in contrast to sporozoites injected intravenously, 
those injected by the mosquito must first traverse the dermis before invading blood vessels (28), 
from where they travel to the liver), but also delivering a parasite inoculum comparable to what 
is encountered in the wild. However, due to the variable infectivity and biting activity of 
mosquitoes it is impossible to reliably deliver equal parasite dosage to every mouse. This 
variability in parasite burden thus necessitated large animal numbers for reliable interpretation of 
results. For a more sustainable approach we continued our investigation using isolated 
sporozoites collected from infected mosquitoes and injected 10,000 per mouse (unless otherwise 
stated) into the lateral tail vein. For comparison, a single mosquito feeding on the ventral 
abdomen of a mouse injects just over 100 sporozoites when allowed to feed for 3 or 15 minutes 
(225, 226). In experiments delivering sporozoites via infectious mosquito bite the confirmed 
number of bites for each mouse was between 1 and 9. Our dosage of isolated sporozoites was 
therefore 10 to 100-fold higher than that administered via infectious mosquito feed, although 
there is evidence that mosquito-delivered sporozoites are more infectious than those that have 
been isolated and delivered intravenously (227, 228). As well as 48 hours after sporozoite 
inoculation, we included imaging time points at 24 and 72 hours to capture early liver stage and 
early blood stage development respectively. Mice used in experiments with isolated sporozoite 
injections were treated with a non-specific IgG antibody in order for them to be used as controls 
in experiments testing whether neutralizing antibodies against cytokines previously implicated in 
inhibition of liver-stage Plasmodium development alleviate Salmonella-induced inhibition. 24 
hours after intravenous injection of isolated sporozoites we found no difference in liver parasite 
burden between Salmonella-infected and control mice. By 48 hours, the peak of liver-stage 
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development, we observed a reduction in Salmonella-infected mice to 38% of the parasite burden 




The lack of discernible impact on early liver-stage P. berghei development 24 hours after 
sporozoite inoculation suggests that the reduced parasite burden seen at 48 hours is due to 
inhibition of development within the liver rather than inhibition of sporozoite migration to the 
liver or of hepatocyte invasion. By 72 hours Salmonella-infected mice had a peripheral parasite 
burden only 12% of that in control mice (figure 3.4). The impact of Salmonella on Plasmodium 

























































































Figure 3.4 Salmonella infection inhibits development of Plasmodium liver stages following intravenous 
injection of isolated sporozoites. 10,000 sporozoites were injected into the lateral tail vein of C57BL/6J mice 3 
days after injection of 300 CFU Salmonella or PBS control. Bars show mean + SD of independent repeats (the 
number of repeats is noted in brackets). ns = not significant; * p < 0.05; ** p < 0.01. 
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Examining potential mechanisms of inhibition. At the broadest level there are two possible 
explanations for how Salmonella infection inhibits P. berghei growth and development. Firstly, 
the bacteria may directly inhibit parasite growth through production of toxins or competition for 
resources. Alternatively, Salmonella may indirectly inhibit P. berghei growth by inducing a host 
response that is detrimental to parasite development. We have investigated how Salmonella 
infection alters the host environment and further tested the contribution of these changes to 
Salmonella-dependent inhibition of P. berghei liver-stage development. 
 
Salmonella infection induces a pro-inflammatory environment within 3 days of infection. 
Several different mediators of inflammatory might create an environment that is hostile to P. 
berghei. Treatment with IFN-γ, TNF-α, IL-12, IL-1, or IL-6 has been shown to protect against 
liver-stage Plasmodium parasite development (89, 102-106, 229). The type I IFN response, 
which requires signaling through the interferon α receptor (IFNαR), plays a crucial role in 
inhibition of a second Plasmodium liver-stage development caused by recent liver-stage 
Plasmodium infection (3 days prior) (230) or Hepatitis C viral infection (2 days prior) (89). 
Elevated IL-10 has also been associated with resistance to Plasmodium infection (113, 231). 
Live Salmonella infection can induce elevated production of IL-2, IL-1β, IL-6, IL-12, TNF-α, 
and IFN-γ, with injection of S. Typhimurium flagellin being sufficient to induce production of 
IL-6 and IL-12 (186-189). We used a multiplexed cytokine bead array assay to determine 
whether IFN-γ, IL-6, TNF, IL-12, IL-2, IL-10, or IL-1β levels are increased in our model 3 days 
after infection with 300 CFU Salmonella and thus might be involved in the observed inhibition 
of P. berghei liver-stage development. We also determined mRNA expression levels of a subset 
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of these (Ifn-γ, Il-6, and Tnf-α) and of a panel of type I IFN-responsive genes, in the livers of 
Salmonella-infected mice. These assays confirmed that, in our model, mice develop a substantial 
increase in plasma IFN-γ, IL-6, and TNF concentrations within 3 days post-Salmonella infection 






We saw no significant changes in levels of IL-12, IL-2, IL-10, or IL-1β. qRT-PCR on whole 
liver RNA likewise showed transcriptional upregulation of Ifn-γ, Il-6, and Tnf-α as well as strong 
induction of type I IFN-responsive genes in livers of mice 3 days after infection with 300 CFU S. 












































Figure 3.5 C57BL/6J mice show elevated plasma IFN-γ , IL-6, and TNF 3 days after i.p. injection 
with 300 CFU Salmonella. Plasma cytokine concentrations were measured by cytokine bead array 






CBA assays on plasma harvested 6 days after Salmonella infection (3 days after Plasmodium 
infection) show that IFN-γ, IL-6 and TNF remain elevated in Salmonella mono-infected and 
Salmonella + Plasmodium co-infected mice compared to uninfected and Plasmodium mono-












































































Figure 3.6 C57BL/6J mice show elevated expression of Ifn-γ , Il-6, Tnf-α , and Type I IFN responsive genes 
3 days after i.p. injection with 300 CFU Salmonella. Livers were harvested three days after Salmonella 
infection. Gene expression was normalized to Hprt. Data is presented as fold change in expression over 
uninfected controls. RNA extraction and expression analyses were performed by Dr Vanessa Zuzarte Luìs in the 






















































































































































































Figure 3.7 Plasma IFN-γ , IL-6, and 
TNF remain elevated 6 days after i.p. 
injection with 300 CFU Salmonella. 
Mice were injected i.p. with 300 CFU 




infected RBCs or an equal hematocrit of 
uninfected RBCs were given via i.p. 
injection. Plasma cytokine 
concentrations were measured 3 days 
after RBC injection by cytokine bead 
array assay. Bars show mean + SD of 
individual mice from 2 independent 
repeats. Significance was determined by 
T-test, using Welch’s correction. nd = 
not detectable; * p < 0.05; ** p < 0.01; 
**** p < 0.0001 
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Invasive Salmonella infection induces a transient increase in hepcidin production. Liver-
stage Plasmodium growth depends heavily on iron availability. It has been previously shown that 
disturbing iron availability through hepcidin upregulation inhibits Plasmodium liver-stage 
development (156). Hepcidin functions both in the innate immune response and as an iron 
regulatory hormone. In its iron-regulatory function hepcidin is upregulated in response to high 
serum iron levels (232), thereby triggering the internalization and degradation of ferroportin, the 
only known cellular iron exporter (233). Ferroportin is a transmembrane protein most commonly 
found in the plasma membranes of enterocytes, macrophages, hepatocytes, and placental cells, 
where it mediates the export of intracellular iron. Ferroportin’s removal from the plasma 
membrane leads to increased accumulation of intracellular iron in these cell types. Reduced 
ferroportin causes reduced iron uptake from the diet, which occurs via enterocytes, and therefore 
reduces serum iron availability in response to hepcidin (234, 235). In the acute phase 
inflammatory response hepcidin upregulation is induced by infection-associated cytokines, 
including IL-6 (236), with the same downstream effect of reduced serum iron availability. 
Bacterial antigens and Salmonella infection itself induce hepcidin upregulation (236, 237) and 
we hypothesized that this might be a mechanism by which invasive Salmonella infection inhibits 
P. berghei liver-stage growth. Salmonella itself benefits from increased hepcidin and reduced 
ferroportin expression due to its niche within macrophages (157) although this can be 
counteracted by nitric oxide-mediated upregulation of ferroportin (238). We sacrificed 
Salmonella-infected or PBS control mice at 3 days post-infection (in the absence of any 
Plasmodium inoculation) and harvested liver and spleen samples for analysis of hepcidin 
expression by Dr. Natasha Spottiswoode, then at the NIH. In the first run of this experiment we 
saw no change in hepcidin. We therefore extended the experiment to include samples from 4 and 
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5 days, as well as 3 days, post-Salmonella infection. In this run we saw a transient 2.4-fold 
increase in Hamp1, the gene encoding hepcidin, in the livers of Salmonella infected mice 
compared to PBS control mice. This increase was significant at 4 days post-infection but not at 3 




Due to the slight and transient nature of the hepcidin response observed in our experimental 
setup we did not pursue hepcidin further as a potential mediator of Salmonella-induced inhibition 





































*** Figure 3.8 C57BL/6J mice show elevated 
expression of Hamp1 on day 4 post-
Salmonella infection. Livers were harvested 
3, 4, and 5 days after Salmonella infection. 
Gene expression was normalized to Hprt1. 
Data are presented as fold change in 
expression over uninfected controls. RNA 
extraction and expression analyses were 
performed by Dr Natasha Spottiswoode in 
the lab of Dr Patrick Duffy. Bars show mean 
+ SD of 5 per group at each timepoint mice. 
Significance was determined by T-test. ns = 























































































































IgG control + PBS + P. b. (n = 5)
IgG control + S. Tm + P. b. (n = 4)
anti-IFN-αR + PBS + P. b. (n = 5)
anti-IFN-αR + S. Tm + P. b. (n = 5)
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IgG control + S. Tm + P. b. (n = 4)
IgG control + PBS + P. b. (n = 5)
anti-IFN-αR + S. Tm + P. b. (n = 5)
anti-IFN-αR + PBS + P. b. (n = 5)
Figure 3.9 Blocking signaling through IFNαR does not alleviate Salmonella-induced inhibition of 
Plasmodium liver-stage development. A-C: Salmonella-infected and PBS control C57BL/6J mice were 
treated with IgG control antibody or anti-IFNαR neutralizing antibody. Mice were injected i.v. with 10,000 
isolated sporozoites 3 days after Salmonella infection. A: Livers were imaged in vivo 48 hours after 
sporozoite injection. Bars show mean + SD of 2 independent repeats. Significance was determined by paired 
t-test. * p < 0.05. Differences between antibody treatments, within infection conditions, were not significant. 
B: Livers were harvested three days after Salmonella infection. Gene expression was normalized to Hprt. 
Data are presented as fold change in expression over Plasmodium-only, IgG control-treated mice. RNA 
extraction and expression analyses were performed by Dr Vanessa Zuzarte Luìs in the lab of Dr Maria Mota. 
Bars show mean ± SD of 2 independent repeats. C & D: Survival and parasitemia were monitored daily until 
death or until day 7 post P. berghei infection respectively. 
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Salmonella-induced inhibition of P. berghei liver-stage development does not rely on the 
Type I IFN response or on TNF-α . We hypothesized that the upregulation of IFN-γ, Type I 
IFN, or TNF induced by Salmonella infection contributes to inhibition of liver-stage P. berghei 
development. To test this hypothesis with regard to Type I IFN and TNF we used neutralizing 
antibodies to block IFN-αR1 signaling or TNF-α activity, injected i.p. on days -3, -1, and 0 of P. 
berghei infection (300 CFU Salmonella was injected on day -3). For testing the requirement for 
IFN-γ we used IFN-γ-/- mice, as will be discussed in the next section. 
 
Type I IFN. Salmonella-induced inhibition of P. berghei liver-stage development, determined by 
liver-stage parasite burden at 48 hours post-infection with 10,000 P. berghei sporozoites, 
remained intact in mice treated with anti-IFN-αR1 antibody (figure 3.9A). To confirm that our 
antibody treatment was sufficient for a maintained reduction in type I IFN signaling throughout 
liver-stage P. berghei development we compared the expression levels of a panel of type I IFN 
responsive genes in anti-IFNαR1-treated and IgG control-treated mice after analyzing liver and 
early blood-stage parasite burden. In both Salmonella-infected and uninfected mice 250 µg anti-
IFNαR1 treatment on days -3, -1, and 0 of P. berghei infection reduced the expression of all 
genes tested until at least 72 hours post-P. berghei infection (figure 3.9B). The failure of anti-
IFN-αR1 treatment to alleviate Salmonella-induced inhibition of P. berghei liver-stage 
development, in spite of maintained suppression of type I IFN signaling, indicates that the 
reduction in parasite burden is independent of type I IFN signaling. We also saw that even when 
using a lower dose of 150 µg anti-IFN-αR1 neutralizing antibody, again on days -3, -1, and 0 of 
P. berghei infection, survival of Salmonella-free P. berghei-infected mice is improved in anti-
IFN-αR1-treated mice compared to controls (figure 3.9C). This is as expected when considered 
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in the context of previous work demonstrating that IFNαR1-/- mice are partially protected against 
early mortality caused by experimental cerebral malaria (239) and further indicates successful 
inhibition of type I IFN signaling in our anti-IFN-αR1-treated mice. A single experiment testing 
the effect of Salmonella on liver-stage P. berghei growth in IFNαR1-/- mice corroborated the 
neutralizing antibody data, showing Salmonella-induced inhibition of liver-stage P. berghei 




TNF-α. In Salmonella-free mice anti-TNF-α antibody had no effect, compared to non-specific 
IgG control antibody, on P. berghei liver-stage burden 48 hours after injection of 10,000 isolated 
sporozoites (figure 3.11A). However, the inhibitory effect of Salmonella on liver parasite 


































































































Figure 3.10 Liver and blood stage Plasmodium burden following sporozoite inoculation of Salmonella-
infected and PBS control IFNαR1
-/-
 mice. 5 WT Plasmodium-only, 5 WT Plasmodium + Salmonella, 3 
IFNαR1
-/-
 Plasmodium-only, and 4 IFNαR1
-/-
 Plasmodium + Salmonella mice. Bars show mean + SD of 5 
wildtype mice per condition, 3 IFNαR1
-/-
 PBS controls, and 4 IFNαR1
-/-
 Salmonella-infected mice. 
Significance was determined by T-test. ns = not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. There 
were no significant differences between genotypes within the same infection conditions in these 
experiments. 
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is not implicated in Salmonella-induced inhibition of P. berghei liver-stage development. Earlier 
reports have shown that inhibiting TNF signaling increases the susceptibility of mice to live S. 
Typhimurium infection challenge (240, 241). The rapid mortality of anti-TNF-α-treated 
Salmonella-infected mice in our present study therefore supports the use of our antibody 




Heat-killed Salmonella treatment is sufficient to reproduce the inhibitory effect of live 
Salmonella infection, and this inhibition does not rely on IFN-γ . We attempted to determine 
the efficacy of anti-IFN-γ neutralizing antibody-mediated knock-down by measuring cytokines 
in the plasma. Blood was collected by saphenous vein bleeds 3 days after Salmonella infection or 
PBS control injection. Analysis of these samples by cytometric bead array (CBA) assay showed 
increased plasma IL-6, TNF, and IFN-γ, and undetectable IL-10 (figure 3.12); however, this 
Figure 3.11 Blocking TNF signaling does not 
alleviate Salmonella-induced inhibition of 
Plasmodium liver-stage development. A & B: 
Salmonella-infected and PBS control C57BL/6J mice 
were treated with IgG control antibody or anti-TNF-α 
neutralizing antibody. Mice were injected i.v. with 
10,000 isolated sporozoites 3 days after Salmonella 
infection. A: Livers were imaged in vivo 48 hours 
after sporozoite injection. Bars show mean + SD of 2 
independent repeats. Significance was determined by 
paired t-test. * p < 0.05. B & C: Survival and 
parasitemia were monitored daily until death or until 
day 5 post P. berghei infection respectively. Data is 


















































IgG control + PBS + P. b. (n = 9)
IgG control + S. Tm + P. b. (n = 8)
anti-TNF-α + PBS + P. b. (n = 7)
























IgG control + PBS + P. b. (n = 9)
IgG control + S. Tm + P. b. (n = 9)
anti-TNF-α + PBS + P. b. (n = 7)
anti-TNF-α + S. Tm + P. b. (n = 4)
C 
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assay cannot determine activity of these cytokines (for example cytokines may be present at high 
concentrations and yet be inactive if bound by neutralizing antibodies) and more accurate 
assessment of the efficiency of knockdown requires assessment of downstream effectors. As 







































































































































Figure 3.12 The effect of anti-IFN-γ  on plasma cytokine levels. Blood was harvested by saphenous vein bleed 
3 days after injection with 300 CFU Salmonella or PBS control. Cytokine concentration was determined by CBA 




IFN-γ knockdown. IFN-γ -/- mice are highly susceptible to Salmonella infection in our model, 
with the majority of mice dying within 5 days post-Salmonella infection. We made a number of 
attempts in both anti-IFN-γ-  treated and IFN-γ-/- mice to determine the impact of live Salmonella 
infection on P. berghei liver-stage growth. However, there was rapid mortality of Salmonella-
infected anti-IFN-γ-treated and IFN-γ-/- mice before the 48 hour liver-stage Plasmodium burden 
could be determined and the remaining mice were extremely ill. Compared with mice receiving 
IgG control antibody, mice treated with anti-IFN-γ neutralizing antibody showed 50-fold and 3-





























Figure 3.13 Bacterial load is elevated in anti-IFN-γ-
treated mice compared to mice receiving non-specific 
IgG. All mice represented here were infected with 
Salmonella and 3 days later with Plasmodium sporozoites. 
Livers and spleens were harvested 2 days after 
Plasmodium infection. Bars show mean + SD of 4 mice 
per antibody treatment. Significance was determined by T-
test. * p < 0.05. 
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Although the surviving anti-IFN-γ-treated, or IFN-γ-/-, mice tended to show no alleviation of 
Salmonella-induced Plasmodium liver-stage inhibition (figure 3.14) we suspected that the  
  
extreme pathology evident in these mice might have additional inhibitory effects on parasite 
development, compounding those at play in Salmonella-infected IgG control-treated or wild-type 
mice. We therefore decided to test whether we could induce Salmonella-dependent inhibition of 
P. berghei liver-stage growth in wild-type mice by treating with heat-killed Salmonella 
(HKSTm). This would allow us to test whether IFN-γ signaling is required for Salmonella-
dependent inhibition of Plasmodium liver-stage development without inducing such extreme 
pathology. Initial experiments with 1 × 106 or 1 × 107 HKSTm, injected intravenously, produced 
little or no effect on P. berghei liver-stage development, prompting us to increase the dosage. 1 × 
108 HKSTm was chosen as it was the highest dosage that did not cause mortality in any mice. In 
one experiment the dosage of HKSTm was miscalculated such that HKSTm-treated mice 
received 3.25 × 108 HKSTm on the second day of treatment. This likely caused the early death, 
Figure 3.14 The effect of anti-
IFN-γ  on liver stage 
Plasmodium burden following 
sporozoite inoculation of 
Salmonella-infected and PBS 
control mice. IgG control and 
anti-IFN-γ treated mice were 
injected with 300 CFU 
Salmonella or PBS control and 
three days later inoculated via 
i.v. injection with 10,000 
isolated sporozoites. Liver stage 
burden was determined in vivo 
48 hours after sporozoite 
inoculation. Bars show mean + 
SD of 4 independent repeats. * 
p < 0.05; ** p < 0.01. There 
were no significant differences 
between antibody treatment 




































prior to sporozoite injection, of two HKSTm-treated mice in that experiment. 1-3.25 × 108 
HKSTm delivered twice (at 3 days and 2 days prior to sporozoite injection) reduced liver stage 
burden at 48 hours post-sporozoite injection, compared to mice receiving control PBS injections 
(figure 3.15). This inhibition was of a similar degree to that seen following infection with 300 
CFU live Salmonella (figure 3.4). HKSTm treatment therefore provided an appropriate model for 




We found that the inhibitory effect of HKSTm is maintained in IFN-γ-/- mice (figure 3.15), 
indicating that HKSTm-induced inhibition of P. berghei liver-stage development is independent 
of IFN-γ signaling. We performed one CBA assay on plasma harvested by saphenous vein bleed 































Figure 3.15 Heat-killed Salmonella treated inhibits 
Plasmodium liver stage development in both wild-
type and IFN-γ
-/-
 mice. Wildtype (WT) and IFN-γ 
knockout (IFN-γ
-/-
) mice were injected i.v. with 1-3.25 
× 10
8
 heat-killed Salmonella (HKSTm) or PBS control 
on two consecutive days. Three days after the first 
HKSTm injection 10,000 sporozoites were delivered 
via i.v. injection. Liver stage burden was determined in 
vivo 48 hours after sporozoite inoculation. Bars show 
mean + SD of 3 independent repeats. * p < 0.05. 
Differences between genotypes, within infection 
conditions, were not significant. 
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harvested on the day of sporozoite inoculation. These assays showed no change in IL-10 or IL-6, 




Preliminary experiments do not support the hypothesis that Type I and Type II IFNs act 
through redundant mechanisms to mediate Salmonella-dependent inhibition of liver-stage 
Plasmodium development. We considered the possibility that in our model of Salmonella/P. 
berghei co-infection there might be redundancy between Type I and Type II IFN signaling 
pathways contributing to Salmonella-induced inhibition of P. berghei liver-stage development. 
Both Type I and Type II IFNs signal via homodimerization of STAT1 while Type I IFNs can 
also signal through heterodimerization of STAT1 and STAT2 (242). STAT1/STAT2 double 
knockout (STAT1/2 dKO) mice therefore lack both Type I and Type II IFN signaling. We 
conducted a pilot experiment using STAT1/2 dKO mice to test if Salmonella-dependent 




























































Figure 3.16 The effect of low HKSTm dose on plasma cytokine levels. Blood was harvested by saphenous 
vein bleed 3 days after the first of two injections with 10
7
 HKSTm or PBS control. Cytokine concentration was 
determined by CBA assay. Bars show mean + SD of 4 PBS control mice and 3 HKSTm-treated mice. 
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and Type II IFNs. As with IFN-γ-/- mice, STAT1/2 dKO mice are highly susceptible to 
Salmonella infection, requiring this experiment to be done using heat-killed Salmonella 
treatment rather than live Salmonella infection. Heat-killed Salmonella did not significantly 
affect liver-stage P. berghei burden in female STAT1/2 dKO mice, but did reduce parasite 
burden in male STAT1/2 dKO mice (figure 3.17). The sample sizes in this experiment were 
small and further repeats are necessary before meaningful conclusions can be drawn. However, 
these initial results indicate that Type I and Type II IFNs are unlikely to act through redundant 
mechanisms to mediate Salmonella-dependent inhibition of P. berghei liver-stage growth. 
 
Figure 3.17 The effect of heat-killed Salmonella on liver and early blood stage Plasmodium burden 
following sporozoite inoculation in male and female STAT1/2 double knockout mice, compared to wild-
type controls. Wild-type and STAT1/2 double knockout (dKO) mice were injected i.v. with 10
8
 heat-killed 
Salmonella (HKSTm) or PBS control on 2 consecutive days. Three days after the first HKSTm injection mice 
were inoculated via i.v. injection with  2400 isolated sporozoites. Liver and blood stage burden were determined 
in vivo 48 and 72 hours after sporozoite inoculation respectively. Bars show mean + SD of 4 wild-type mice of 
each sex in each condition, 2 PBS control and 4 HKSTm-treated female STAT1/2 dKO mice, and 2 PBS control 





























































































































Live Salmonella infection alters the composition of immune cell populations in the liver and 
spleen. Two major sites of Salmonella infection foci are the liver and spleen. As well as 
investigating changes to the cytokine environment we hypothesized that Salmonella-induced 
changes in the immune cell populations present in these organs might contribute to inhibition of 
Plasmodium liver-stage development. Within the liver this could be, for example, accomplished 
by recruiting phagocytes that directly destroy P. berghei-infected hepatocytes. Conversely, 
proximity to the foci of Salmonella infection in either spleen or liver might further activate 
recruited cells to alter cytokine production levels, which could in turn alter circulating cytokine 
concentrations. Salmonella infection has been shown to induce infiltration of macrophages and 
neutrophils into the liver and spleen (183). Work from other labs has demonstrated a correlation 
between low liver-stage Plasmodium burden and increased numbers of macrophages and 
neutrophils in inflammatory foci surrounding Plasmodium-infected hepatocytes (243). Although 
no direct effect of macrophages or neutrophils on Plasmodium growth was demonstrated, we 
hypothesized that Salmonella infection inhibits P. berghei liver-stage development at the cellular 
level by recruitment of cell types that may be involved in anti-plasmodial defense. We first 
determined whether recruitment of neutrophils and monocytes to the spleen and liver occurs in 
our Salmonella-infected mice within 3 days, such that in our experimental timecourse P. berghei 
sporozoites are introduced into a neutrophil and monocyte-rich environment. In 2 independent 
experiments we saw a 5-10 fold increase in the percentage of leukocytes isolated from the spleen 
and liver that stained with monocyte or neutrophil-specific markers (figure 3.18). Ex vivo 
hepatocyte cultures are capable of supporting Plasmodium liver-stage development following 
inoculation with isolated sporozoites (244). Such a system could be useful for evaluation of 
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whether monocytes and neutrophils from either naïve or Salmonella-infected mice impede 





Figure 3.18 The effect of Salmonella infection immune cell populations in the liver and spleen. C57BL/6J 
mice were injected with 300 CFU Salmonella or PBS control and 3 days later sacrificed to harvest liver and 
spleen. Cells were stained and analyzed by flow cytometry. Bars show median + interquartile range of 4 infected 
and 4 uninfected mice, from 2 independent experiment. Significance was calculated by Mann-Whitney Test. ns = 


























































































































Liver-stage P. berghei infection may promote Salmonella multiplication. Our aim in this 
chapter was to investigate how invasive Salmonella infection impacts P. berghei liver-stage 
development. In pursuing these investigations we made an observation that raised the question of 
whether liver-stage P. berghei infection in turn increases susceptibility to Salmonella infection. 
Although there is solid evidence that blood-stage Plasmodium infection increases susceptibility 
to Salmonella (124, 125), such an effect has, to our knowledge, neither been demonstrated nor 
investigated for liver-stage Plasmodium. In our pilot experiment in which Salmonella-infected 
and PBS control mice received P. berghei sporozoites via infectious mosquito bite we noted that 
all but one of the Salmonella-infected mice died within 2 weeks of Salmonella infection, with the 
remaining mouse dying only 16 days after introduction of the bacteria (figure 3.19). This was 
























Plasmodium only (n = 5)
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Plasmodium only (n = 5)
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Figure 3.19 Pilot experiment 
observation: rapid mortality of 
Salmonella co-infected C57BL/6J mice 
following infectious mosquito feed. 
C57BL/6J mice were injected with 300 
CFU Salmonella or PBS control and 3 
days later exposed to infectious 
mosquito feed. Survival and parasitemia 
were monitored daily following 
Plasmodium infection. Bars show mean 
+ SD of 5 mice per condition. 
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despite none of these mice developing detectable blood-stage parasitemia. Although no 
Salmonella mono-infected control was included this struck us as unusually rapid mortality: in 
previous experiments only 9 out of 26 Salmonella mono-infected mice died within 16 days of 
bacterial infection. Although blood-stage parasites are those that cause the symptoms of malaria 
our observation raised the question of whether liver-stage Plasmodium might be indirectly 
harmful by increasing susceptibility to Salmonella. To test this we repeated the experiment with 
the inclusion of a Salmonella mono-infected control group and sacrificed all mice at 5 or 6 days 
after mosquito feed (8 days after Salmonella infection) to determine bacterial burden. We saw a 
trend towards higher bacterial burden in both liver and spleen for co-infected mice compared to 




At the time of organ harvest there was no detectable blood-stage parasitemia in any of the 




















































































Figure 3.20 Salmonella burden is higher in mice receiving infectious mosquito feed than in those receiving 
uninfectious mosquito feed. C57BL/6J mice were injected with 300 CFU Salmonella and 3 days later exposed 
to infectious mosquito feed or uninfectious mosquito feed control. Livers and spleens were harvested 5 or 6 days 
after mosquito feed. Bars show mean + SD of individual mice from 2 independent experiments. Significance was 
determined by T-test. ns = not significant; *** p < 0.001. 
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Plasmodium mono-infected mice that received infectious mosquito feed in parallel to those 
presented in figure 3.20 did have detectable blood-stage parasites at this timepoint. However, in 
further experiments, which will be discussed in Chapter 4, we discovered that the majority of 
Salmonella-infected mice do eventually develop detectable blood-stage parasitemia (table 3.1). 
We therefore could not be certain that the increased bacterial burden in mice exposed to 
infectious mosquito feed is due to P. berghei liver-stage-induced susceptibility to Salmonella 
rather than to P. berghei blood-stage-induced susceptibility, which may be potent even at sub-
detectable parasitemia. Further experiments using genetically attenuated parasites that are 
incapable of egress from the liver would be beneficial in determining whether P. berghei liver 
stages alone increase susceptibility to invasive Salmonella infection. 
 
DISCUSSION 
The overlap in populations that are at risk of contracting malaria and invasive non-typhoidal 
Salmonella has prompted studies both in the field and in animal models investigating the effect 
of blood-stage Plasmodium infection on susceptibility to Salmonella. Increased susceptibility of 
Plasmodium-infected mice and humans to Salmonella has been solidly demonstrated but no 
studies have undertaken to investigate the inverse relationship (112, 120, 121, 124, 125). A likely 
reason for this bias is that the estimated incidence of malaria infection in 12 countries in Sub-
Saharan Africa is more than 10 times higher than the estimated incidence of invasive Salmonella 
infection, with almost 40 countries having at least equal incidence (1, 197-199). The common 
assumption, therefore, is that one is far more likely to contract the Plasmodium infection prior to 
the Salmonella infection than the other way around. In spite of this, we believe that an 
understanding of the impact of Salmonella on Plasmodium infection is important for two reasons. 
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Firstly, the estimated incidence of Salmonella is likely to be substantially underestimated due to 
technical and economic difficulties associated with diagnosing Salmonella and also due to the 
capacity of Salmonella to establish chronic asymptomatic infections. We have not been able to 
find estimates of incidence or prevalence of such asymptomatic infections although exposure 
levels are high enough in some regions that 100% of people appear to have been infected at some 
point before they are 16 months of age (127). Secondly, several countries in Sub-Saharan Africa 
do have roughly equal estimated incidence of both infections, making either order of infection 
equally likely. Additionally, children living in areas with low levels of Plasmodium transmission 
do not develop strong immunity to the parasites. If these children become infected, they remain 
at high risk of developing severe malarial anemia and cerebral malaria for several more years 
than do children in high transmission areas (245). Understanding the implications of Salmonella 
infection on development of clinical manifestations of malaria is therefore likely to be pertinent 
to these populations. Survival studies revealed implications concerning the effect of Salmonella 
on development of severe malaria and will be discussed in Chapter 4. 
 
In this chapter we have demonstrated that invasive Salmonella infection inhibits liver-stage 
Plasmodium development in mice (figures 3.1 and 3.3). The absence of any detectable difference 
in early liver-stage burden implies that this inhibitory effect acts on parasite growth within 
hepatocytes, rather than on migration to the hepatocytes or initial establishment of infection in 
the liver. Further experiments have allowed us to reject a number of hypotheses as to the 
mechanism of Salmonella-induced inhibition. We focused on potential mechanisms that would 
involve indirect inhibition via induction of host immune responses, rather than on determining 
whether Salmonella competes with Plasmodium for nutrients or produces factors that are toxic to 
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liver-stage Plasmodium. In agreement with work from other labs, we found that live Salmonella 
infection promotes production of several pro-inflammatory cytokines (187, 189) (figures 3.5, 3.6, 
and 3.7). Individual knockdown of two of these cytokine signaling pathways, Type I IFN and 
TNF, did not alleviate Salmonella-induced inhibition of Plasmodium liver-stage development 
(figures 3.9, 3.10, and 3.11), indicating that inhibition is independent of these pathways. 
Knockdown or knockout of IFN-γ mice caused rapid Salmonella-induced mortality, necessitating 
changing our model to using heat-killed Salmonella (HKSTm). IFN-γ-/- mice displayed a similar 
degree of HKSTm-dependent Plasmodium liver-stage inhibition to wild-type mice (figure 3.15), 
indicating that inhibition does not depend on IFN-γ signaling. Preliminary experiments in 
STAT1/2 dKO mice indicated that redundant Type I IFN and IFN-γ-dependent mechanisms are 
also unlikely to be responsible for inhibition of liver-stage growth in our co-infection model 
(figure 3.17). We did not test whether IL-6, which we found to be upregulated in Salmonella-
infected mice, is required for inhibition of P. berghei liver-stage growth. It would be reasonable 
to hypothesize that IL-6 does play a role and this should be tested, ideally in IL-6-/- mice. 
 
In spite of the mechanism being as yet unidentified, the fact that HKSTm treatment can mimic 
the effect of live Salmonella infection implies that inhibition is at least in part via a host response 
to the bacteria rather than due to direct competition or inhibitory interactions between the two 
pathogens. HKSTm clearly cannot invade cells or conduct any of the metabolic processes of live 
Salmonella and therefore occupies a very different niche. It is therefore not possible to determine 
what is an equivalent load of HKSTm to live bacteria in inducing the Salmonella-dependent host 
response that indirectly inhibits liver-stage Plasmodium. The significance of this is that although 
our chosen dosage of HKSTm induced inhibition of liver stage development roughly equivalent 
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to that of live Salmonella, this is not incompatible with there being additional effects of live 
Salmonella infection that are not mimicked by HKSTm treatment. We would therefore be 
interested to examine the impact of live Salmonella infection on availability of glucose and iron 
to Plasmodium-infected hepatocytes, as well as other metabolites that both pathogens depend 
heavily upon. 
 
Glucose can be detected by enzymatic assay (246) by which we could determine whether live 
Salmonella infection in our model alters serum glucose and hence glucose availability to 
Plasmodium parasites in the liver. Salmonella mutants deficient in glucose uptake (220) may be 
a useful tool in determining whether reversing any Salmonella-induced reduction in glucose 
availability alleviates Salmonella-induced inhibition of Plasmodium liver-stage development. 
Such experiments would have to be carefully controlled to take into account the impact of these 
mutations on Salmonella growth rate (220). 
 
Non-heme iron content of hepatocytes can be measured by digesting dried tissues in 
trichloroacetic acid and hydrochloric acid before adding a solution containing 
bathophenanthroline-disulfonic acid, thioglycolic acid, and sodium acetate. The absorbance of 
this mixture, measured at 535 nm, can then be compared to standards of known non-heme iron 
concentration to determine iron content (247). Altered iron availability would not necessarily 
depend on live Salmonella infection: expression of the iron-regulatory hormone hepcidin is 
increased in response to LPS injections in humans (248) and in response to heat-killed Brucella 
abortus in mice (249). A similar upregulation may therefore occur in mice treated with HKSTm. 
Hepatocytes express ferroportin on the cell membrane (250) and thus would be expected to 
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initially accumulate iron following increases in hepcidin. However, the immense iron 
requirements of liver-stage Plasmodium are likely to quickly deplete these stores (251). Elevated 
hepcidin prevents release of iron from intracellular stores and iron uptake from the diet, 
preventing infected hepatocyte iron stores from being replenished and potentially inhibiting 
liver-stage Plasmodium growth. Indeed, upregulated hepcidin has previously been shown to 
inhibit development of liver-stage Plasmodium berghei (156). We found only a slight and 
transient increase in hepcidin expression in the livers of Salmonella-infected mice and did not 
pursue this as a potential mechanism of Salmonella-dependent inhibition of Plasmodium 
development in the liver. Apparently slight changes in hepcidin can however have profound 
effects (Dr Natasha Spottiswoode, personal communication) and hepcidin may yet mediate 
Salmonella-dependent inhibition in our model of co-infection. High-affinity antibodies to human 
hepcidin can be used in mice expressing human rather than mouse hepcidin to efficiently block 
hepcidin function (252). This model could be exploited to determine whether ablating the 
hepcidin response to Salmonella infection prevents inhibition of liver-stage Plasmodium 
development. 
 
Our investigations have concentrated almost exclusively on the role of chemical mediators of 
immunity in Salmonella-induced inhibition of P. berghei infection. However, it is possible that 
inflammatory cells are recruited to foci of Salmonella infection in the liver thus priming cellular 
defense mechanisms prior to introduction of Plasmodium parasites. We produced preliminary 
evidence that the liver environment into which sporozoites are introduced is enriched in 
neutrophils and macrophages, two cell types that have been negatively correlated with 
Plasmodium liver-stage burden. Fully powered studies are necessary to confirm this observation, 
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although our results are in agreement with studies conducted by other labs (183). Transgenic 
mice in which diphtheria toxin receptor is expressed under the control of the CD11b promoter 
(CD11b-DTR) allow for specific ablation of macrophages, achieved upon injection of diphtheria 
toxin (253). Neutrophils can be ablated by repeated anti-Gr-1 antibody treatment (254). These 
two models could be used separately or could be combined (by anti-Gr-1 treatment of CD11b-
DTR mice) to determine whether increased neutrophil and/or macrophage proportions in the 
liver impede liver-stage P. berghei growth in the context of Salmonella co-infection.  
 
Several studies have demonstrated that blood-stage Plasmodium infection increases 
susceptibility of mice to invasive Salmonella infection. All these prior works initiated 
Plasmodium infection through the injection of infected RBCs, but a serendipitous observation in 
the course of our co-infection study suggested that this effect may extend to liver-stage 
Plasmodium also increasing susceptibility to Salmonella. As we have discussed, further 
experiments are required before a conclusion can be drawn. If confirmed, this would be an 
important piece of understanding, especially given the long duration of liver-stage development 
for human Plasmodium species, which takes 6-15 days. Depending on the strength of the effect, 
if any, such knowledge might affect policy in vaccine distribution if live attenuated Plasmodium 
vaccines become available. For example, being aware of an increased risk of invasive 
Salmonella disease could aid swifter diagnosis in patients that are known to have recently 
received such a vaccine. 
 
In this chapter we have presented an outcome of co-infection not previously described, namely 
Salmonella-dependent inhibition of Plasmodium berghei liver-stage development. The 
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mechanism by which this inhibition occurs remains elusive but several avenues of investigation 
have been opened up. Determining the mechanism of Salmonella-induced inhibition is not only 
an academically interesting pursuit but also carries real-world value. Increased understanding of 
the host responses to Plasmodium liver stages and how they may be manipulated has potential 
benefits in guiding vaccine development, treatment regimens, and allocation of resources for 
monitoring patients. 
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CHAPTER 4 - EXAMINING THE IMPACT OF INVASIVE NTS CO-INFECTION ON BLOOD-STAGE 





















Drs. Eric H Ekland and David A Fidock helped to design the experiments. Drs. Eldad A Hod 
and Steven L Spitalnik helped with initial conception of the project.  
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ABSTRACT 
Clinical malaria is caused solely by the asexual blood stages of the Plasmodium life cycle. Blood 
stage Plasmodium infection can be asymptomatic or mild in people who have acquired immunity. 
In those without immunity, however, the symptoms range from fever to life-threatening 
syndromes of severe malarial anemia, metabolic acidosis, or cerebral malaria. Whether a person 
develops mild or more severe disease depends on a combination of host and parasite factors. As 
with liver-stage Plasmodium development, asexual blood-stage parasites are susceptible to 
perturbations in the host environment that may influence metabolite availability or activation of 
host defenses. Parasite burden is not the sole determinant of disease progression and altering the 
host response to the parasites can also have profound effects on the outcome of infection. 
 
In this chapter we again use a mouse model of invasive NTS-Plasmodium co-infection, and 
assess progression of disease following sporozoite infection or parasitized RBC injection. The 
latter mode of infection bypasses liver-stage development, allowing assessment of the direct 
effects of co-infection on blood-stage Plasmodium. In both cases we show that blood-stage 
parasite burden is reduced in NTS co-infected mice. In contrast to liver-stage development, 
however, heat-killed NTS is not sufficient to replicate this reduction, signifying that there may be 
direct competition or toxicity between the two pathogens. Further, we present evidence that, in 
spite of having no effect on parasite burden, heat-killed NTS may prolong survival of 
Plasmodium-infected mice, possibly through preventing development of experimental cerebral 
malaria. This observation mirrors the relatively low prevalence of invasive NTS infection among 
people suffering from cerebral malaria, compared to those suffering from severe malarial anemia, 
and further investigation may advance our understanding of the pathogenesis of cerebral malaria.   
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INTRODUCTION 
We have shown in the previous chapter that invasive Salmonella infection impedes development 
of P. berghei through the liver stages of the life cycle. In this chapter we will discuss the impact 
of invasive Salmonella infection on blood-stage plasmodial disease. Upon completion of 
Plasmodium liver-stage development, parasites exit the liver and enter the blood stream (figure 
1.5). In the blood stream parasites undergo repeated rounds of asexual reproduction within red 
blood cells (RBCs) (with a generation time of 22-24 hours in P. berghei) until the host either dies 
or clears the infection. These blood-stage parasites are the only life cycle stages responsible for 
malarial disease. Where any impact of invasive Salmonella infection on liver-stage Plasmodium 
development may have implications for vaccine design and administration, Salmonella-induced 
changes to blood-stage replication and associated pathology may have implications for clinical 
case management. We therefore undertook investigations to describe the impact of Salmonella 
pre-infection on progression of this phase of infection. Severity of Plasmodium infection is not 
determined solely by parasite burden, although it does play a role: parasite burdens of more than 
4% infected RBCs, or 10% in the absence of evidence of vital organ dysfunction, are considered 
by the World Health Organization to be an indicator of severe malaria in humans, requiring 
urgent treatment (42). Malarial disease also develops through a variety of host responses to the 
parasites that can lead to complications such as severe malarial anemia or cerebral malaria. 
Malarial anemia is not solely due to destruction of parasite-infected RBCs but also follows from 
suppression of erythropoiesis and destruction of uninfected RBCs (58, 59). Similarly, cerebral 
malaria is likely to be exacerbated by local and systemic inflammatory responses and activation 
of brain endothelial cells (62, 255, 256). Bearing these syndromes in mind it is clear that any 
interventions that modulate how the host responds to Plasmodium infection are likely to have 
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implications for progression of clinical disease and such effects would be unlikely to be confined 
to inhibition or promotion of parasite replication. As discussed in the previous chapter, invasive 
Salmonella infection induces an inflammatory response in our mouse model (figures 3.5, 3.6 and 
3.7). All four cytokines or pathways that we found to be upregulated in Salmonella-infected mice 
have been implicated in development of severe malaria. High concentrations of circulating TNF 
have been associated with increased risk of severe malaria, including specifically for cerebral 
malaria, and even higher concentrations have been correlated with greater cerebral malaria 
mortality (62, 255). For IFN-γ, the picture is more complicated, with one study implicating this 
cytokine as being protective against development of cerebral malaria (257). However, in another 
study individuals heterozygous for IFN-γ receptor 1 promoter polymorphisms that dramatically 
alter expression levels (258) were found to be at lower risk of developing cerebral malaria than 
homozygotes of either allele, suggesting that more IFN-γ is not necessarily beneficial (259). A 
possible explanation for the protective effect of heterozygosity over homozygosity with either 
allele is that homozygous individuals of one genotype may be unable to mount a strong enough 
immune response to control the parasite infection, whilst homozygotes of the other genotype 
may mount an excessive response that is itself harmful (259). IFNαR SNP variants have also 
been associated with protection or susceptibility to cerebral malaria (260, 261). Increased IL-6 
concentrations have been found in fatal cases of severe malaria compared to severe malaria 
survivors (262) and also in severe malaria cases compared to uncomplicated malaria (256). The 
latter study also showed that within the group of severe malaria sufferers, IL-6 levels were higher 
in those with cerebral symptoms than those without. Additionally, IL-6 alleles associated with 
lower production of IL-6 during acute phase responses vastly predominate in Western Kenya, 
where severe malarial anemia is common in children (263). The fact that the different IL-6 
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alleles studied appear to be in Hardy-Weinberg equilibrium suggests that this skew towards low 
IL-6-producing alleles is likely attributable to it being a protective adaptation, rather than to the 
predominance of this genotype being a factor in producing the high incidence of severe malarial 
anemia in Western Kenya. From just this small sample of cytokine species, we can see that there 
is a complex balance to be attained: it is crucial to mount a sufficient response to control 
Plasmodium parasite burden but an excessive inflammatory response may predispose malaria 
sufferers to developing life-threatening complications. The multifaceted response to Salmonella 
may tip this balance, either protecting co-infected hosts by increasing protective cytokines or 
threatening co-infected hosts by predisposing them to development of pathogenically extreme 
immune responses. 
 
Malaria control efforts over the centuries have focused not only on clearing parasites from 
infected individuals, but also on reducing transmission between people and populations. Once 
the vector for malaria was discovered, massive efforts were undertaken to eliminate the 
offending mosquito species and otherwise reduce human exposure to them (21). In more recent 
years there have been increasing endeavors to develop transmission-blocking drugs that prevent 
production of gametocytes, the parasite forms that are infectious to mosquitoes, and to determine 
the transmission-blocking capacities of antimalarials in current use (264-268). Gametocyte fate 
determination happens during blood-stage replication (269), leading to a subset of parasites 
exiting the asexual cycle and developing into either male or female gametocytes. In the mosquito 
midgut these sexual forms mature into gametes and fuse to form the zygote from which 
thousands of sporozoites will be produced (270), with the potential to be deposited into a new 
vertebrate host when the mosquito again takes a blood meal. In this way Plasmodium parasites 
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are disseminated through host populations and changing the rate of gametocyte production has 
clear implications for propagation of malaria. A number of host factors enhance gametocyte 
production, including reduced packed cell volume, increased reticulocyte count, and increased 
lymphocyte count (271, 272). These are all parameters with the potential to be influenced by 
Salmonella infection. If Salmonella infection indeed alters gametocyte carriage, and particularly 
if Salmonella co-infection promotes gametocyte production, this may encourage more aggressive 
screening for and treatment of Salmonella infections, both invasive and enteric. 
 
We have adapted our model of co-infection to bypass Plasmodium liver-stage development, 
allowing us to investigate what impact Salmonella co-infection has directly on blood-stage 
parasite replication and progression of disease. We have found that Salmonella co-infection 
inhibits blood-stage population growth in C57BL/6J mice and in spite of there being no such 
reduction in parasite burden in co-infected 129S1/SvImJ mice, they do show increased survival. 
This increased survival echoed observations that co-infected C57BL/6J mice may be protected 
from development of experimental cerebral malaria, warranting further investigation to confirm 




Salmonella infection inhibits P. berghei blood-stage growth, independently of liver-stage 
development. In vivo imaging at 72 hours after P. berghei sporozoite infection, i.e. roughly one 
generation into asexual blood-stage replication, showed an even greater reduction in parasite 
burden caused by Salmonella infection than was seen at the peak of liver-stage parasite burden 
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(48 hours) (figure 3.4). This reduction in peripheral blood-stage parasite burden was maintained 
through subsequent asexual blood-stage replication cycles until the majority of PBS control mice 
died by 7 days after sporozoite inoculation (figure 4.1). This maintained reduction in blood-stage 
parasite burden could be solely due to continued effects of liver-stage inhibition, or may be 
compounded by independent inhibitory effects of Salmonella infection on blood-stage parasite 
population expansion. These two possibilities cannot be discriminated in experiments in which 
 
Figure 4.1 Blood stage parasite burden and survival of Salmonella-infected and PBS control 
C57BL/6J mice following infection with Plasmodium berghei isolated sporozoites. Mice were 
infected with 300 CFU S. Typhimurium on day -3 and inoculated with 10,000 sporozoites on day 0. 
Peripheral parasitemia was monitored daily from day 3 until death. 1 µl of blood was sampled from tail 
veins and stained with SYBRG and MTDR for analysis by flow cytometry. Parasitemia is presented as 
mean + SD of 13 PBS control mice and 12 S. Typhimurium-infected mice, from 3 independent 
experiments. Significance measured by T-test with Welch’s correction: * p < 0.05; ** p < 0.01; *** p < 
0.001. 
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mice are infected via isolated sporozoites or infectious mosquito bite. It is possible, however, to 
initiate Plasmodium infection via transfer of blood-stage parasites harvested from a donor mouse 
to recipient mice, thereby bypassing liver-stage development. To test whether Salmonella   
directly inhibits blood-stage P. berghei population expansion we therefore injected C57BL/6J 
mice with 300 CFU Salmonella or PBS control and 3 days later introduced P. berghei parasites 
via intraperitoneal (i.p.) injection of 106 iRBCs. When plasmodial infection was initiated in this 
way Salmonella-infected C57BL/6J mice showed lower parasite burden, indicating that 
Figure 4.2 Salmonella inhibits blood-stage P. berghei development in C57BL/6J mice 
independently of liver-stage inhibition. Mice were injected i.p. with 10
6
 Plasmodium berghei-infected 
red blood cells 3 days after i.p. injection with 300 CFU S. Typhimurium or PBS vehicle control. Blood 
was sampled daily from tail veins and stained with SYBRG and MTDR for analysis by flow cytometry. 
Survival was monitored daily. Bars show mean + SD of 12 PBS control mice and 11 S. Typhimurium-
infected mice, from 2 independent repeats. Significance measured by T-test with Welch’s correction: * 
p < 0.05; ** p < 0.01; **** p < 0.0001. 
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Salmonella infection does indeed have an inhibitory effect on blood-stage P. berghei 
development (figure 4.2), regardless of whether parasites are required to undergo liver-stage 
development. The rapid mortality seen in co-infected C57BL/6J mice, in spite of reduced 
parasite burden, is likely to be due to increased susceptibility of Plasmodium-infected mice to 
Salmonella infection, as described previously (124, 125). In agreement with these previous 
studies, in experiments in which we included Salmonella mono-infected mice, these controls had 
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***
***
Figure 4.3 Mice co-infected with Salmonella and parasitized red blood cells have reduced survival 
compared to mice infected only with Salmonella. C57BL/6J Mice were infected with 300 CFU 
Salmonella on day 0 and inoculated with 10
6
 parasitized red blood cells on day 3. Survival was 
monitored daily until death or euthanasia based on the clinical score described in table 2.1. Significance 
was determined by logrank test. *** p < 0.001. 8 Salmonella mono-infected mice were censored at day 
16, with 7 mice surviving until termination of the experiment at 26 days post Salmonella infection. 1 
and 3 Salmonella + P. berghei mice were censored at days 15 and 16 respectively, and 1 P. berghei 
mono-infected mouse was censored at day 16. Data are combined from 5 independent experiments. 
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Figure 4.4 Correlation between antibody-mediated staining of reticulocyte surface markers 
versus SYBRG plus MTDR staining in C57BL/6J mice and 129S1/SvImJ mice. Each point 
represents one sample for a single mouse at a single timepoint. Data exclude Plasmodium-infected mice 
as parasites take up the SYBRG and MTDR stains. For C57BL/6J mice y = 0.439x - 0.3725; R
2
= 
0.5850. For 129S1/SvImJ mice y = 0.4159x + 0.1245; R
2
 = 0.7664. 
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Salmonella-infected mice exhibit altered proportions of circulating reticulocytes. We 
noticed that blood samples from Salmonella-infected mice had lower proportions of reticulocytes 
(immature red blood cells, identified by blue staining of red blood cells in Giemsa-stained 
smears, and by intermediate staining of cells in SYBRG and MTDR-  stained flow samples). As 
Plasmodium berghei has a slight preference for infecting reticulocytes (132) we hypothesized 
that this reduction in availability of the preferred host cell might explain Salmonella-induced 
reduction in blood-stage Plasmodium growth. To more precisely identify the reticulocyte 
population we stained daily blood samples with antibodies against three surface markers: Ter119 
(present on immature and mature RBCs (273, 274)), CD71 (present on early immature RBCs 
only (273)), and CD45 (present on all non-erythroid cells arising from hematopoietic progenitors 
(275)). Stained samples were then analyzed by flow cytometry. RBCs were identified as all 
Ter119+CD45- cells, and reticulocytes as the CD71+ cells within this group. Although the 
proportion of cells identified as reticulocytes by antibody staining was lower than that identified 
by SYBRG and MTDR (which label DNA and mitochondria respectively), the two labeling 
methods showed good positive correlation in both mouse strains (figure 4.4). We chose to pursue 
with antibody-based identification as SYBRG and MTDR staining also labels parasitized RBCs, 
confounding our ability to specifically identify reticulocytes in Plasmodium-infected mice. Daily 
measurements showed that C57BL/6J mice infected with 300 CFU Salmonella exhibit an initial 
reduction in reticulocyte proportions between 4 and 8 days post Salmonella infection compared 
to PBS-treated control mice (figure 4.5). From 8 days post-infection onwards the proportion of   
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reticulocytes in Salmonella-infected C57BL/6J mice overtakes the proportion seen in uninfected 
mice and maintains a sustained increase for around one month post-infection (fig 4.5). The 
period within which reticulocyte proportions are reduced in Salmonella-infected mice coincides 
with the time at which parasites first become detectable in the blood stream of mice infected with 
P. berghei three days after Salmonella or PBS control injection. It is therefore possible that 
initial establishment of blood-stage parasitemia is hindered in Salmonella-infected mice due to 
reduction in preferred host-cell availability, although P. berghei can also infect mature red blood 





















































Figure 4.5 Changes in reticulocyte proportions in C57BL6/J and 129S1/SvImJ mice induced by 
Salmonella infection. 15 uninfected and 15 Salmonella infected C57BL6/J mice are shown, from 2 
independent experiments. 5 uninfected and 5 Salmonella infected 129S1/SvImJ mice are shown, from one 




cells. Further experiments in C57BL/6J mice infected with P. berghei several weeks after 
Salmonella infection (i.e. when the proportion of reticulocytes is substantially higher in 
Salmonella infected mice than in PBS controls) gave contradictory results between independent 
experiments. In some cases mice harboring a month-old Salmonella infection did have reduced 
parasitemia compared to controls whereas in others there was no difference between the 
infection groups (figure 4.6). There being either no difference, or a reduced parasitemia in 
Salmonella-infected mice even at a timepoint when reticulocyte proportions in these mice are 
elevated, indicates that reduced reticulocyte numbers are unlikely to be a major factor in 
Salmonella-dependent reduction in parasite growth in mice inoculated with P. berghei 3 days 
after Salmonella infection. A literature review indicated that mice carrying Nramp1 null alleles, a 
category which includes C57BL/6 mice, either die early or start to resolve the Salmonella 
infection roughly one month after inoculation (276). The poor reproducibility of our results 





Figure 4.6 Long-term Salmonella infection had an unreliable effect on Plasmodium blood-stage 
growth in C57BL/6J mice. 3 independent experiments are presented. Pb inf’n = time of Plasmodium-
infected RBC inoculation. In long-term experiment 1 reticulocyte proportions at the point of 
Plasmodium infection were (mean ± SD) 1.336 ± 0.2114 and 1.825 ± 0.0778 for PBS-treated and 
Salmonella-infected mice respectively. In long-term experiment 2 reticulocyte proportions at the point 
of Plasmodium infection were (mean ± SD) 4.048 ± 0.7211 and 11.49 ± 4.978 in PBS-treated and 
Salmonella-infected mice respectively. Long-term experiment 3 reticulocyte proportions at the point of 
Plasmodium infection were not recorded. Parasitemia is presented as mean + SD. 
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129S1/SvImJ mice provide a model for determining the effects of long-term Salmonella 
infection on P. berghei blood stages and disease progression. Viewing the Salmonella-
dependent inhibition of parasite growth mice in the context of peoples at risk of contracting 
invasive Salmonella and malaria, it is important to recognize that the delay between acquiring 
the two infections could also be shorter or much longer than 3 days. Indeed in humans it is 
possible to acquire a subclinical invasive non-typhoidal Salmonella infection that lasts for many 
months, and even years (277), meaning that in endemic areas with high exposure levels there are 
likely to be people harboring long-term invasive Salmonella infections. In hosts that have only 
very recently acquired the Salmonella infection it could be that not enough time has elapsed to 
induce the mechanisms responsible for inhibition of P. berghei growth. Conversely, a host that 
has been harboring a Salmonella infection for several weeks is likely to have mounted an 
adaptive immune response that may create a more or less hostile environment (compared to that 
found early in Salmonella infection) for incoming P. berghei parasites. We will first discuss the 
impact of long-term Salmonella infection on P. berghei blood-stage growth and then address the 
impact of Salmonella infection when it is introduced simultaneously with Plasmodium parasites. 
C57BL/6 mice are susceptible to Salmonella-induced mortality and numbers of mice surviving 
long enough to carry out long-term Salmonella infection experiments were variable. The 
susceptibility of C57BL/6J to Salmonella is due to their lack of a functional Nramp1 allele (276). 
As well as C57BL/6J mice we therefore also included a Salmonella-resistant strain, 
129S1/SvImJ, which carry a functional Nramp1 allele (278). As well as much increased survival 
compared to C57BL/6J mice 129S1/SvImJ mice have the advantage of more reliably establishing 
and maintaining chronic Salmonella infections (179). 129S1/SvImJ mice harboring a long-term 
Salmonella infection did not show any reduction in parasite burden, nor a statistically significant 
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change in survival (figure 4.7). As already mentioned, long-term Salmonella infection had 
inconsistent effects on P. berghei parasite burden in C57BL/6J mice (figure 4.6). 
 
 
Long-term Salmonella infection in 129S1/SvImJ mice did not inhibit P. berghei growth (figure 
4.7). We also found no significant impact of Salmonella infection on survival in 129S1/SvImJ 
mice. However, it is likely that our study lacked sufficient numbers of mice to have the statistical 
power required to detect a difference in survival. Median survival of long-term Salmonella co-
infected 129S1/SvImJ mice was 17.5 days after P. berghei inoculation (interquartile range = 5 
days), twice that of Plasmodium mono-infected controls (median = 8 days, interquartile range = 
14 days).  
Figure 4.7 Long-term Salmonella 
infection in 129S1/SvImJ mice has no 
inhibitory effect on parasitemia. Mice 
were injected i.p. with 10
6
 Plasmodium 
berghei-infected red blood cells 28 or 49 
days after i.p. injection with 300 CFU 
Salmonella or PBS vehicle control. 
Blood was sampled daily from tail veins 
and stained with SYBRG and MTDR for 
analysis by flow cytometry. Survival was 
monitored daily. Differences in survival 
were not statistically significant. Bars 
show mean + SD of parasitemia in 10 
mice per condition, from 2 independent 
experiments. 










































Recently acquired Salmonella infection lengthens survival in 129S1/SvImJ mice in spite of 
having no inhibitory effect on parasite burden. In measuring reticulocyte proportions in 
129S1/SvImJ mouse blood we noted that although these mice show the same prolonged 
elevation in reticulocyte proportions as in C57BL/6J mice, this rise starts earlier, at day 3 or 4, 
and is not preceded by any reduction in reticulocyte proportions (figure 4.5). Given the differing 
reticulocyte responses of 129S1/SvImJ and C57BL/6J mice we were curious about whether the 
impact of short-term Salmonella infection on Plasmodium blood-stage growth is also different. 
In contrast to C57BL/6J mice we saw no reduction in parasitemia in short-term Salmonella-
infected 129S1/SvImJ mice compared to PBS controls (figure 4.8). However, it is of note that 
Salmonella-infected 129S1/SvImJ mice survived longer after Plasmodium infection than did 
PBS controls, in spite of the comparable parasite burden (figure 4.8). This prolonged survival 
may signify a protective effect of Salmonella against development of experimental cerebral 
malaria (ECM), to which both C57BL/6J and 129S1/SvImJ mice are susceptible (142). More 
repeats testing short-term Salmonella/P. berghei co-infection in 129S1/SvImJ mice are necessary 
to determine the reproducibility of prolonged survival. Any equivalent effect in C57BL6/J mice 
may be masked by their greater susceptibility to Salmonella infection and, compounding this, by 
the fact that blood-stage Plasmodium infection itself increases susceptibility of both mice and 
humans to Salmonella infection (112, 120, 124, 125).  However, the prolonged survival of 
Salmonella co-infected 129S1/SvImJ mice mirrored casual observations that Salmonella co-
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infected C57BL/6J mice, in contrast to PBS controls, did not appear to develop symptoms of 
ECM. Most notable in our experiments was the lack of seizures in Salmonella co-infected 
C57BL/6J mice whereas Plasmodium mono-infected controls did develop these symptoms. 
Further experimentation to determine if these observations reflect a true protection of 
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Figure 4.8 Short-term Salmonella infection in 129S1/SvImJ mice prolongs survival following blood-stage 
Plasmodium infection, despite having no inhibitory effect on parasitemia. Mice were injected i.p. with 10
6
 
Plasmodium berghei-infected red blood cells 3 days after i.p. injection with 300 CFU Salmonella or PBS vehicle 
control. Blood was sampled daily from tail veins and stained with SYBRG and MTDR for analysis by flow 
cytometry. Survival was monitored daily. Bars show mean + SD of 14 PBS control mice and 15 Salmonella-
infected mice, from 2 independent experiments. 4 Salmonella-infected mice and 1 PBS control mouse were 




Salmonella-infected mice against development of ECM require careful monitoring and 
quantitation of specific indicators of ECM. These indicators include behavioral changes such as 
paralysis and convulsions, as well as histological changes such as leukocyte adherence to 
cerebral blood vessel endothelium and leakage of the blood brain barrier (142). 
 
Simultaneous delivery of Salmonella with P. berghei has no effect on progression of 
plasmodial disease. As well as testing how long-term Salmonella infection impacts blood-stage 
P. berghei growth we looked at how delivering Salmonella infection on the same day as P. 
berghei alters the course of infection. Two independent experiments were conducted in 
C57BL/6J mice; neither exhibited any significant difference in parasitemia or survival in 
Salmonella-infected compared to PBS control mice (figure 4.9). In one of these two experiments 
it should be noted, however, that the dosage of Salmonella given to the mice receiving the two 
infections simultaneously was miscalculated such that these mice received only 140 CFU 
Salmonella. The lack of inhibition when P. berghei is introduced at the same time as Salmonella 
might occur because time is needed for the Salmonella-induced P. berghei-inhibiting host 
response to become established. Alternatively, this response might only be elicited once the 
bacterial burden is higher. Testing multiple Salmonella dosages in parallel may help to 




Treatment of mice with heat-killed Salmonella may alter the progression of disease caused 
by blood-stage P. berghei. We made two attempts to determine the effect of heat-killed 
Salmonella (HKSTm) directly on blood-stage P. berghei growth, independent of liver-stage 
development. Both attempts were conducted in C57BL/6J mice but they produced starkly 
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B 
Figure 4.9 Salmonella infection delivered simultaneously with Plasmodium infection has no effect 
on parasite burden or host mouse survival. Mice were injected i.p. with 10
6
 Plasmodium berghei-
infected red blood cells immediately after i.p. injection with 140 or 300 CFU Salmonella or PBS 
vehicle control. A: Blood was sampled daily from tail veins and stained with SYBRG and MTDR for 
analysis by flow cytometry. B: Survival was monitored daily. Bars show mean + SD of individual mice, 
from 2 independent experiments. 2 Salmonella-only infected mice were censored from survival analysis 
at day 23 post-infection. 
 
 119 
different outcomes. On the first attempt, 103, 105, or 107  HKSTm were injected intraperitonealy 
3 days and 2 days before i.p. injection of 106 iRBCs. These mice were monitored daily for 
survival and parasitemia. HKSTm-treated P. berghei-infected mice showed no change in 
survival compared to PBS control mice, although mice infected with live Salmonella and P. 
berghei in parallel with those receiving HKSTm survived substantially longer (figure 4.10). Mice 
receiving the highest dose of HKSTm developed peak parasitemia that was roughly two-fold that 
of PBS control mice (p = 0.03), peaking with equal rapidity (figure 4.10). Our second test of the 
impact of HKSTm directly on blood-stage Plasmodium growth followed the same timing, with 
HKSTm injections on days 3 and 2 before Plasmodium infection. However, in this experiment, 
HKSTm was delivered i.v. into the lateral tail vein, rather than i.p., at a dose of 107 HKSTm per 
injection. In this experiment there was no clear difference in parasitemia but HKSTm-treated 
mice survived substantially longer than PBS controls (figure 4.11). Experiments in which mice 
treated with heat-killed Salmonella via i.v. injection were infected with Plasmodium sporozoites 
showed similarly increased survival despite also showing no change in peripheral parasite burden 
(figure 4.12). It is of note that not only did mice treated with HKSTm survive longer than control 
mice but also tolerated much higher parasitemias than control mice before dying. This prolonged 
survival in spite of fulminant parasitemia suggests that i.v. HKSTm-treated mice may be 
protected against development of ECM. Our experiments involving i.v. administration of 
HKSTm therefore support our earlier conjecture that invasive Salmonella infection may protect 
mice against development of ECM. Furthermore, the fact that these bacteria are killed and 
therefore not competing with P. berghei populations suggest that if this effect is real, it is 
indicative of an altered response of the host towards blood-stage parasite infection.  
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Figure 4.10 Heat-killed Salmonella treatment delivered i.p. in C57BL/6J mice did not affect 
survival and may exacerbate parasite burden. Mice were injected i.p. with the stated dosage of heat-
killed Salmonella (HKSTm) over two consecutive days, starting 3 days before injection of 10
6
 
Plasmodium-infected RBCs. Blood was sampled daily from tail veins and stained with SYBRG and 
MTDR for analysis by flow cytometry. Survival was monitored daily. Bars show mean + SD of 
individual mice in one experiment. Numbers of mice are shown in brackets. 
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Figure 4.11 Heat-killed Salmonella treatment delivered i.v. in C57BL/6J mice prolonged survival 
despite having no clear effect on parasite burden. Mice were injected i.v. with 10
8
 heat-killed 
Salmonella (HKSTm) on two consecutive days, starting 3 days before injection of 10
6
 Plasmodium-
infected RBCs. Blood was sampled daily from tail veins and stained with SYBRG and MTDR for 
analysis by flow cytometry. Survival was monitored daily. Bars show mean + SD of individual mice in 
one experiment. The number of mice in each condition is noted in brackets. 
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Figure 4.12 Heat-killed Salmonella treatment delivered i.v. in C57BL/6J mice prolongs survival 
following inoculation with isolated Plasmodium sporozoites, despite having no inhibitory effect on 
parasitemia. Mice were injected i.v. with 10,000 Plasmodium berghei sporozoites 3 days after the first 
of 2 i.v. injections with 10
8
 heat-killed Salmonella (HKSTm) or PBS vehicle control. Blood was 
sampled daily from tail veins and stained with SYBRG and MTDR for analysis by flow cytometry. 
Survival was monitored daily. Bars show mean + SD of 11 PBS control mice and 9 HKSTm-treated 
mice, from 3 independent experiments. 
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Further experiments should first repeat these tests to confirm the initial findings, not only in 
terms of the impact of heat-killed Salmonella on pathogenesis of P. berghei blood stages, but 
also to determine whether there is a real difference between intravenous and intraperitoneal 
delivery. Such a difference would not be unprecedented. Previous work comparing responses to 
Escherichia coli LPS delivered by either intravenous or intraperitoneal injection showed higher 
potency of i.p.-injected LPS in eliciting a TNF response (279). In the Asari et al study (279) rats 
injected i.v. with LPS showed 10-fold higher LPS concentration in arterial and portal vein 
plasma compared to rats injected i.p. In spite of this, serum and peritoneal cavity TNF 
concentrations were 2-fold higher in rats receiving i.p. LPS injections. If the differences between 
injection routes in our HKSTm studies are real, further analysis of the immune responses in 
either group may help to identify the mechanism by which live and heat-killed Salmonella 
prolong survival in specific contexts. 
 
Preliminary experiments showed no impact of Salmonella co-infection on transmission 
from mouse to mosquito. Our investigations thus far have concentrated on the impact of 
invasive Salmonella infection on plasmodial disease within an individual host. On a population 
level we were also interested in how Salmonella infection may alter transmission of P. berghei. 
In order for Plasmodium to be transmitted from the vertebrate host to the mosquito vector 
gametocytes must be produced (figure 1.5). The environmental factors promoting the production 
of gametocytes are poorly defined but parasites may respond to inhospitable host environments 
by altering the proportion of parasites that commit to becoming gametocytes. Whether more or 
fewer gametocytes are produced may depend on the level of stress created by the host 
environment (280). Factors involved in the host response to Salmonella, or competition between 
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the two co-habiting pathogens, might constitute such a stress. For example it is known that 
reticulocytosis promotes gametocytogenesis in certain species that are only slightly reticulocyte 
tropic, if at all (133, 134). Anemia and increased lymphocyte and reticulocyte counts have also 
been shown to promote gametocyte production in P. falciparum infections in humans (271, 272). 
In light of these previous studies we hypothesized that Salmonella co-infection might lead to 
heightened production of gametocytes. We assessed transmission potential in terms of the 
infectivity of P. berghei-infected 129S1/SvImJ mice to mosquitoes taking a blood meal. 
129S1/SvImJ mice were injected with Salmonella or PBS control, followed either three or 49 
days later by i.p. injection of 106 P. berghei-infected RBCs. P. berghei gametocyte production in 
mice is highly variable in terms of both gametocyte conversion rate (the proportion of ring-stage 
parasites developing into gametocytes) and the ratio of male to female gametocytes (Dr. Shahid 
M. Khan and Dr. Chris J. Janse, personal communication). We were therefore advised to initiate 
gametocytogenesis experiments using synchronized blood-stage parasites in an effort to 
minimize variability. Our synchronization attempts involved overnight culture of P. berghei-
infected blood from donor mice. P. berghei parasites can develop to the schizont stage in culture 
but are unable to egress from the red blood cells. We then enriched for parasitized red blood cells 
by magnetic activated cell sorting (MACS), made possible due to the magnetic properties of the 
hemozoin found in trophozoite and schizont stage iRBCs. Infections initiated with these 
synchronized parasites commonly failed to establish detectable blood-stage parasitemia, 
indicating problems with survival of parasites through the synchronization procedure. Removing 
the MACS step of synchronization did not fix the issue and we therefore proceeded with 
unsynchronized parasites for the experiments presented here. 4 or 5 days after P. berghei 
infection(for long-term and short-term Salmonella infection respectively), uninfected Anopheles 
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stephensi mosquitoes were allowed to feed for at least 5 minutes on the co-infected and control 
mice. 13 days after feeding on P. berghei-infected mice the mosquitoes were dissected to 
examine midguts for the presence of oocysts. Oocysts were visualized by fluorescence 
microscopy for their constitutive GFP expression and infection of mosquitoes was recorded as 
the number of oocysts per individual mosquito and as the mean number of oocysts per mosquito 
fed on each individual mouse. We saw no difference in oocyte numbers between mosquitoes fed 
on Salmonella-infected or PBS control mice, in either short-term or long-term Salmonella 
infections (figure 4.13). These experiments were not repeated and require optimization before 
being able to draw reliable conclusions as to the impact of Salmonella co-infection on the 
production of P. berghei gametocytes. It should be noted that some oocysts burst in preparation 
for microscopy, as evidenced by the presence of many free sporozoites. If these experiments 
were to be repeated it would therefore be preferable to reduce the delay between blood feeding 
and midgut dissection, as well as optimizing the protocol for synchronization in order to be able 







In this chapter we have shown that the inhibitory effects of invasive Salmonella infection are not 
limited to liver-stage Plasmodium development. Both blood-stage parasite burden and 
progression of clinical pathologies are reduced, depending on the host mouse strain. Parasite 
burden was decreased only in C57BL/6J mice. Although it is possible that altered reticulocyte 
numbers in Salmonella-infected C57BL/6J mice played a small role in reducing parasite burden 


























































































































































































Figure 4.13 Salmonella infection had no effect on infectivity of Plasmodium-infected 129S1/SvImJ 
mice to mosquitoes. A & B: Mice were injected i.p. with 10
6
 Plasmodium berghei-infected red blood 
cells 3 days after i.p. injection with 300 CFU Salmonella or PBS vehicle control. One experiment. C & 
D: Mice were injected i.p. with 10
6
 Plasmodium berghei-infected red blood cells 49 days after i.p. 
injection with 300 CFU Salmonella or PBS vehicle control. One experiment. A-D: 4-5 days after 
parasite inoculation mosquitoes were allowed to feed on Plasmodium-infected mice for 10 minutes. 
Mosquitoes were dissected 13 days after blood feeding to isolate midguts for visualization of oocysts. 
Bars show mean ± SD. 
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it is very unlikely to be a major factor. The ability of Salmonella infection to increase survival of 
129S1/SvImJ mice independently of parasite burden may make it tempting to dismiss the effect 
on parasite burden in C57BL/6J mice in further experimentation. However, if the same is true for 
human co-infections involving P. falciparum malaria there are implications for both host 
morbidity and also potentially for production of gametocytes and hence transmission of malaria. 
In contrast to our liver-stage investigations, treatment with heat-killed Salmonella (HKSTm), 
regardless of the injection route, did not replicate the reduced blood-stage parasite burden 
achieved by live Salmonella co-infection. It is thus possible that in these P. berghei life cycle 
stages growth inhibition through co-infection is a consequence of nutritional competition or 
toxins produced by live Salmonella bacteria. We have not identified the process by which live 
Salmonella infection reduces blood-stage growth in C57BL/6J mice. We therefore cannot yet test 
whether this process is absent in HKSTm-treated mice or simply reduced or curtailed due to 
there being no maintained Salmonella-induced insult. Further experiments to determine whether 
inhibition of blood-stage Plasmodium growth relies on live Salmonella co-infection should 
repeat those described in this chapter using HKSTm, with an adaptation: repeated daily 
injections until parasite burdens reach sufficient heights to accurately compare infection levels 
between HKSTM-treated and control groups ensure that host responses to the killed bacteria are 
maintained throughout this early stage of infection. If such experiments continue to show no 
effect of HKSTm on parasite burden this would support concentrating further mechanistic 
investigations on those that depend on live Salmonella. Invasive non-typhoidal Salmonella 
infection in humans is commonly accompanied with hypoglycemia (281, 282). This could either 
be indicative of hypoglycemic individuals being more susceptible to Salmonella, or of invasive 
Salmonella infection predisposing the host towards becoming hypoglycemic. If the latter, this 
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should be further tested as a potential mechanism of Salmonella-dependent inhibition of blood-
stage P. berghei growth. Plasmodium blood stages, like liver stages, are heavily reliant on 
glucose availability, to the extent that the P. falciparum hexose transporter has been proposed as 
a viable drug target (283, 284). If Salmonella infection in C57BL/6J mice reduces blood glucose, 
further experiments could test whether replenishing glucose in these animals alleviates inhibition 
of blood-stage parasite population expansion. A four-day regime of glucose infusions is well 
tolerated in mice, resulting in mild sustained hyperglycemia (285). With careful optimization to 
determine the appropriate dosage this intervention could be made use of as a means to replenish 
glucose in Salmonella co-infected mice. 
 
Another potential player in the observed reduction in parasite burden seen in Salmonella co-
infected mice is the increased erythrophagocytic activity of Salmonella Typhimurium-infected 
macrophages (216). The first step in determining whether such a mechanism is at play in our co-
infection model would be to isolate macrophages from the spleen, where parasitized red blood 
cells are cleared from the circulation (286). If the ratio of macrophages-engulfed parasites RBCs 
to parasite density in the blood in increased in Salmonella-infected mice compared to controls 
this would support the hypothesis that Salmonella infection suppresses P. berghei blood-stage 
burden by increasing phagocytic clearance of parasitized RBCs.  
 
Asexual blood-stage replication is the only stage of Plasmodium infection that causes clinical 
symptoms of malaria. Anything that impacts on this stage therefore has clear potential to alter the 
course of malarial disease. The course of disease is not entirely a function of parasite burden, and 
also depends on other host factors responsible for eliciting severe malarial anemia and cerebral 
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malaria. Human cerebral malaria (HCM) is commonly modeled in mice, susceptible strains of 
which develop an overlapping set of symptoms referred to as experimental cerebral malaria 
(ECM). Although the validity of ECM as a model for HCM is controversial, the ethical 
impediments to conducting detailed mechanistic studies in humans and non-human primates 
necessitate the ongoing use of rodent models (136). Even with treatment HCM has a case fatality 
rate of almost 10% in patients treated with artesunate, or 12% in patients treated with quinine 
(287). The pathogenesis of HCM remains incompletely understood and any indications that can 
be gleaned from ECM may be useful in guiding human studies. In our model of co-infection 
increased host survival did not depend on reduced parasite burden, indicating that these two 
effects of Salmonella co-infection are independently realized. As discussed in the introduction to 
this chapter there are a number of cytokines induced in response to Salmonella infection that 
have also been implicated in predisposition to or protection against development of cerebral 
malaria. Equivalent antibody and genetic knockdown experiments as were presented in chapter 3 
should be implemented to determine whether specific cytokine responses are necessary for 
Salmonella-dependent increase in survival. These experiments should be done in conjunction 
with detailed observations and histological analyses to investigate the degree of ECM caused by 
P. berghei infection in Salmonella-infected and Salmonella-free mice, both with and without 
neutralizing antibody or genetic knockdown of implicated cytokines. 
 
It is worth noting that the differing effects of HKSTm on parasite burden in liver versus blood 
stages suggest that these effects are likely caused at least in part by separate mechanisms. Indeed 
even in HKSTm-treated mice that exhibit reduced liver-stage burden compared to controls, early 
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blood-stage burden was equivalent or in some cases greater than in controls (figure 3.16). A 
similar independence of mechanisms may well apply in human co-infections. 
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CHAPTER 5 -  DISCUSSION AND FUTURE PERSPECTIVES 
OVERVIEW 
The burden imposed by malaria on peoples in Sub-Saharan Africa is not in isolation from 
other diseases. Instead, Plasmodium co-exists with a multitude of other pathogens 
including HIV, Mycobacterium tuberculosis, other pathogenic bacterial species, 
Schistosomes, and other parasites, all of which contribute to morbidity and mortality. 
This co-existence creates the potential for individuals to contract multiple infections 
concurrently and indeed, co-infections between P. falciparum and bacteria, parasites, and 
viruses have been described in many field and case studies. When co-infection occurs, 
within-host interactions between the different infectious species, either directly or via 
host responses, can impact the virulence of the pathogens involved, thereby altering 
disease progression and morbidity (288-290). A positive correlation between malaria and 
infections with Salmonella species was noted in 1929 (119) and since at least 1987 there 
has been evidence that malaria causes increased susceptibility to invasive non-typhoidal 
Salmonella (NTS) (120). 
 
Bloodstream NTS infections in Sub-Saharan Africa are estimated to have an incidence of 
at least 0.2-0.4% in children under the age of five, the most susceptible age group (197, 
198). However, it is reasonable to suppose that the prevalence of invasive infections that 
are not detectable in the bloodstream is significantly higher, bearing in mind three 
factors:   
1) High exposure levels to the bacteria - a 2008 study in Malawi found that 100% 
of healthy children aged 16 months to 9 years, with no known history of either 
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Salmonella infection or vaccination, had serum levels of anti-Salmonella antibodies with 
substantial S. Typhimurium killing capacity (127). 
2) The ability of NTS to establish chronic subclinical invasive infections - 
recurrence, as opposed to reinfection, of invasive NTS infections in HIV-positive 
individuals indicates that NTS, like typhoidal Salmonella, is capable of establishing 
chronic subclinical systemic infection (291-293). Additionally, otherwise healthy people 
exhibiting chronic fecal shedding of the bacteria, indicative of liver and gall-bladder 
infection, have been identified (277). 
3) The predominance of the highly invasive NTS serotype ST313 in many sites in 
Sub-Saharan Africa (168). In one study 100% of Malawian isolates and 65% of Kenyan 
isolates were of this serotype (166). 
 
Although it is well established that malaria causes increased susceptibility to invasive 
NTS, the impact of invasive NTS on malaria has as yet been undetermined. Given the 
substantial presence of NTS bacteria in Sub-Saharan Africa, we feel that a significant 
number of Plasmodium infections are likely to occur in individuals already harboring 
invasive NTS infections. Understanding how these invasive NTS infections affect the 
course of plasmodial infection and disease is therefore an important part of tropical health 
and disease research.  
 
Here we present our findings using a mouse model of co-infection, demonstrating that 
live invasive NTS infections and heat-killed S. Typhimurium (HKSTm) induce a host 
response that inhibits progression of both liver and blood stages of P. berghei 
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development. To our knowledge this is the first demonstration of bacterial inhibition of 
Plasmodium liver-stage infection, although in vivo inhibition of Plasmodium blood 
stages by Mycoplasma or by components of Escherichia coli or Coxiella burnetii was 
observed in the 1960s and 70s (294-298). 
 
ALTERNATIVE MECHANISMS OF P. BERGHEI LIVER-STAGE INHIBITION BY INVASIVE NTS 
Previous studies have shown inhibitory effects on progression of liver-stage P. berghei or 
P. yoelii development after prior Plasmodium liver-stage (90, 230) or hepatitis C virus 
(89) infection. In all three of these studies inhibition required functional type I IFN 
signaling. In the case of prior Plasmodium liver-stage infections, an intact IFN-γ response 
was also necessary. In contrast, our current findings show no evidence of a requirement 
for either type I IFN or IFN-γ signaling. It is possible that in our model of S. 
Typhimurium-P. berghei co-infection there is some redundancy between these two 
signaling pathways contributing to Salmonella-induced inhibition of P. berghei liver-
stage development. However, preliminary experiments in STAT1/STAT2 dKO mice, 
which are deficient in both Type I IFN and IFN-γ signaling (242) and in which 
Salmonella-dependent inhibition of P. berghei liver-stage growth is upheld, suggest that 
this is unlikely. We also found no evidence of TNF signaling being necessary for 
inhibition of P. berghei development in invasive NTS-infected mice. In light of our 
results we propose that an entirely distinct mechanism of inhibition might be at play. We 
chose to focus on the roles of type I IFN, IFN-γ, and TNF as they show the most striking 
increases in expression in S. Typhimurium-infected mice compared to controls in our 
model. However, we also saw increased liver expression and plasma concentration of IL-
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6, which has been previously demonstrated as being inhibitory to liver-stage Plasmodium 
development (103). Another acute phase immune response factor that is known to inhibit 
P. berghei liver-stage development is the iron regulatory hormone hepcidin (156). In our 
experimental model we saw a transient two-fold increase in liver hepcidin expression at 4 
days post-S. Typhimurium infection. This increase was not evident at days 3 or 5 post-S. 
Typhimurium infection and therefore was not pursued as a potential mechanism of S. 
Typhimurium-induced inhibition of P. berghei liver-stage development. It is possible that, 
though showing relatively slight increases, either IL-6 or hepcidin is a potent inhibitor of 
P. berghei liver-stage development and might be a key player in the inhibitory effect of S. 
Typhimurium seen in the current study. Another possibility is that Salmonella infection 
boosts the host’s cellular response. Neutrophils, followed by mononuclear phagocytes, 
are recruited to liver foci of Salmonella infection within the first few days (183, 299) and 
a large increase in the proportion of liver leukocytes being neutrophils or macrophages 
was indeed evident in our S. Typhimurium-infected mice. As both cell types have been 
indirectly implicated in aiding clearance of liver-stage Plasmodium (243) their 
heightened presence even before introduction of the parasite may bolster the efficiency of 
cell-mediated defense. 
 
IMPLICATIONS FOR VACCINE DEVELOPMENT AND ADMINISTRATION 
Our finding that invasive NTS infection inhibits P. berghei liver-stage development may 
have implications for vaccine development and administration. One might hypothesize a 
number of contrasting possibilities. Firstly, it has been suggested that the tolerogenic 
properties of the liver might hamper the host’s abilities to mount an adaptive immune 
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response to Plasmodium (300). The pro-inflammatory environment induced by invasive 
NTS infection may counter any such effect, thereby improving vaccine efficacy. Indeed, 
priming mice with live S. Typhimurium infection has previously been shown to enhance 
the antibody response to Plasmodium antigens (301). Conversely, invasive NTS infection 
may have deleterious effects on the efficacy of live-attenuated Plasmodium vaccines, 
which have already completed one phase I clinical trial (153). This could be the case if 
co-infection inhibits liver-stage growth of genetically attenuated parasites, thereby 
reducing the degree of antigen presentation and immunogenicity. Any such effect could 
have implications for potential vaccine administration, for example in targeting periods of 
delivery to avoid rainy seasons when Salmonella transmission is at its highest (162, 302, 
303).  
 
As well as the robust inhibitory effect of invasive NTS infection on liver-stage 
Plasmodium growth we made preliminary observations that suggested liver-stage 
Plasmodium infection may increase susceptibility to invasive NTS. This too has 
implications for vaccine development and administration: if confirmed, vaccines in 
development phases should be tested not only in isolation but also in the context of 
invasive NTS co-infection; if live-attenuated sporozoite vaccines promote invasive 
Salmonella infection this would be another indication to target vaccine delivery to 
seasons with lower NTS transmission. Vaccine development efforts should in general be 
mindful of the potential impact of co-infections, both from the point of view of vaccine 




MECHANISM OF BLOOD-STAGE P. BERGHEI INHIBITION BY INVASIVE NTS 
We have shown that pre-existing invasive S. Typhimurium infection inhibits growth of P. 
berghei blood-stage populations and that this inhibition is lost when live S. Typhimurium 
infection is replaced by treatment with HKSTm. This finding should be further explored 
using longer durations of HKSTm treatment to exclude the possibility that any inhibitory 
effect was simply too short-lived to be evident in our model. However, if true, the loss of 
inhibitory effect on parasite burden when the bacteria are killed indicates that the 
mechanism by which blood-stage growth is inhibited is distinct from the mechanism of 
liver-stage inhibition. IFN-γ, TNF-α, and Type I IFN have all been implicated in blood-
stage parasite clearance, with deficient mice having prolonged clearance times or being 
unable to control Plasmodium blood-stage infections (304-306). It could therefore be 
informative to learn whether our observed S. Typhimurium-induced inhibition of blood-
stage parasite population expansion is lost in mice deficient in these cytokines, either 
through neutralizing antibody treatment or genetic knockout. 
 
DEVELOPMENT OF CEREBRAL MALARIA IN THE CONTEXT OF CO-INFECTION 
Further to the inhibitory impact of live S. Typhimurium infection, we have shown that 
treatment with HKSTm not only inhibits liver-stage parasite development but also 
prolongs survival following infection with P. berghei sporozoites and possibly infected 
RBCs. This prolonged survival cannot be attributed to a reduction in blood-stage parasite 
burden as HKSTm treatment does not replicate this effect and in fact allows mice to 
tolerate much higher parasitemias: the median (interquartile range) of peak parasitemia in 
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PBS controls and HKSTm-treated mice being 5.5% (5.2-10.7%) and 44.5% (26.7-48.0%) 
respectively, p = 0.0009. This suggested to us that HKSTm-treated mice might be 
protected against developing experimental cerebral malaria (ECM), to which C57BL/6 
mice are highly susceptible when infected with P. berghei (192, 307). At first glance this 
appears to be incongruent with field studies in which severe malaria syndromes have 
been associated with invasive bacterial infections including NTS. However, it should be 
noted that bacteremia caused by NTS and other bacterial species is less common in cases 
of cerebral malaria than it is in children with severe malarial anemia (SMA) or cerebral 
malaria plus SMA (123). Previously this has been interpreted as SMA being a stronger 
predisposing factor to invasive bacterial disease than cerebral malaria. However, field 
studies of co-infection cannot determine the sequence in which the infections were 
acquired. Considering this, and in light of our supposition that HKSTm-treated mice may 
be protected against development of ECM, an alternative hypothesis might be that 
invasive bacterial disease is less common in cerebral malaria patients than in SMA 
patients because pre-existing bacterial infections somehow protect against the 
development of cerebral symptoms. Cerebral malaria in humans remains poorly 
understood and is associated with a mortality rate of 10-12% even with treatment (287). 
Understanding mechanisms by which the onset of cerebral malaria might be inhibited 
could help aid development of therapies to protect at-risk individuals. There is 
precedence for co-infecting pathogens having such an effect both in mice and in humans. 
Mice co-infected with Schistosoma japonicum and P. berghei show reduced 
susceptibility to development of ECM compared to Schistosoma-free mice (288). Human 
studies have similarly found the outcome of P. falciparum infection to be modulated by 
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some co-infecting parasites, with Ascaris lumbricoides and P. vivax both apparently 
protecting against development of cerebral malaria (308, 309). As the prolonged survival 
of HKSTm-treated mice occurs in the absence of any change in parasitemia, it is likely to 
be a consequence of a mechanism separate to that responsible for the reduced parasite 
burden. 
 
IMPLICATIONS FOR TREATMENT OF MALARIA 
Current WHO guidelines recommend treating with broad-spectrum antibiotics as well as 
antimalarials in children with suspected severe malaria (42). This multi-drug 
recommendation is necessary because overlapping clinical signs of plasmodial and 
bacterial infections hamper rapid differential diagnosis, and because there is as an 
association between septicemia and some forms of severe malaria. Our data do not argue 
for any change in these recommendations. In contrast to pre-infection with Salmonella, 
mice infected simultaneously with live S. Typhimurium and P. berghei-infected RBCs 
show no reduction in parasite burden compared to Salmonella-free mice, even after 
several days. This implies that S. Typhimurium-induced inhibition of P. berghei blood-
stage growth depends on a delayed host response and would therefore not be a 
consideration in treating current blood-stage Plasmodium infections. Additionally, many 
studies have shown that plasmodial infections in both mice and humans increase 
susceptibility to Salmonella and other invasive bacterial diseases (112, 121, 124, 125, 201, 
310). Given the high mortality rate of blood culture-positive invasive bacterial diseases 
(reports of in-hospital case fatality vary between 10% and 21% for NTS (311-314) and 
between 12% and 33% for invasive bacterial diseases in general (196, 313-315)), 
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clearance of such pathogens should take a high priority regardless of any potential 
inhibitory impact on newly acquired plasmodial infections.  
 
OTHER BACTERIAL SPECIES AND RECENT INVASIVE NTS INFECTION 
In this study we have focused on the impact of invasive NTS infection on the progression 
of plasmodial infection and disease. Populations in Sub-Saharan Africa are also at risk of 
invasive infection from a number of other bacterial species including Streptococcus 
pneumoniae, Staphylococcus aureus, Escherichia coli and Mycobacterium tuberculosis 
(316). Adapting our co-infection model to test whether these other bacterial species have 
similar effects on plasmodial development could help determine how wide-ranging the 
implications of this study are. As of 2013, the WHO’s recommended treatment for 
suspected septicemia was ampicillin plus gentamicin or ceftriaxone alone (317). It would 
be pertinent to determine how a recent, antibiotic-treated invasive NTS infection impacts 
susceptibility to Plasmodium infection and disease progression. This would be important 
both as it pertains to whether the Plasmodium-inhibitory host response to Salmonella 
lasts beyond clearance of the bacteria, and also because antibiotics themselves can 
modulate the immune system (318, 319). A prospective study of people admitted with 
signs of septicemia and treated successfully with these antibiotics, to investigate the 
impact of recent antibiotic-treated invasive bacterial infections on Plasmodium infections, 





UTILITY OF CO-INFECTION STUDIES 
We have presented in this thesis a number of ways in which invasive NTS infection alters 
the progression of Plasmodium infection and disease. Further questions have been raised 
as a result of these investigations concerning the mechanisms by which invasive NTS 
inhibits liver and blood-stage Plasmodium growth, and the mechanisms by which 
HKSTm increases survival in sporozoite-infected mice. The value in pursuing the 
answers to these questions is twofold. Firstly, as exemplified in the investigations 
presented here, this co-infection model serves as a valuable tool in highlighting host 
responses to and defenses against Plasmodium. Discerning the mechanisms by which 
invasive NTS inhibits Plasmodium liver and blood-stage growth and by which HKSTm 
prolongs survival may help to elucidate modes of Plasmodium pathogenesis and highlight 
vulnerabilities in its life cycle to target therapies towards. Secondly, Plasmodium-
invasive NTS co-infections pose a very real risk for populations in Sub-Saharan Africa. 
Understanding the reciprocal relationships between the two diseases may therefore have 
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a b s t r a c t
In the human malaria parasite Plasmodium falciparum, the major determinant of chloroquine resistance, P.
falciparum chloroquine resistance transporter (pfcrt), likely plays an essential role in asexual blood stages,
thus precluding conventional gene targeting approaches. We attempted to conditionally silence the
expression of its ortholog in Plasmodium berghei (pbcrt) through Flp recombinase-mediated excision of
the 30untranslated region (UTR) during mosquito passage. However, parasites maintained pbcrt expres-
sion despite 30UTR excision. Characterisation of these pbcrt mRNAs, by 30rapid amplification of cDNA
ends, identified several replacement 30UTR sequences. Our observations demonstrate the astounding
genetic plasticity of this parasite when faced with the loss of an essential gene.
! 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
Mutations in the Plasmodium falciparum chloroquine resistance
transporter (pfcrt; PlasmoDB ID: MAL7P1.27) play a central role in
resistance of the human malaria parasite, P. falciparum, to several
antimalarial drugs, most notably chloroquine (Petersen et al.,
2011; Roepe, 2011; Ecker et al., 2012; Summers et al., 2012). pfcrt
encodes an integral membrane protein that localises to the para-
site’s digestive vacuole, the site of haemoglobin digestion and chlo-
roquine action. Early secondary structure predictions and
homology modelling predicted that PfCRT is a transporter (Fidock
et al., 2000; Martin and Kirk, 2004), and recent biochemical and
pharmacological studies lend support to the hypothesis that mu-
tant PfCRT can transport chloroquine out of the digestive vacuole
(Summers and Martin, 2010; Baro et al., 2011; Sanchez et al.,
2011; Griffin et al., 2012; Papakrivos et al., 2012). Nevertheless,
more than a decade after its discovery, the native function of PfCRT
remains unknown. Failed gene targeting attempts in P. falciparum
and the mouse malaria parasite, Plasmodium berghei, suggest that
this function is essential, at least in the parasite’s asexual blood
stages (Waller et al., 2003; Ecker et al., 2011). Intriguingly, PfCRT
peptides have also been detected by mass spectroscopy in sporozo-
ites (Florens et al., 2002), an extracellular stage that neither pos-
sesses a digestive vacuole nor digests haemoglobin.
To gain insight into the functional requirement for CRT across
the parasite lifecycle, we made use of a conditional knockout
(cKO) system recently optimised for P. berghei by the Ménard labo-
ratory (Combe et al., 2009; Lacroix et al., 2011). This method is
based on the Flp recombinase/Flp recognition target (Flp/FRT)
site-specific recombination system from yeast, involving Flp
recombinase-mediated recognition of two 34 bp FRT sites leading
to excision of the intervening DNA (referred to as the FRTed se-
quence). For P. berghei, this cKO approach begins by replacing the
endogenous 30untranslated region (UTR) of the targeted gene with
a FRTed sequence comprising a 30UTR sequence from the thrombo-
spondin related adhesive protein (trap; PlasmoDB ID: PBAN-
KA_134980) gene followed downstream by the human
dihydrofolate reductase (hdhfr) selectable marker. This double
crossover homologous recombination event is undertaken in para-
site strains that harbour an integrated copy of Flp recombinase that
is expressed under a mosquito stage-specific promoter such that
passaging of these parasites to Anopheles mosquitoes initiates exci-
sion of the FRTed 30UTR. This leaves the gene of interest with no
30UTR, thereby destabilising transcripts and generating a functional
KO. The power of this cKO system was initially demonstrated by
Combe et al. (2009) who used it to silence msp1 (essential for
parasite invasion of erythrocytes) and uncovered a second role for
this gene in the formation of merozoites in infected hepatocytes.
More recently this system was applied to conditionally silence
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the parasite invasion molecules AMA1 and RON4, revealing that the
former is important only for merozoite invasion of erythrocytes
whereas RON4 is required for sporozoite invasion of hepatocytes
(Giovannini et al., 2011). This system was also used to conditionally
inactivate the P. berghei cGMP-dependent protein kinase (PKG),
leading to the developmental arrest of late liver stage parasites
and the demonstration that these stages can induce potent immu-
nity against sporozoite challenge (Falae et al., 2010).
To conditionally silence the P. berghei ortholog of pfcrt (known
as pbcrt; PlasmoDB ID: PBANKA_121950), we first engineered the
pPbcrt-cKO transfection plasmid to replace the endogenous pbcrt
30UTR with the FRTed trap 30UTR and hdhfr marker (Fig. 1A). Briefly,
the last 0.6 kb of the pbcrt coding sequence was PCR-amplified
using primers p1 + p2 (listed in Table 1); and the first 0.6 kb of
pbcrt 30UTR was amplified using primers p3 + p4. These fragments
were cloned into p30TRAP_hdhfr_FRT (Combe et al., 2009) via SphI
and NotI (for the coding sequence) or HindIII and SphI (for the
30UTR). Notably, our pPbcrt-cKO plasmid unintentionally lacked
the first 12 nucleotides of the trap 30UTR compared with the plas-
mid used by Combe et al. (2009) (see below). SphI-linearised plas-
mid was then electroporated into asexual blood stage parasites of
two ‘‘deleter’’ strains, TRAP/FlpL or UIS4/Flp. These recipient
strains express either Flp recombinase or the thermolabile version
FlpL (Lacroix et al., 2011). In the TRAP/FlpL strain, recombinase
expression is driven by the trap promoter, which becomes active
in maturing oocysts and peaks in salivary gland sporozoites (Rosin-
ski-Chupin et al., 2007). The UIS4/Flp deleter strain controls Flp
expression using the uis4 promoter, which becomes highly upreg-
ulated in salivary gland sporozoites (Matuschewski et al., 2002).
Deleter strain parasites electroporated with the pPbcrt-cKO
plasmid were inoculated into CD-1 (Charles River) mice and sub-
jected to two rounds of in vivo drug pressure with the parasite
B
A
Fig. 1. Generation of Plasmodium berghei chloroquine resistance transporter (pbcrt) conditional knockout (cKO) parasites via 30untranslated region (UTR) excision mediated
by Flp/FRT site-specific recombination. (A) Schematic of the double crossover event between the linearised transfection plasmid and the endogenous pbcrt locus, resulting in
the pre-excision pbcrt-trap 3’UTR locus and the post-excision pbcrt-no3’UTR locus. The structure of the 13-exon pbcrt gene is shown stylistically, with introns in grey and
exons in white. The thick black line denotes the plasmid backbone. Flp, Flp recombinase; FRT, Flp recognition target; trap, thrombospondin related adhesive protein; hdhfr;
human dihydrofolate reductase selectable marker. H, HindIII; N, NotI; S, SphI. (B) PCR analysis of the pbcrt locus pre- and post-excision. The non-excised locus was detected
using primers p5 + p6 (that yield a 1.5 kb band). The excised locus, post mosquito passage, was detected using primers p5 + p7 (yielding a 0.86 kb product), and primers
p1 + p7 (0.73 kb). These primer pairs can also amplify the non-excised locus, yielding 3.1 and 3.0 kb products, respectively, in the pre-excision parasites (the presence of the
0.6 kb band in those lanes and in the post-excision bulk blood stages was determined by sequencing to be off-target amplification of the mouse integrin a-8 gene). Absence of
the wild-type pbcrt locus was confirmed in all recombinant parasites using primers p1 + p4 (that yield a 1.2 kb product in wild-type parasites; data not shown). These primers
yielded a large (> > 3 kb) product spanning the plasmid backbone in the pbcrt-no30UTR locus in post-excision blood stage parasites (this product would theoretically also be
present in sporozoites with an excised locus, but it is difficult to amplify a product of this size from the low yield of parasite genomic DNA that can be obtained from infected
mosquitoes). Excision of the trap 30UTR was not observed in blood stage parasites prior to mosquito transmission, but was evident in midgut and salivary gland sporozoites.
Following transmission to naïve mice, most but not all blood stage parasites had excised the FRTed trap30UTR locus. The re-cloned post-excision parasites T9-rc and U4-rc
harbour the excised locus (pbcrt-no30UTR) exclusively.
970 A. Ecker et al. / International Journal for Parasitology 42 (2012) 969–974
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DHFR-specific inhibitor WR99210 (de Koning-Ward et al., 2000).
This agent selects for double crossover events that have inserted
the FRTed trap 30UTR and the WR99210-resistant human dhfr
selectable marker into the pbcrt target locus (Fig. 1A). Integrants
were detected by PCR and recombinant clones were obtained by
limiting dilution in mice. This cloning yielded pbcrt CKO-TRAP/FlpL
clone 9 and pbcrt CKO-UIS4/Flp clone 4, hereafter referred to as the
clones T9 and U4. All procedures with CD-1 and C57BL/6 (Jackson
Laboratories) mice were carried out in accordance with protocols
approved by the Institutional Animal Care and Use Committee at
the Columbia University Medical Center, USA.
To test whether excision of the FRTed 30UTR would occur as pre-
dicted, the pre-excision T9 and U4 clones were passaged through
Anopheles stephensi mosquitoes. Both clones produced oocysts as
well as midgut and salivary gland sporozoites at normal numbers
and with apparently normal morphology (data not shown). We ex-
tracted genomic DNA from oocysts and salivary gland sporozoites
(harvested from mosquitoes 20–25 days after ingestion of blood
meals harbouring pre-excision blood stage parasites) and assessed
the pbcrt locus by diagnostic PCR and sequencing. PCR analysis of
clone T9 is illustrated in Fig. 1B (analysis of the U4 clone yielded
the same results; data not shown). These data confirmed that exci-
sion of the FRTed trap 30UTR was occurring in midgut sporozoites
and went largely to completion in salivary gland sporozoites
(Fig. 1B; note that the p5 + p6 band specific for the pbcrt-trap30UTR
locus was present in the pre-excision blood stage population but
was almost absent in salivary gland sporozoites).
We also allowed T9- or 6U4-infected mosquitoes to feed on
naïve, anaesthetised C57BL/6 mice in order to test whether pbcrt
post-excision cKO sporozoites (harbouring the pbcrt-no30UTR lo-
cus; Fig. 1A) were infectious. Surprisingly, both the T9 and U4
post-excision parasites were readily transmitted following sporo-
zoite inoculation, with all mice being blood smear-positive on days
5 (T9, three out of three mice) or 7 (U4, four out of four mice; these
mice were not checked on day 5). For comparison, in the same
experiment two out of two mice bitten by mosquitoes infected
with the parental TRAP/FlpL deleter strain (used to generate the
cKO T9 parasites) were smear-positive on day 7, but not on day
5. The majority of the transmitted T9 and U4 parasites appeared
to possess the pbcrt-no30UTR locus, although a small signal for
the non-excised pbcrt-trap30UTR locus was also detected by PCR
(see p5 + p6 lane in post-excision bulk culture; Fig. 1B). We
quantified the excision rate by SYBR Green I (Bio-Rad, USA) quan-
titative PCR analysis using an Opticon2 Real-Time PCR Detector
(Bio-Rad). Primers p8 + p9 were directed to the hdhfr segment of
the FRTed sequence, and primers p10 + p11 were directed to the
reference gene hsp70 (PlasmoDB ID: PBANKA_091440). The per-
cent excision was then calculated based on the 44C(t). This anal-
ysis demonstrated a 99.3% ± 0.2% and 97.1% ± 0.1% loss of the FRTed
30UTR in the transmitted T9 and U4 parasites, respectively
(mean ± S.D., calculated from three mice per line; each sample
was run in triplicate). We note that this high degree of excision
is consistent with earlier reports (Combe et al., 2009).
To obtain a pure population of pbcrt-no30UTR parasites lacking a
30 regulatory sequence, we re-cloned the transmitted parasite
populations by limiting dilution, yielding the post-excision blood
stage clones, T9-rc and U4-rc. PCR analysis confirmed the complete
absence of the FRTed trap 30UTR (Fig. 1B; see absence of band with
p5 + p6). These post-excision clones were passaged by i.v. injection
into naïve mice for closer analysis of their replication fitness com-
pared with the parental deleter strains TRAP/FlpL (for T9-rc) and
UIS4/Flp (for U4-rc). For this experiment, 105 parasites were in-
jected i.v. into naïve C57BL/6 mice (five mice per line in each of
two separate experiments), and their parasitaemias were moni-
tored daily by flow cytometry using the DNA dye SYBR Green I
and the mitochondrial vital dye MitoTracker Deep Red (Ekland
et al., 2011). All four parasite lines revealed essentially the same
progression of infection: a rise in parasitaemia until days 5–6 peak-
ing at !2%, followed by a modest decline for !3–4 days prior to
resurgence of the infection (coinciding with an increase in reticu-
locytes towards which P. berghei is tropic, data not shown; (Fidock
et al., 2004)). Parasitaemias attained 9–12% by day 11 in all lines,
confirming that all lines displayed similar growth kinetics
(Fig. 2A). Given that past failed KO attempts have suggested that
PfCRT and PbCRT are essential, at least in the parasite’s asexual
blood stages (Waller et al., 2003; Ecker et al., 2011), parasite sur-
vival following excision of the 30UTR was surprising.
We suspected that PbCRT expression might somehow be main-
tained in the pbcrt-no30UTR parasites and extracted RNA and pro-
tein to assess whether this was indeed the case. pbcrt mRNA was
readily amplified from both post-excision clones by reverse trans-
criptase (RT)-PCR (results for T9-rc and the pre-excision T9 clone
Table 1
List of primers used in this study.
Name Nucleotide Sequence Description
p1 5’-ccGCATGCTACACCATTGTTAGTTGTATACAAGG Forward primer of pbcrt 3’ coding sequence; SphI site underlined
p2 5’-ttGCGGCCGCTTATGCCCTTGATGTTTCTATAGAAG Reverse primer of pbcrt 3’ coding sequence; NotI site underlined
p3 5’-ccAAGCTTTTGATACAACATTTTTATTTCTTAAATGATTTTTG Forward primer of pbcrt 3’UTR; HindIII site underlined
p4 5’-ccGCATGCCTCTCTATACATAGGCAAATAAGG Reverse primer of pbcrt 3’UTR; SphI site underlined
p5 5’-CATATGTGATAATTTACTTGCTTGC Forward primer of pbcrt upstream coding sequence
p6 5’-CTGGTGCTTTGAGGGGTGAGC Reverse primer from hdhfr selectable marker cassette
p7 5’-CAGGAAACAGCTATGAC Reverse primer specific to the plasmid backbone
p8 5’-GTTGGTTCGCTAAACTGCATC Forward primer for hdhfr qPCR
p9 5’-CTGTTTACCTTCTACTGAAGAGG Reverse primer for hdhfr qPCR
p10 5’-TGCAGCAGATAATCAAACTC Forward primer for hsp70 qPCR
p11 5’-ACTTCAATTTGTGGAACACC Reverse primer for hsp70 qPCR
p12 5’-CCTTATCTCATTATTAGATGCTTCTAC Forward primer for pbcrt RT-PCR
p13 5’-CCAATATTCTTGGTTTTCTTACAGC Reverse primer for pbcrt RT-PCR
p14 5’-TATGGGTCCAAGATATTGTAGTAATAA Forward primer for Plasmodium berghei ama1 RT-PCR
p15 5’-GAATTAGCTTTACCATAAATATCTGC Reverse primer for P. berghei ama1 RT-PCR
QT 5’-CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGC(T)17 Primer to generate cDNA for 3’RACE
QO 5’-CCAGTGAGCAGAGTGACG Outer primer for 3’RACE
QI 5’-GAGGACTCGAGCTCAAGC Inner primer for 3’RACE
SP6 5’-ATTTAGGTGACACTATAG pGEM vector-specific primer to sequence 3’RACE products
M13F 5’-GTAAAACGACGGCCAGT pGEM vector-specific primer to sequence 3’RACE products
ama1, apical membrane antigen 1; hdhfr human dihydrofolate reductase selectable marker; hsp70, heat shock protein 70; pbcrt, Plasmodium berghei chloroquine resistance
transporter; qPCR, quantitative PCR; RACE, rapid amplification of cDNA ends; RT-PCR, reverse transcription PCR; UTR, untranslated region.
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are shown in Fig. 2B; similar results were obtained with U4-rc and
are not shown). PbCRT expression was also upheld in the post-
excision T9-rc and U4-rc clones (Fig. 2C). We cannot quantify levels
of protein expression due to the possible presence of truncated
forms, as discussed below.
We hypothesised that in order to maintain expression without a
30UTR being present in the pbcrt genomic locus, parasites em-
ployed alternative 30UTRs to stabilise pbcrt mRNAs and permit pro-
tein production. To identify any such sequences, 30 rapid
amplification of cDNA ends (30RACE; Scotto-Lavino et al., 2006)
was performed on the transmitted, recloned parasites from both
deleter backgrounds (T9-rc and U4-rc). These 30RACE reactions
produced a single dominant band of just over 0.5 kb in T9-rc, and
several bands of different length in clone U4-rc (ca. 0.25, 0.3–0.4,
0.55, 0.7 and 2.2 kb) (Fig. 3A). These products included the last
0.24 kb of pbcrt plus the alternative 30UTRs. Most of the observed
sizes were therefore consistent with the only previously character-
ised Plasmodium 30UTRs (!0.45 kb for Plasmodium gallinaceum
pgs28 (Golightly et al., 2000) and 0.16–0.25 kb for pfcpna (Wong
et al., 2011)). The 30RACE products were gel-extracted and ligated
into a pGEM-T Easy vector (Promega, USA), and five and 14
pbcrt-specific independent plasmids were sequenced from the
T9-rc and U4-rc reactions, respectively. Fig. 3B illustrates the iden-
tified sequences.
In 30 RACE products from the U4-rc clone, we observed three
different types of mRNA (Fig. 3B). First, in five pGEM-T Easy clones
a poly(A) tail was directly attached to the pbcrt fully spliced coding
sequence upstream of the stop codon. Two different attachment
sites were observed ("10 and "77 nucleotides from the stop
codon) with the resulting PbCRT protein lacking the last four or
26 C-terminal amino acids, respectively. Second, in seven pGEM-
T Easy clones a poly(A) tail was attached to the plasmid backbone
that remained in the pbcrt-no30UTR locus, with attachment sites
observed at either +112, +214 or +448 nucleotides from the stop
codon. In this second set of sequences, therefore, the entire pbcrt
coding sequence was retained, followed by the NotI restriction site
used for cloning the pPbcrt-cKO plasmid, the single FRT site
remaining after site-specific recombination, and 62, 164 or 398
nucleotides of plasmid backbone, respectively. These sequences
were followed by the poly(A) tail. Third, in two pGEM-T Easy
clones a poly(A) tail was attached to an unspliced pbcrt sequence
upstream of its stop codon. This resulted in PbCRT being prema-
turely terminated with the last 58 C-terminal amino acids being
replaced by six different amino acids. These RACE-PCR products
were of mRNA origin, and not due to genomic DNA contamination,
as no product was obtained in a control RACE-reaction that did not
include reverse transcriptase.
For T9-rc, four of the five bacterial clones contained the same
sequence (sequence A), with the fifth bacterial clone containing a
very similar sequence (sequence B). In these sequences the 30end
of pbcrt was followed by an inverted trap 30UTR followed by a
poly(A) tail. Importantly, at the genomic level the T9-rc clone
had the expected arrangement of the pbcrt-no30UTR locus
(Fig. 1A), as assessed by diagnostic PCR and sequencing. This sug-
gests that the pbcrt mRNAs acquired the inverted trap 30UTR se-
quence during the process of transcription. Of note, the P. berghei
A B
C
Fig. 2. Post-excision parasites harbouring pbcrt -no30UTR (Plasmodium berghei chloroquine resistance transporter – no3’untranslated region) show no marked loss of fitness
and express pbcrt transcripts and protein product. (A) Growth kinetics of post-excision (T9-rc and U4-rc) and parental strains (TRAP/FlpL and UIS4/Flp) propagated in mice.
Parasitaemias are shown as means ± S.E.M. calculated from groups of 10 mice per line, plotted as a function of days post infection (p.i.). (B) Reverse transcriptase (RT)-PCR
analysis of pre-excision T9 blood stage parasites and the post-excision clone T9-rc. pbcrt and P. berghei apical membrane antigen 1 (pbama1, PlasmoDB ID: PBANKA_091500)
transcripts were detected from parasite cDNA using primers p12 + p13 (yielding a 0.74 kb band) and p14 + p15 (yielding a 1.0 kb band), respectively. + and " RT denote
reactions with and without reverse transcriptase. (C) PbCRT expression was assayed by western blot hybridisation with saponin-lysed protein extracts from the post-excision
clones (T9-rc and U4-rc) and the parental deleter strains. Membranes were stained for PbCRT using a mouse monoclonal anti-PfCRT hybridoma supernatant (monoclonal
antibody (mAb) CU1711.626 generated against the synthetic PfCRT peptide (KKMRNEENEDSEGELTNVDC), diluted 1:100; Covance, USA) followed by incubation with a
horseradish peroxidase-conjugated sheep anti-mouse IgG (NXA931 diluted 1:10,000; GE Healthcare, USA), and then detected using a chemiluminescent substrate (Pico West;
Thermoscientific, USA). Membranes were then re-probed with rat monoclonal anti-P. berghei AMA1 antibody (mAb 28G2 diluted 1:100; (Kocken et al., 1998)) followed by
incubation with a horseradish peroxidase-conjugated goat anti-rat IgG (NA935 V diluted 1:10,000; GE Healthcare) and detection by chemiluminescence (ECL Plus; GE
Healthcare). Each lane contains protein extract from a separate mouse infected with the indicated parasite line. Differences in band intensity are likely to reflect stage-
dependent variation in levels of PbCRT and AMA1 expression (from samples collected at different times) as well as variable protein loading.
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trap genomic locus is located on chromosome 13, as opposed to
chromosome 12 for pbcrt. Interestingly, the trap gene is positioned
in a tail-to-tail arrangement with PBANKA_134970 (non-anno-
tated), with only 0.6 kb separating the two stop codons. It is there-
fore quite likely that the trap 30UTR is bidirectional and the
inverted sequence might therefore provide a functional 30UTR
when joined onto the 30 end of the pbcrt coding sequence. Interest-
ingly, this inverted trap 30UTR was connected imperfectly to the
pbcrt coding sequence, resulting in a modified PbCRT C-terminus.
In sequence A, the last 15 PbCRT amino acids (NDSEAELTSIETSRA⁄;
where ! denotes the C-terminal end of the sequence) were
replaced with YDHDYAKRAINPH⁄, while in sequence B the
last three PbCRT amino acids (SRA⁄) were replaced with
AMTMITPSAQLTLTKGNKSWSLGGPSIIFVS⁄.
It is worth pointing out that the anti-PfCRT monoclonal anti-
bodies used herein are directed to a C-terminal amino acid stretch
(residues 401–419; (Fidock et al., 2000)) that was lost from
sequence A of T9-rc and from some of the U4-rc alternate mRNA
species (Fig. 3B). Our western blots of clones T9-rc and U4-rc
(Fig. 2C) are therefore qualitative and cannot provide quantitative
assessment of the level to which PbCRT protein expression was
preserved. It is clear, however, that at least some of the alternate
30UTRs identified retain function, both in T9-rc and U4-rc parasites,
such that PbCRT protein can still be produced. Of note, neither T9-
rc nor U4-rc displayed any reduction in growth compared with the
parental lines (Fig. 2A). Given that in P. falciparum a reduction of
PfCRT levels by 30–40% (achieved through truncation of the
3’UTR) resulted in slower growth (Waller et al., 2003), the lack of
a growth phenotype in our pbcrt-no3’UTR clones is further evi-
dence for the ability of the aberrant 3’UTRs to maintain pbcrt
expression.
Of note, we have recently learned that our pPbcrt-cKO plasmid
design differed subtly from plasmids described in the earlier Flp/
FRT reports (Combe et al., 2009; Lacroix et al., 2011) in that our
plasmid was missing the first 12 nucleotides of the trap 30UTR. This
did not appear to affect expression of pbcrt prior to excision, nor
did it impact excision of the FRTed sequence (see Fig. 1), which
was found to be highly efficient at the genomic DNA level by quan-
titative PCR, and was verified by sequence analysis. The lack of this
short sequence stretch constitutes the only difference between our
construct and plasmids used to successfully silence other genes
(Combe et al., 2009; Lacroix et al., 2011), and as such provides a
possible explanation for the production of aberrant pbcrt mRNAs
observed in our post-excision parasites.
In summary, pbcrt expression was maintained following re-
moval of its 30UTR in independent clones derived from two differ-
ent deleter strains. Several alternative 30UTR sequences were
identified (Fig. 3B), underscoring the astounding plasticity of this
parasite at the nucleic acid level. Notably, following mosquito bite
or direct inoculation with post-excision blood-stage parasites,
mice became blood smear-positive with clones T9 and U4 with
no delay compared with the parental deleter lines TRAP/FlpL and
UIS4/Flp, respectively. This suggests that these modified pbcrt
mRNAs are readily generated. We cannot be certain that all of
these mRNAs result in the production of functional PbCRT protein.
However, given the continued expression of PbCRT in both T9-rc
and U4-rc, we are confident that at least some of these alternate
30UTRs are able to sufficiently stabilise pbcrt mRNAs for successful
translation into protein. These sequences may therefore provide
insights into the necessary characteristics of endogenous Plasmo-
dium 30UTRs, which remain largely undefined (Horrocks et al.,
2009). These findings also call for careful molecular analysis of
cKO events based on 30UTR excision, as Plasmodium may adopt
alternative elements to overcome gene silencing. In addition, our
observations demonstrate that the parasite is under enormous
selective pressure to maintain pbcrt expression, consistent with
its protein product having an important or essential function in
the stages following the 30UTR excision process.
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Summary
The successful navigation of malaria parasites
through their life cycle, which alternates between
vertebrate hosts and mosquito vectors, requires a
complex interplay of metabolite synthesis and
salvage pathways. Using the rodent parasite Plas-
modium berghei, we have explored the synthesis
and scavenging pathways for lipoic acid, a short-
chain fatty acid derivative that regulates the
activity of a-ketoacid dehydrogenases including
pyruvate dehydrogenase. In Plasmodium, lipoic
acid is either synthesized de novo in the apicoplast
or is scavenged from the host into the mitochon-
drion. Our data show that sporozoites lacking the
apicoplast lipoic acid protein ligase LipB are mark-
edly attenuated in their infectivity for mice, and in
vitro studies document a very late liver stage arrest
shortly before the final phase of intra-hepatic
parasite maturation. LipB-deficient asexual blood
stage parasites show unimpaired rates of growth
in normal in vitro or in vivo conditions. However,
these parasites showed reduced growth in lipid-
restricted conditions induced by treatment with the
lipoic acid analogue 8-bromo-octanoate or with the
lipid-reducing agent clofibrate. This finding has
implications for understanding Plasmodium patho-
genesis in malnourished children that bear the
brunt of malarial disease. This study also high-
lights the potential of exploiting lipid metabolism
pathways for the design of genetically attenuated
sporozoite vaccines.
Introduction
Despite recent reductions in its morbidity and mortality,
malaria afflicts over 220 million and kills over 600 000
individuals each year (WHO, 2012). Infection begins with
a small inoculum of Plasmodium sporozoites (thought to
be < 100; Medica and Sinnis, 2005) that are delivered into
the host dermis during the blood meal of a female Anoph-
eles mosquito (Amino et al., 2006; Yamauchi et al., 2007).
These sporozoites rapidly migrate to and infect host hepa-
tocytes, where they begin to divide at one of the fastest
rates of cell division known for any eukaryotic cell
(Graewe et al., 2012). This amplification event generates
thousands of daughter parasites that burst from the
infected hepatocytes and invade red blood cells (RBCs),
initiating the pathogenic asexual blood stage cycle (Silvie
et al., 2008). The clinically silent nature of liver stage
infection, its low numbers of infected cells, and the exist-
ence of MHC-mediated antigen presentation in the hepa-
tocyte host cell, make this a very attractive target for the
development of vaccines or chemoprophylactic agents
(Prudencio et al., 2006) that prevent the onset of clinical
manifestations.
To meet the prodigious metabolic demands associated
with the high multiplication rate in the liver, Plasmodium
parasites upregulate a series of de novo synthesis path-
ways including type II fatty acid biosynthesis (FAS-II; Tarun
et al., 2008). The FAS-II pathway generates an eight-
carbon chain precursor (octanoic acid) that is used for the
synthesis of lipoic acid (6,8-thioctic acid), a cyclic disulfide-
containing derivative of octanoic acid that is an essential
cofactor for a number of multi-enzyme complexes found in
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almost all eukaryotic cells (Spalding and Prigge, 2010;
Goraca et al., 2011). In addition to being synthesized de
novo, lipoic acid can also be absorbed from dietary
sources. Cells maintain active systems to scavenge non-
protein bound lipoic acid from their environment (Biewenga
et al., 1997; Shay et al., 2009).
In Plasmodium, covalently attached lipoic acid regu-
lates the function of three a-ketoacid dehydrogenases,
namely pyruvate dehydrogenase (PDH), a-ketoglutarate
dehydrogenase (KGDH) and branched-chain a-ketoacid
dehydrogenase (BCDH). These multi-enzyme complexes
contribute to amino acid and energy metabolism and
consist of multiple copies of a substrate-specific
a-ketoacid decarboxylase (the E1 subunit), an acyltrans-
ferase (the E2 subunit) and a dihydrolipoamide dehydro-
genase (the E3 subunit) (Storm and Muller, 2012). These
a-ketoacid dehydrogenases generally convert an
a-ketoacid, NAD+ and coenzyme A (CoA) to CO2, NADH
and acyl-CoA. E2 subunits include a lipoyl domain that
when bound to lipoic acid acts as a swinging arm to
transfer reaction intermediates between E1, E2 and E3.
Lipoic acid is also attached to the H-protein, a component
of the glycine cleavage system that reversibly decarboxy-
lates glycine (Storm and Muller, 2012). PDH, comprised
of the lipoylated subunit E2 as well as subunits E1 and
E3, is located in the parasite apicoplast, a plastid-like
organelle that performs a variety of metabolic functions
including isoprenoid and fatty acid biosynthesis (Ralph
et al., 2004; Foth et al., 2005). In the apicoplast, PDH is
thought to catalyse the oxidative decarboxylation of pyru-
vate to generate acetyl-CoA (Pei et al., 2010). In contrast
to the PDH complex, components of the other lipoylated
protein complexes are located in the mitochondrion
(Gunther et al., 2005; McMillan et al., 2005; Spalding
et al., 2010). In the mitochondrial organelle, KGDH is
believed to catalyse the oxidative decarboxylation of
a-ketoglutarate to succinyl-CoA as an integral part of the
TCA cycle, whereas BCDH is involved in the degradation
of the branched-chain amino acids valine leucine and
isoleucine (Storm and Muller, 2012).
Plasmodium parasites synthesize lipoic acid within the
apicoplast, where the FAS-II pathway produces octanoic
acid attached to acyl-carrier protein (ACP) as one of its
products (Gunther et al., 2007). The derivation of lipoic
acid from octanoyl-ACP requires two apicoplast-targeted
enzymes: octanoyl-ACP transferase (LipB) and lipoate
synthase (LipA). LipB transfers the octanoyl group to a
lipoyl-accepting domain, whereas LipA is responsible for
catalysing the introduction of two sulfurs at positions 6
and 8, forming the lipoyl group (Fig. 1A). LipA is capable
of generating lipoic acid from the octanoyl-ACP precursor
before or after its transfer by LipB, although it is thought
that LipA prefers the E2 protein-bound substrate. In the
apicoplast, these enzymes mediate the attachment of
lipoic acid to PDH-E2 (Wrenger and Muller, 2004). In the
human parasite P. falciparum, LipB was earlier shown to
be important for lipoylating PDH-E2 but was itself non-
essential to blood stage replication (Gunther et al., 2007).
In that study, LipB-deficient (PfDLipB) parasites were
reported to have an increased growth rate during the
asexual blood stages, a reduced level of lipoylated
PDH-E2 protein, and a reduction in the total lipoic acid
content in the parasite. The lipoate protein ligase LplA2,
which is apparently targeted to both the apicoplast and
the mitochondria, was hypothesized to compensate for
the loss of PfLipB function and to account for the residual
PDH-E2 lipoylation that was observed in those knock-out
(KO) parasites (Gunther et al., 2007).
In addition to the lipoic acid synthesis pathway, Plas-
modium parasites have an active scavenging pathway
that appears to be essential for both blood- and liver stage
development and that has been shown to lead to lipoyla-
tion of KGDH-E2, BCDH-E2 and the H-protein in the
mitochondrion (Allary et al., 2007; Deschermeier et al.,
2012). Host lipoic acid may be imported via the parasite
pantothenate transporter (Saliba and Kirk, 2001; Kirk
and Saliba, 2007; Spalding and Prigge, 2010). Scav-
enged radiolabelled lipoic acid was found to sequester
solely in the mitochondrion and appeared to be attached
to these proteins by the action of lipoic acid protein ligase
LplA1 (Allary et al., 2007). This enzyme can also ligate the
lipoic acid analogue 8-bromo-octanoate (8-BOA), an
antimetabolite that is thought to compete with lipoic acid
as a substrate, thereby inhibiting lipoylation of mitochon-
drial target proteins by irreversibly attaching to their E2
subunits and inactivating the multi-component complexes
(Crawford et al., 2006; Allary et al., 2007). Addition of
8-BOA to P. falciparum asexual blood stage or P. berghei
liver stage parasites cultured in vitro affected their
growth in a dose-dependent manner (Allary et al., 2007;
Deschermeier et al., 2012). The synthesis and scaveng-
ing pathways have generally been considered to operate
separately, with no lipoic acid exchange occurring
between the mitochondrion and apicoplast organelles
(Allary et al., 2007; Gunther et al., 2009).
While the studies with PfLipB suggest that its role in de
novo lipoic acid synthesis is not required for blood stage
growth (Gunther et al., 2007), no study to date has inves-
tigated its requirement for rapid liver stage growth. The
observation that LipA expression is upregulated during
early liver stage development in the rodent parasite
P. yoelii nevertheless suggests an important role for de
novo synthesis (Tarun et al., 2008). Indeed, P. yoelii para-
sites engineered to lack the PDH complex (whose func-
tionality is dependent on E2 lipoylation) were unaffected
in their kinetics of blood stage replication in mice yet were
severely attenuated during the liver stage (Pei et al.,
2010).
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In this study, we have disrupted the P. berghei LipB
gene to determine its essentiality throughout the parasite
life cycle. Our studies reveal that parasites lacking PbLipB
progress unimpeded through the asexual and sexual
blood stages in normal mice and develop normally in the
mosquito, but fail to mature properly during the liver stage
both in vivo and in vitro, indicating a key requirement for
lipoic acid synthesis during intra-hepatic replication. We
also identify an important role for this synthesis pathway
during asexual blood stage replication in host environ-
ments whose exogenous lipid levels have been dimin-
ished, either through the use of lipid-lowering drugs or via
8-BOA mediated blockage of the lipoic acid scavenging
pathway.
Results
Disruption of the LipB gene in P. berghei
To monitor the effect of disrupting lipoic acid synthesis in
Plasmodium parasites, we chose LipB that is known to be
non-essential for asexual blood stage proliferation in
P. falciparum (Gunther et al., 2007), and performed dis-
ruption studies in the rodent species P. berghei (ANKA
strain) in order to examine the entire life cycle. We first
constructed the pL0001-DPbLipB plasmid that carried the
Toxoplasma gondii dhfr-ts selection cassette flanked by 5′
and 3′ untranslated regions (UTRs) from the PbLipB
locus. A linearized DNA fragment containing the selection
cassette flanked by the targeting sequences was then
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Fig. 1. Generation of PbDLipB knockout parasites in Plasmodium
berghei.
A. Schematic representation of lipoic acid synthesis and
scavenging in the Plasmodium apicoplast and mitochondrion
respectively. Enzymes responsible for the synthesis or attachment
of lipoic acid to its target proteins are represented in blue. LipB and
LipA synthesize lipoic acid from the octanoyl-acyl carrier protein
(ACP) precursor generated by the fatty acid biosynthesis type II
(FAS-II) pathway. LipB is responsible for the attachment of
octanoyl-ACP to the E2 subunit of the pyruvate dehydrogenase
(PDH) complex within the apicoplast. LipA is responsible for
creating the thiosulfur bonds. PDH converts pyruvate into
acetyl-CoA, which primes the FAS-II pathway. In the mitochondria,
LplA1 attaches scavenged lipoic acid to a-ketoglutarate
dehydrogenase (KGDH) and branched-chain a-ketoacid
dehydrogenase-E2 subunit (BCDH), which both feed into the
tricarboxylic acid (TCA) cycle, as well as the H-protein of the
glycine cleavage system. Attachment of scavenged lipoic acid can
be inhibited by the analogue 8-BOA that targets the ligase LplA1.
A second lipoate ligase, LplA2, has been localized to both the
apicoplast and the mitochondria.
B. Schematic representation of the replacement strategy used to
delete the PbLipB gene, based on homologous recombination and
double cross-over events between the pL0001-DPbLipB donor
plasmid and the PbLipB genomic locus.
C. PCR confirmation of the PbLipB gene deletion and its
replacement with Tgdhfr-ts. The left panel shows PCR products
specific to the PbLipB coding sequence and its 5′ and 3′ UTRs in
the parental P. berghei ANKA strain. This showed the expected
band sizes of 0.70, 0.76 and 0.98 kb for p1 + p2, p3 + p4 and
p5 + p6 respectively. The right panel shows the replacement of
PbLipB sequence with the Tgdhfr-ts marker in a PbDLipB knockout
clone. This shows the expected band sizes of 1.0, 0.98 and 0.93 kb
for p3 + p7, p6 + p8 and p9 + p10 respectively.
D. Reverse transcriptase (RT)-PCR studies showing the loss of
PbLipB transcription in PbDLipB parasites and the expression of
this gene in asexual blood stages (ABS) and liver stages (LS) in
wild-type (WT) P. berghei ANKA parasites. ‘+’ and ‘–’ denote with
and without RT. Reactions with the LipB-specific primers p1 + p2
showed the expected 0.7 kb transcription product in WT but not in
KO parasites. Control reactions with P. berghei actin I-specific
primers yielded the expected products with both KO and WT cDNA
preparations (data not shown).
Lipoic acid metabolism in the Plasmodium life cycle 1587
© 2013 John Wiley & Sons Ltd, Cellular Microbiology, 15, 1585–1604
 181 
parasites. Transformed parasites were selected using
pyrimethamine. Double cross-over events between the
plasmid and genomic regions of homology were predicted
to result in deletion of PbLipB and its replacement by the
dhfr-ts marker (Fig. 1B; primer locations listed in Table
S1). This was confirmed by PCR assays conducted with
cloned PbDLipB knockout (KO) parasites and the parental
ANKA wild-type (WT) strain (Fig. 1C). The loss of PbLipB
expression in these KO parasites was also confirmed
by RT-PCR with primers specific to the LipB coding
sequence. These assays identified PbLipB transcripts in
liver and asexual blood stages in WT parasites but not in
the PbDLipB clone (Fig. 1D).
P. berghei LipB-deficient parasites maintain
normal asexual blood stage growth rates and
apicoplast development
Earlier studies in P. falciparum reported a modestly
increased rate of proliferation in asexual blood stage
parasites carrying a disruption in the LipB gene. This was
attributed to a slight decrease in the cell cycle duration
(Gunther et al., 2007). To test for a similar phenotype in
P. berghei, we intravenously inoculated either 10 000 or
1000 asexual blood stage parasites from either PbDLipB
or WT parasites into Swiss–Webster mice and monitored
their parasitemia daily by blood smears. Results from
three independent experiments (with 5 mice per strain per
experiment) showed no significant differences in growth
rates at either starting inocula (Fig. 2A and B).
To further characterize the phenotype of PbDLipB para-
sites during the blood stages, we assessed the morphol-
ogy of the apicoplast, the site of lipoic acid synthesis. This
organelle undergoes a striking morphological change
over the course of blood stage development. Beginning
as a compact dot in the ring stage, the apicoplast grows
during schizogony into a highly branched structure that
then segregates into individual daughter cells (mero-
zoites), ensuring its inheritance (van Dooren et al., 2005).
After overnight incubation to generate a greater number
of mature parasites, we identified similar apicoplast
forms between WT and KO parasites in the mixed blood
stage parasite population. Immunofluorescence assays
with apicoplast-specific anti-ACP antibodies revealed no
evident difference in the morphology of this organelle
between WT and LipB-deficient asexual blood stage para-
sites (Fig. 2C; Fig. S1).
Parasites lacking PbLipB show reduced lipoylation
of apicoplast and mitochondrial a-ketoacid
dehydrogenases
We determined the effect of PbLipB deletion on parasite
protein lipoylation by Western blot analysis using lipoic
acid-specific antibodies. Results showed markedly
reduced levels of lipoylated PDH-E2 (estimated at
84% reduction) in the LipB-deficient parasites compared
with the WT control (Fig. 2D). This result is consistent
with the proposal that LipB lipoylates PDH-E2 within
the apicoplast (Gunther et al., 2007). We note that
PbLipB contains an apicoplast-targeting motif as pre-
dicted by PlasmoAP (Foth et al., 2003) and PDH-E2 is
the only protein within the apicoplast that is known to
require lipoylation (Foth et al., 2005). The other three
proteins known to be lipoylated in Plasmodium are
BCDH-E2, KGDH-E2, and the H-protein, which appear
to localize to the mitochondria (Gunther et al., 2005;
Spalding et al., 2010). These proteins were predicted to
be lipoylated by the mitochondrial ligases LplA1 or LplA2
(Wrenger and Muller 2004). Surprisingly, we found a
substantial reduction in lipoylation of the BCDH-E2
protein (estimated at 98% reduction from overexposed
Western blot images) in the PbDLipB parasites com-
pared with WT (Fig. 2D), suggesting that LipB also con-
tributes to BCDH-E2 lipoylation in P. berghei. In contrast,
KGDH-E2 lipoylation levels appeared unaffected by the
loss of LipB. We note that this assay did not detect
lipoylated forms of the 26 kDa H-protein, which is known
to be difficult to detect because of its low abundance
(Allary et al., 2007).
Given the reduced degree of lipoylation of BCDH-E2 in
PbDLipB parasites, we sought to investigate whether this
protein might also localize to the apicoplast. This was
tested by generating a P. berghei line in which gfp was
integrated into the 3′ end of the coding sequence of the
bcdh gene, using Tgdhfr-ts as a selectable marker for
homologous recombination and single site cross-over.
Live-cell imaging of BCDH–E2–GFP parasites stained
with MitoTracker Red localized this fusion protein to the
mitochondria (Fig. 2E). In contrast, BCDH–E2–GFP did
not colocalize with the apicoplast, which was visualized
using anti-ACP antibodies (Fig. 2F). These findings
suggest that LipB might be responsible for the lipoylation
of the mitochondrial protein BCDH-E2, and evoke the
possible movement of lipoic acid from the apicoplast to
the mitochondria. An alternative explanation would be that
LipB, which has a N-terminal bipartite peptide that is pre-
dicted to traffic this protein to the apicoplast, could in part
also traffic to the mitochondria. Experiments are under-
way to localize LipB by either GFP tagging or the use of
polyclonal antisera.
Inhibition of lipoic acid scavenging with 8-BOA results
in a decrease in asexual blood stage replication of
PbDLipB parasites
Our evidence suggesting that deleting the apicoplast-
targeted octanoyl-ACP transferase may be impacting the
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Fig. 2. PbDLipB parasites show normal kinetics of blood stage replication but show reduced lipoylation of parasite dehydrogenases.
A and B. Blood stage growth kinetics of PbDLipB and parental wild-type (WT) strains, in mice inoculated with 10 000 or 1000 asexual blood
stage parasites. Five mice were infected with each strain and the experiment performed on three occasions. Mean parasitemias were
calculated from each experiment and used to determine the average ! SEM shown here for each day post inoculation. Mann–Whitney U-tests
showed no significant differences in growth kinetics between the two strains.
C. Apicoplast morphology in WT and PbDLipB asexual blood parasites. These parasites were collected from infected mice, allowed to mature
overnight in vitro, fixed, and stained with ACP-specific antibodies that label the apicoplast as well as DAPI that stains the nucleus. Microscopic
examination revealed no significant difference in apicoplast morphology between these strains.
D. Western blot analysis of WT and PbDLipB parasite protein extracts (16 mg per lane) labelled with antibodies specific to lipoic acid. PDH-E2,
pyruvate dehydrogenase E2 subunit; BCDH-E2, branched-chain a-ketoacid dehydrogenase E2 subunit; KGDH-E2, a-ketoglutarate
dehydrogenase E2 subunit. The membrane was stripped and re-probed with antibodies specific to P. falciparum Hsp70 as a loading control.
Data are presented as one representative image from three independent experiments. BCDH-E2 was detected in the PbDLipB parasites at
longer exposures (data not shown). Based on band intensity quantification (using ImageJ; NIH), we estimated that lipoylated PDH-E2,
BCDH-E2 and KGDH-E2 were present in the LipB-deficient parasite at 16%, 2% and 98% of WT, normalized for loading based on the
intensity of Hsp70 labelling.
E. The BCDH-E2 protein localizes to the mitochondria in blood stages. Parasites expressing BCDH–E2–GFP fusion proteins were stained with
MitoTracker Red, revealing colocalization with the mitochondrial dye.
F. The BCDH-E2 protein is not localized to the apicoplast. BCDH–E2–GFP parasites were fixed and stained with anti-ACP antibodies to
identify the location of the apicoplast, which did not localize with BCDH-E2. White bar, 10 mm (for all panels in this Fig.).
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lipoic acid supplied to the mitochondrial protein BCDH-E2
led us to test whether PbDLipB and WT parasites differed in
their susceptibility to chemical inhibition of lipoic acid scav-
enging. For this we used the lipoic acid analogue 8-BOA
that is known to competitively inhibit the ligation of scav-
enged lipoic acid to its target a-ketoacid dehydrogenases
within the mitochondria (Morris et al., 1994; Allary et al.,
2007). 8-BOA is attached to enzymatic complexes by the
scavenge pathway machinery; LplA1 protein attaches the
antimetabolite in place of lipoic acid, rendering the com-
plex metabolically inactive. 8-BOA inhibits the growth of
P. falciparum asexual blood stage parasites by 70% at
~ 100 mM after 96 h of parasite exposure (Allary et al.,
2007) implying that scavenging of host lipoic acid is impor-
tant for parasite blood stage proliferation. To assess the
effect of short-term 8-BOA treatment on P. berghei replica-
tion, we collected WT and PbDLipB parasites from infected
mice, and cultured these in vitro for 15 h in the presence of
8-BOA (at concentrations of 100, 200 or 400 mM). Para-
sites were then reinjected into naïve mice (10 000 per
mouse) to determine blood stage growth kinetics, without
any further 8-BOAtreatment. Experiments were performed
on three independent occasions with five mice per group
per experiment and parasitemias monitored daily once the
infections became patent. We note that the asexual blood
stage cycle of P. berghei is 24 h.
Treatment of WT parasites with 8-BOA resulted in a
modest reduction in parasitemia that generally attained
statistical significance only at the highest inhibitor concen-
tration (400 mM) and only in the first three days following
the onset of patent infections (Fig. 3A). In comparison,
8-BOA treatment showed a greater effect against LipB-
deficient parasites, which showed significant decreases in
parasitemia compared with DMSO-treated controls at the
two higher concentrations for each day of monitoring
(Fig. 3B). One explanation for these different blood stage
growth kinetics of WT and LipB-deficient parasites treated
with 8-BOA would be that apicoplast-generated lipoic acid
might provide an important supplement for parasite
growth. Specifically, synthesized lipoic acid might function
to outcompete the 8-BOA present in the cell and the loss
of de novo lipoic acid synthesis would shift the balance
towards 8-BOA, generating a greater impact on parasite
replication. These results suggest that the loss of LipB in
the apicoplast is impacting the level of lipoic acid through-
out the parasite, allowing mitochondrial enzymes to be
more susceptible to inactivation by conjugation with the
antimetabolite. Alternatively, KO parasites might contain
relatively less BCDH-E2 protein, although our RT-PCR
analyses revealed similar levels of BCDH-E2 transcripts
between WT and KO lines (data not shown). There also
remains the possibility that LipB is partially localized within
the mitochondria, despite its evident apicoplast-targeting
motif.
PbDLipB parasites demonstrate reduced blood
stage growth rates upon reduction of host serum
lipid concentrations
To test whether perturbation of host lipid levels would
exacerbate the effect of PbLipB deletion and potentially
reveal a blood stage phenotype, we lowered the levels of
circulating lipids through the use of clofibrate. This pre-
scription medicine activates the peroxisome proliferator-
activated receptor-alpha in the liver, thereby inducing
peroxisome biogenesis. This activation results in
increased beta-oxidation of lipids and lowers the levels of
cholesterol, triglycerides and non-esterified fatty acids
(NEFA) circulating in the serum (Fruchart et al., 1999;
Wheelock et al., 2007).
We treated mice daily for 9 days with 0, 0.5 or
5.0 mg kg-1 clofibrate, administered intraperitoneally.
Mice were then rested for 5 days and the plasma was
sampled to measure triglyceride and NEFA levels. Five
mice were tested per group and the experiment was per-
formed on three independent occasions. NEFA values
in the three separate experiments were reduced by an
average of 21.3 ! 6.3% and 37.2 ! 17.9% (mean ! SD)
in mice treated with 0.5 and 5.0 mg kg-1 clofibrate respec-
tively. Triglyceride values were only measured in the two
latter experiments and were reduced by an average
of 19.8 ! 4.6% and 27.8 ! 5.3% (mean ! SD) in the
0.5 and 5.0 mg kg-1 groups respectively. These results
confirm the lipid-lowering properties of clofibrate.
Five days following the cessation of clofibrate treatment
(i.e. the day of plasma sampling), mice were inoculated
with 10 000 blood stage parasites and parasitemias were
monitored daily by blood smear. We observed a statisti-
cally significant, dose-dependent reduction in the rate of
blood stage parasite growth among WT parasites in
treated mice for each day of monitoring (Fig. 3C). This
effect was noticeably greater with the KO parasites,
exemplified by the lack of detectable parasitemias by day
seven in clofibrate-treated mice as compared with a mean
parasitemia of 7% in DMSO-treated controls (Fig. 3D).
This significant reduction was maintained in subsequent
days.
To test whether clofibrate treatment might have affected
reticulocyte numbers, and skewed the rate of growth of
reticulocyte-tropic parasites, we repeated the clofibrate
dosing regimen with once-daily dosing for nine days, and
sampled whole blood via tail vein collection on days 0, 3,
6, 9 and 14. Reticulocyte densities were measured by
labelling cells with antibodies specific to the reticulocyte
surface marker CD71 and the erythroid cell surface
marker Ter119, and counting cells by flow cytometry.
Results showed no significant impact of clofibrate on
reticulocyte densities, which ranged from an average of
1.6–2.1% over time in mice administered clofibrate (0.5 or
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5.0 mg kg-1 daily) or DMSO vehicle as a control (12 mice
per group; Table S2). These data are consistent with
clofibrate exerting an effect on LipB-deficient parasites as
a result of its lipid-lowering properties.
Taken together, our 8-BOA and clofibrate results
provide evidence that P. berghei parasites utilize circulat-
ing host lipids during blood stage growth and that lipid
depletion impacts parasite growth. These data suggest
that the LipB-deficient parasites are more dependent on
scavenging host lipid species, and support the hypothesis
that the apicoplast lipoic acid de novo synthesis pathway
provides an important substrate for asexual blood stage
growth in conditions where host lipids are limited.
PbDLipB parasites do not demonstrate a discernible
phenotype during mosquito stage development
Prior investigations into the effect of LipB disruption on
P. falciparum assessed only asexual blood stage growth
(Gunther et al., 2007). To assess whether disruption of the
LipB gene had any major impact on the mosquito stages
of Plasmodium, we fed mosquitoes on mice infected with

































































































Fig. 3. Blood stage PbDLipB parasites display reduced growth rates following inhibition of lipoic acid scavenging from the host or reduction of
host lipid levels with clofibrate.
A and B. Effect of 8-BOA on growth rates of LipB KO and WT asexual blood stage parasites. (A) P. berghei WT or (B) PbDLipB parasites
were treated with concentrations of 100, 200 or 400 mM 8-BOA or DMSO control during overnight in vitro incubations, followed by injections of
10 000 parasites into each mouse. Parasitemias were monitored daily, and are presented as means ! SEM of three independent experiments
each with 5 mice per group. The 8-BOA treatments showed a dose-dependent effect and a stronger impact on the PbDLipB parasites than on
the WT control. Tests for significance employed the Mann–Whitney U-test that compared parasitemias between the groups of 15 mice injected
with parasites that were untreated, versus those injected with parasites treated at a given 8-BOA concentration. *P < 0.05; **P < 0.01;
***P < 0.001.
C and D. Mice were treated with either 0.5 mg kg-1, 5.0 mg kg-1 of clofibrate or DMSO as vehicle control prior to inoculation with either
P. berghei ANKA or PbDLipB parasites. Untreated controls showed TG and NEFA mean ! SD concentrations of 0.17 ! 0.03 and
0.16 ! 0.06 mM respectively (n = 30). Parasitemias were monitored daily for 9 days and are represented as the averages ! SD of three
independent experiments each with 5 mice per group. Statistical tests employed the Mann–Whitney U-test that compared DMSO-treated
controls with each clofibrate concentration. **P < 0.01; ***P < 0.001.
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WT or PbDLipB parasites, dissected salivary glands and
viewed midguts for the presence of oocysts on day 21
post blood meal by phase-contrast microscopy. This
experiment was performed on three separate occasions,
and sporozoite numbers were calculated from groups of
5 to 20 mosquitoes per parasite strain. We observed
mean ! SD sporozoite loads of 15 313 ! 8055 and
13 611 ! 6286 for the WT and KO respectively. These
assays indicate that the loss of LipB did not noticeably
impair parasite development in the Anopheles mosquito
vector, and provide evidence that normal levels of
lipoylated protein are not required for P. berghei develop-
ment within the mosquito host.
PbDLipB pre-erythrocytic stage parasites display
reduced infectivity in vivo
To test whether disruption of LipB impacted the progres-
sion of Plasmodium sporozoites through the liver, we
inoculated mice with KO or WT sporozoites, and meas-
ured the pre-patent periods. For these experiments we
used female C57BL/6 mice, which are highly susceptible
to P. berghei infections (Scheller et al., 1994; Yu et al.,
2008). The pre-patent period, defined as the number of
days until detection of parasites in the blood stream, dem-
onstrates the ability of sporozoites to establish infection
and complete liver stage development in the mammalian
host. Sporozoites were dissected from salivary glands of
infected mosquitoes and injected by intravenous injection
into C57BL/6 mice. Using inocula of either 10 000 or 1000
sporozoites, we consistently saw a delay in the pre-patent
period with the PbDLipB sporozoites (Table 1). Only 2 of 9
mice developed a blood stage infection following inocula-
tion with 1000 PbDLipB sporozoites, as compared with all
mice becoming infected with the same dose of WT spo-
rozoites. Furthermore, the mice that became infected with
the KO parasites showed a 4-day delay in the pre-patent
period compared with those infected with WT parasites. At
an inoculum of 10 000 sporozoites, all mice infected with
the PbDLipB strain developed a blood stage infection, but
with a marked increase in the pre-patent period (from an
average of 3.0 days with the WT strain to 7.6 days with the
KO strain). It has been stated in the literature that a
one-day delay in patency roughly signifies a 10-fold
decrease in sporozoite infectivity (Gantt et al., 1998).
Overall, these data suggest that PbLipB is important for
normal liver stage development in P. berghei. In light of
our findings, we suggest that the ability of some LipB-
deficient parasites to progress through to asexual blood
stage infection is made possible by the residual lipoylation
of PDH-E2 that maintains sufficient PDH functionality for
some KO parasites to complete their liver stage develop-
ment, albeit far less efficiently than with WT parasites.
Treatment of PbLipB-deficient parasites with the
scavenging inhibitor 8-BOA confirms the dual
contribution of the lipoic acid synthesis and scavenging
pathways during liver stage development
We used 8-BOA to deplete protein lipoylation coming from
the scavenging pathway active in the mitochondria (Allary
et al., 2007; Deschermeier et al., 2012) and examined
whether treated liver stage parasites displayed any
residual lipoylation that was attributable to apicoplast-
synthesized lipoic acid. Developing parasites were
treated with this competitive inhibitor and stained at 48 h
post invasion (hpi) with lipoic acid-specific antibodies,
which can detect lipoylated proteins within the parasite
and in the host hepatocyte (Fig. 4). For the WT control, we
used a P. berghei ANKA line that expresses mCherry in
the parasite mitochondria (Graewe et al., 2009). In the
case of the KO parasites, MitoTracker Red was used to
label the mitochondria (both of the parasite and the host
cell). Representative parasite images are shown in Fig. 4,
with additional parasites shown in Fig. S2. WT parasites
(treated with DMSO vehicle) showed lipoic acid staining
both within the parasite mitochondria (see colocalization
of green lipoic acid and red mitochondrial signals in top
row of Fig. 4A), as well as outside the parasite in the host
cell (see green signal external to the parasite boundaries).
Treatment with 8-BOA led to reduced lipoic acid staining
in the parasite mitochondria, as expected (second row,
Fig. 4A). Lipoylated proteins were nonetheless observed
in the host hepatocyte, likely because the rate of protein
turnover is slower and because the host mitochondria
primarily rely on lipoic acid synthesis (Yi and Maeda,











I WT 1 000 5 of 5 5.0
PbDLipB 1 000 1 of 5 9.0
II WT 1 000 4 of 4 5.0
PbDLipB 1 000 1 of 4 9.0
III WT 10 000 5 of 5 3.0
PbDLipB 10 000 5 of 5 7.6
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Fig. 4. PbDLipB parasites show no residual lipoylated proteins after 8-BOA treatment.
A. HepG2 cells were infected with P. berghei ANKA mCherry-mito sporozoites and treated with either 200 mM 8-BOA or DMSO as vehicle
control. At 54 hpi, infected cells were fixed and stained with anti-lipoic acid (shown in green) to identify lipoylated proteins within the parasite
and the HepG2 cell host. The mitochondria is shown in red, while the nucleus (stained with DAPI) is in blue. DIC, differential interference
contrast. The dashed white line outlines the portion of the parasite magnified as the Inset in the last column (also for B). White bar, 10 mm.
White arrows in the inset of WT parasites treated with DMSO control illustrate lipoic acid signal in the mitochondrion (evident as an orange
signal). White triangles represent parasite boundaries inside the infected cells (A and B).
B. HepG2 cells infected with PbDLipB sporozoites were treated with either 200 mM 8-BOA or DMSO as a vehicle control. At 48 hpi, infected
cells were stained with MitoTracker Red to label the mitochondria (red). Cells were fixed and stained with anti-lipoic acid to identify lipoylated
proteins (shown in green). DAPI dye identified nuclear structures (blue). White bar, 10 mm. The white arrow in the KO parasite treated with
DMSO illustrates some lipoic acid signal in the mitochondrion. This signal is largely absent in 8-BOA treated KO parasites.
C. The amount of lipoylated protein within the parasite was quantified using Python and the MATLAB Image Analysis Toolbox and the signal
intensity determined from the anti-lipoic acid images, after cropping for parasite-specific areas, for WT and PbDLipB parasites treated with
8-BOA or DMSO vehicle control. Data are presented as the mean ! SEM intensity per mm2 of parasite. This analysis revealed significant
differences between WT and KO parasites, including reduced lipoylation in PbDLipB compared with WT parasites following 8-BOA treatment
(*P < 0.05; **P < 0.01; Mann–Whitney U-test; n = 4 to 8 parasites per condition and per strain).
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2005), making them less affected by the addition of
8-BOA. With LipB-deficient parasites (treated with
DMSO), we saw colocalization of lipoic acid and the mito-
chondria in the parasite (as well as in the host cell; see top
row in Fig. 4B). Treatment with 8-BOA led to a marked
loss of lipoic acid staining in the parasite mitochondria
(see bottom row, Fig. 4B).
To quantify this analysis, we developed a program to
measure the intensity of lipoic acid staining in multiple WT
and KO liver stage parasites. Results, expressed as
signal intensity per mm2 of parasite, showed a significant
decrease in the amount of lipoylated proteins in both WT
and KO parasites following 8-BOA treatment, as com-
pared with DMSO controls (estimated at 40% and 54%
respectively; Fig. 4C). When compared with WT para-
sites, KO parasites also showed a significantly reduced
amount of protein lipoylation following 8-BOA treatment
(estimated at 68%; Fig. 4C). These data confirm that
without scavenging of exogenous lipoic acid, only minimal
lipoylated protein remained within the confines of LipB-
deficient parasites.
To extend these observations, we examined lipoylated
proteins within the apicoplasts of liver stage parasites
at 48 hpi by performing a sequential staining procedure
with anti-lipoic acid and anti-ACP antibodies. When
merging these images, the majority of apicoplast struc-
tures colocalized with lipoylated proteins in WT parasites.
However, significant portions of the apicoplast organelle
were not lipoylated in KO parasites (example provided in
Fig. S3). These preliminary data are consistent with our
Western blot results showing reduced lipoylation of the
apicoplast PDH-E2 subunit in LipB-deficient liver stage
parasites (Fig. 2D).
PbDLipB parasite apicoplast appears smaller and more
constricted during the liver stage of development
Given that LipB is an apicoplast-targeted protein, we
decided to examine the overall morphology of apicoplast
development during the liver stage. WT and PbDLipB
parasites were stained with antibodies to the apicoplast
marker ACP as well as other antibodies that enabled us to
measure the surface area of the developing parasite.
These antibodies were specific to the Circumsporozoite
Protein (CSP), Exported Protein-1 (EXP-1), or Merozoite
Surface Protein-1 (MSP-1). CSP is expressed on the spo-
rozoite surface (Ejigiri and Sinnis, 2009) and was used to
identify the morphology of the young intra-hepatic para-
site at 6 hpi. P. berghei EXP-1 is inserted into the parasi-
tophorous vacuole membrane (PVM) that separates the
replicating parasites from the host hepatocyte (Simmons
et al., 1987) and was used to measure the confines of the
PVM. MSP-1 is a glycosylphosphatidylinositol (GPI)-
anchored surface protein that peaks in expression at ~ 50
hpi in WT liver stage parasites (corresponding to late
schizogony and the early cytomere stage) (Combe et al.,
2009). This protein becomes integrated into the parasite
plasma membrane (PPM) and mediates attachment of
merozoites to the surface of RBCs (Cowman and Crabb,
2006). Mature hepatic merozoites express abundant
amounts of MSP-1 on their surface, similar to the asexual
blood stage counterparts. Antibodies to MSP-1 were used
to determine the morphology of the PPM of late liver
stages (schizonts, cytomeres and mature infectious mero-
zoites) (Stanway et al., 2009). Fluorescence imaging
revealed no evident difference between WT and PbDLipB
KO liver stage parasites at 6 and 24 hpi (see example in
Fig. 5A). However, at later time points (48 h and 54 hpi)
we observed fewer branched structures in KO parasites.
To quantify this, we measured the intensity of labelling
with antibodies to the apicoplast marker ACP, for 12–18
parasites per strain and per time point. This MATLAB-
based analysis showed a statistically significant, 65 to
67% reduction in total apicoplast surface area in KO com-
pared with WT parasites (Fig. 5B). Exemplar parasite
images are shown in Fig. 5A and additional parasites
examined at 48 and 54 hpi are represented in Figs S4 and
S5 respectively. These findings contrast with the lack of
observable differences between the apicoplasts of WT
and LipB KO asexual blood stage parasites, and suggest
that the deletion of PbLipB impacted the morphology of
this organelle late in liver stage maturation.
We also counted the number of ACP-positive branch
points reaching into the periphery of the developing para-
site and contacting the MSP-1 labelled PPM for 40 para-
sites per time point, divided equally between WT and KO
cultures. WT parasites yielded 7.4 ! 5.8 and 13.1 ! 4.3
(mean ! SD) ‘contact points’ between branches of the
apicoplast and the PPM, at 48 and 54 hpi respectively. In
comparison, KO parasites had an average of 4.4 ! 3.6
and 3.9 ! 2.1 contact points at 48 and 54 hpi (the latter
time point was significantly different between the WT and
KO lines; P < 0.0001 based on Mann–Whitney U-test).
These data further suggest impaired apicoplast develop-
ment in the KO line as it progresses to the late liver stage.
PbDLipB parasites have major defects during late liver
stage development and do not produce detached cells
during in vitro culture
To further probe the defect in liver stage development in
PbDLipB parasites, we generated a new PbDLipB KO
parasite in the P. berghei ANKA GFP–luciferase back-
ground, which expresses GFP–luciferase from the strong
ef-1a promoter active throughout the parasite life cycle
(Janse et al., 2006a). We used PbDLipB-GFP–luciferase
and control GFP–luciferase sporozoites to infect
HepG2 cells. At 48 hpi, we determined the size of the
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exo-erythrocytic forms. The area of the developing para-
sites, as identified by measuring the area of the fluores-
cence emitted from the GFP-positive parasites, was found
to not differ significantly between the two parasite lines
(Fig. 6A). Nevertheless, quantitative RT-PCR studies with
RNA harvested 48 hpi revealed a 10- to 12-fold reduction
in msp-1 transcript levels in the KO parasites compared
with WT parasites, as determined using the 2DDC(t) method
(Price et al., 2004) with actin as an internal control (data
not shown).
To further test for defects in liver stage development, we
determined the total number of infected cells at several
time points of liver stage development, using our PbDLipB
parasites. From three independent experiments we iden-
tified no significant difference between the absolute
number of developing parasites at 24 and 48 hpi (Fig. 6B),
confirming our earlier results that the KO parasites initially
develop normally. At 65 hpi (data not shown) and 84 hpi
(Fig. 6B), the numbers of infected HepG2 cells with WT
parasites began to decrease, as cells containing mature
merozoites detached from the adherent surface. Approxi-
mately 20–30% of WT ANKA parasites were capable of
successfully completing in vitro liver stage development,
resulting in the detachment of the infected hepatocytes
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Fig. 5. PbDLipB parasites have a less branched apicoplast in comparison to wild-type cells.
A. HepG2 cells were infected with WT or PbDLipB sporozoites and the apicoplast was labelled using ACP-specific antibodies (labelling shown
in green) at several time points throughout liver stage development. To visualize the developing parasite, primary antibodies (labelling shown
in red) were used as follows: anti-CSP at 6 hpi; anti-Exp-1 at 24, 48 and 54 hpi; and anti-MSP-1 at 62 hpi for WT parasites and 72 hpi for
PbDLipB parasites. White bar, 10 mm.
B. Plot of intensity of apicoplast staining for WT versus KO parasites sampled at 48 and 54 hi. Intensity was measured from the anti-ACP
image and determined per mm2 of parasite after cropping the images for the parasite-specific areas (bounded by the parasitophorous vacuole).
Results showed a statistically significant two-thirds reduction in apicoplast signal in KO compared with WT parasites (***P < 0.001;
Mann–Whitney U-test, n = 12–18 per group). Additional images of parasites sampled at 48 and 54 hpi are provided in Figs S4 and S5
respectively.
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from the culture surface. These detached cells floating in
the culture supernatant were quantified at 65 hpi, showing
a clear contrast between the presence of detached cells in
the WT cultures and their absence in the KO (Fig. 6B).
These data suggest a defect in the maturation of late liver
stage parasites in LipB-deficient parasites.
To more precisely define the stage of developmental
arrest of LipB liver stage parasites, we performed immuno-
fluorescence assays with cultured KO and WT parasites at
54 hpi and beyond. MSP-1 elucidated the morphology of
the parasite plasma membrane (PPM), which at late time
points invaginates around the individual daughter mero-
zoites (Sturm et al., 2009). WT ANKA parasites had well
segregated individual nuclei by 54 hpi, with PPMs that
evenly surrounded the developing clumps of merozoites
(Fig. 6C, left panel; additional WT and KO images provided
in Figs S6 and S7). At similar or later time points, PbDLipB
parasites demonstrated uneven MSP-1 staining that
appeared to clump and not uniformly surround the daugh-
ter cells (Fig. 6C; see the representative 62 h cytomere
stage in the right panel). Rarely, we observed PbDLipB-
infected cells containing what appeared to be morphologi-
cally normal merozoites. These parasites, however, were
only seen at ~ 84 hpi, in comparison to the normal time-
frame of 65 hpi required for complete in vitro development
of WT parasites. The abnormal MSP-1 staining in the
PbDLipB parasites suggests that the PPM is improperly
segregating late in development, and suggests a key
requirement for lipoic acid synthesis for successful intra-
hepatic parasite maturation.
Discussion
Here, we show that P. berghei sporozoites lacking the
octanoyl-ACP transferase enzyme LipB have a pro-
found loss of infectivity for the rodent host, caused by a
defect in liver stage parasite development. These data
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Fig. 6. PbDLipB parasites are defective in
late liver stage development.
A. HepG2 cells were inoculated with either
P. berghei WT or PbDLipB sporozoites, both
constitutively expressing GFP. Sizes of
developing parasite forms were measured at
48 hpi from 150 to 200 parasites per well
(obtained from two independent experiments
performed in duplicate) and were quantified
using ImageJ. Data are presented as a box
and whiskers plot that illustrates the mean,
interquartile range (25–75%) and 95%
confidence interval.
B. HepG2 cells were infected with equal
numbers of WT and KO sporozoites. Parasite
numbers were determined by counting fixed
and stained developing liver stage parasites,
shown for time points 24, 48 and 84 hpi, and
counting of live Hoechst-stained detached
cells at 65 hpi. Data are shown as the
mean ! SEM generated from two
independent experiments performed in
duplicate.
C. Liver stage parasites were imaged for
DAPI (blue) and MSP-1 (green) expression at
different stages of development. The left
column shows WT control parasites imaged at
the cytomere stage (sampled at 54 hpi). The
three right panels show PbDLipB liver
parasites developing within HepG2 cells at
cytomere and merozoite stages (sampled at
54, 62 and 70 hpi). White bar, 10 mm.
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functionality of the a-ketoacid dehydrogenases PDH and
BCDH during this phase of prodigious replication. These
multi-enzyme complexes contribute to the FAS-II
pathway (in the case of PDH) and the tricarboxylic acid
(TCA) cycle (for BCDH). In contrast to the late liver
stage arrest, LipB-deficient P. berghei parasites pro-
gressed unimpeded through their asexual blood stage
cycle under standard in vitro or in vivo conditions, where
the scavenging pathway is thought to supply most of the
lipoic acid requirements. Nonetheless, chemical inhibi-
tion of the scavenging pathway using the lipoic acid ana-
logue 8-BOA, or lowering of host lipid levels by clofibrate
treatment, provides evidence for an important contribu-
tion of the synthesis pathway in asexual blood stage
parasites in lipid-limiting host environments.
A striking feature of these LipB-deficient parasites was
the late stage at which intra-hepatic arrest occurred.
Immunofluorescence assays with PbDLipB parasites
showed the presence of the merozoite surface marker
MSP-1, indicating progression through to the cytomere
stage that precedes the final phase of maturation.
However, MSP-1 labelling appeared abnormal, and in
vitro we could not detect detached cells. These cells are
indicative of the mature merosomes that are enveloped by
host hepatocyte membrane and that contain merozoites
that can invade erythrocytes (Prudencio et al., 2006;
Rankin et al., 2010). In comparison, P. berghei or P. yoelii
parasites lacking FAS-II enzymes typically arrested prior
to MSP-1 expression, as did the P. yoelii KO parasites
lacking PDH-E1 or PDH–E3 (Yu et al., 2008; Vaughan
et al., 2009; Pei et al., 2010; Annoura et al., 2012).
Indeed, the LipB KO arrest occurred later than any of the
genetically attenuated parasites reported to date (van
Dijk et al., 2005; Mueller et al., 2005a,b; Khan et al.,
2012). This is of particular interest for the development of
genetically attenuated vaccines, as recent evidence indi-
cates that mature liver stages are a superior immunogen
to early stages in terms of eliciting robust, durable pro-
tective immunity (Friesen et al., 2010; Borrmann and
Matuschewski, 2011; Butler et al., 2011). Clearly, the LipB
KO would not suffice, as we observed breakthrough infec-
tions in the sensitive P. berghei ANKA – C57BL/6 mouse
model (Annoura et al., 2012), and additional layers of
attenuation would be required. One candidate could be
LplA2, a lipoate ligase that is targeted to both the apico-
plast and the mitochondria and that has been proposed to
mediate partial PDH-E2 lipoylation in LipB-deficient P. fal-
ciparum parasites (Gunther et al., 2007).
To probe the biological basis of why LipB-deficient
parasites arrest later than their FAS-II or PDH counter-
parts during liver stage development, one must consider
the different roles of these related pathways. Our data
suggest that LipB is important for maintaining normal
levels of lipoylation of the a-ketoacid dehydrogenases
PDH and BCDH in P. berghei. Without a lipoylated
E2 subunit, dehydrogenases are catalytically inactive
(Perham, 2000). In most eukaryotic cells, PDH trans-
forms pyruvate into acetyl-CoA for the generation of TCA
intermediates for cellular respiration and glycolysis
(Dumollard et al., 2009). However, Plasmodium encodes
only a single PDH that is targeted to the apicoplast,
where its likely role is to provide acetyl-CoA for the
FAS-II pathway (Foth et al., 2005; Pei et al., 2010).
PDH-E2 lipoylation requires octanoyl-ACP produced by
FAS-II; hence the enzymatic activity of PDH is tightly
regulated because of the interdependence between
these pathways. One interpretation of our findings is that
the LipB KO liver stage arrest is simply due to reduced
lipoylation of PDH-E2 that can no longer functionally
generate acetyl-CoA for FAS-II. The fact that the LipB KO
parasites still have a residual amount of lipoylated
PDH-E2 protein might explain why these parasites con-
tinue developing very late during the liver stage, and
arrest later as compared with the PDH or FAS-II KO
parasites. Another explanation would involve BCDH,
whose E2 subunit was observed to be substantially less
lipoylated in blood stage parasites. In eukaryotic cells,
BCDH degrades the branched chain amino acids valine,
leucine and isoleucine, presumably for the generation of
acetyl-CoA or succinyl-CoA intermediates for the TCA
cycle (Gunther et al., 2005). Intermediates of this cycle
have been isolated from P. falciparum blood stage para-
sites, which use glutamate and glutamine as major
carbon sources (Olszewski et al., 2010). The importance
of the TCA cycle in liver stages remains to be clarified.
Intriguingly, transcriptional profiling by microarrays has
revealed upregulation of other TCA-related genes,
including components of the BCDH complex, in intra-
hepatic parasites (Tarun et al., 2008). Therefore, the
importance of LipB during liver stage development could
involve both the FAS-II and the TCA cycles that depend
on acetyl-CoA. A third possibility could relate to the
known role of lipoic acid as an antioxidant (Goraca et al.,
2011; Packer and Cadenas, 2011). This property is
related to the ability of oxidized lipoate and its reduced
form, dihydrolipoate, to form a redox couple that can
effectively quench reactive oxygen species (including
hydroxyl, peroxyl and superoxide radicals), as well as
interact with other antioxidants including glutathione,
vitamins C and E and coenzyme Q (Spalding and Prigge,
2010). While much has yet to be elucidated about
whether Plasmodium-infected hepatocytes generate oxi-
dative stress that can impede intracellular parasite devel-
opment, indirect evidence comes from the observation
that parasitized hepatocytes upregulate host cell redox
pathways (Albuquerque et al., 2009; Dey et al., 2009). It
is tempting to speculate that Plasmodium may require
the antioxidant properties of lipoic acid to protect itself
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against hepatocyte defence mechanisms. Redox-
perturbing agents would be useful for future studies to
test this hypothesis.
One intriguing finding from our study was the reduced
lipoylation of BCDH-E2 in our LipB-deficient P. berghei
asexual blood stage parasites. Similar results were
obtained with P. falciparum LipB KO parasites that
showed reduced lipoylation of BCDH-E2 and PDH-E2 but
not KGDH-E2 (Gunther et al., 2007). These data suggest
that apicoplast-derived lipoic acid can be delivered to the
mitochondria, a scenario that differs from the current
working models in Plasmodium and T. gondii that the
mitochondrial a-ketoacid dehydrogenases are only modi-
fied with lipoic acid scavenged from the host (Allary et al.,
2007). In preliminary Western blot studies with our
P. berghei parasites incubated ! 8-BOA (tested at
400 mM), we found minor (13–41%) reductions in lipoyla-
tion of apicoplast and mitochondrial dehydrogenases in
KO parasites, contrasting with zero reduction of lipoyla-
tion in WT parasites (S. Gulati, T. Santha Kumar and D.
Fidock, unpubl. obs.). In P. falciparum, the effects of
400 mM 8-BOA are readily reversed by only 2 mM of addi-
tional lipoic acid (Allary et al., 2007). Human serum is
known to typically contain 160–700 nM lipoic acid (Storm
and Muller, 2012), however we could not find any litera-
ture on rodents. While further studies are required to
control for exogenous lipoic acid in these assays, these
results are consistent with LipB contributing to lipoylation
of mitochondrial BCDH-E2 (Fig. 2D). These findings also
support other data suggesting that the reduction of de
novo lipoic acid results in the parasite becoming more
dependent on the scavenge pathway and hence more
susceptible to the scavenge inhibitor, 8-BOA.
We also propose that liver stage development requires
both active lipoic acid synthesis and its import into the
mitochondria. This proposal is based on the liver stage
arrest phenotype that we observed with LipB-deficient
parasites as well as earlier reports of liver stage inhibition
with the lipoic acid analogue 8-BOA that inactivates mito-
chondrial a-ketoacid dehydrogenases (Allary et al., 2007;
Deschermeier et al., 2012). This differs from asexual
blood stage parasites where disruption of the apicoplast
FAS-enzymes, the PDH complex or, in the present study
LipB, does not impede parasite development that appears
to depend primarily on parasite pathways to import
host fatty acids or lipoic acid. Of note, a recent study in
P. falciparum implicated isoprenoid synthesis as the sole
apicoplast pathway required for asexual blood stage
development (Yeh and DeRisi, 2011). This pathway pro-
duces isopentenyl pyrophosphate, which is used to syn-
thesize isoprenoids whose uses include post-translational
protein modifications (Nguyen et al., 2010). Available evi-
dence suggests that, compared with the asexual blood
stages, liver stage parasites are much more dependent
on apicoplast de novo biosynthetic pathways, including
for the production of lipoic and fatty acids (Yu et al., 2008;
Vaughan et al., 2009; Pei et al., 2010; Annoura et al.,
2012).
While arrested in their maturation in hepatocytes, no
developmental or growth defect was observed with LipB
KO parasites during their asexual blood stage replication.
These findings are similar to the published reports with
the FAS-II and PDH KO lines (Yu et al., 2008; Vaughan
et al., 2009; Pei et al., 2010). In the case of the FAS-II
KOs, this has been attributed to fatty acid salvaging being
sufficient for asexual blood stage replication and growth,
which would also explain the lack of a requirement for the
PDH product acetyl-CoA that primes the FAS-II pathway.
Interestingly, our study detected an effect of the LipB KO
in conditions where host lipid levels were perturbed. Using
the lipoic acid analogue 8-BOA that competitively inhibits
lipoic acid attachment in the mitochondria (Allary et al.,
2007), we found significantly reduced rates of asexual
blood stage growth in the synthesis-deficient KO line.
Less pronounced inhibition was observed with WT para-
sites. These data are consistent with parasites having a
mechanism to import lipoic acid into their mitochondria,
and suggest that this import pathway is even more critical
when parasites can no longer furnish their own source
of lipoate.
Our findings suggest that LipB plays an active role in
asexual blood stage parasites and might become critical
for parasite proliferation in cases where insufficient lipoic
acid can be scavenged from the host plasma. This con-
clusion is further supported by the findings in vivo by
reducing the circulating lipid levels of mice with clofibrate
treatment. Under these conditions, the LipB-deficient
parasites showed a substantially greater attenuation
of blood stage growth compared with the WT control
strain, suggesting a need for lipoylated PDH to sup-
port FAS-II activity in lipid-deprived conditions. This could
be especially relevant in malnourished individuals with
very low levels of circulating lipids. While we could not
identify any published reports of lipoic acid levels in
African children, there is abundant literature on the preva-
lence of moderately or severely acute malnutrition in
young African children, who bear the brunt of malarial
disease (Victora et al., 2008; LaGrone et al., 2012). We
conjecture that parasite pathways such as lipoic acid or
fatty acid synthesis, which are apparently not required for
asexual blood stage proliferation in vitro, might be impor-
tant pathways that P. falciparum can exploit to sustain
rapid growth in malnourished individuals.
Recent years have seen an increasing focus on how
Plasmodium co-opts host metabolites for its benefit
and how this parasite balances scavenging pathways
with the need for supplementation via de novo synthesis,
as it progresses through its life cycle. Deciphering the
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key molecular determinants and their stage specificity
should expose weaknesses that can be exploited to
develop genetically attenuated parasite vaccines or
chemotherapeutic agents designed to prevent or cure
disease. Plasmodium clearly exploits human metabolism,
and one suspects that this includes the use of pathways
that sustain growth in instances of human malnutrition. A
core challenge will be to develop ways to intervene in
these pathways to cure infections and reduce the burden
of disease.
Experimental procedures
Propagation of P. berghei parasites
Plasmodium berghei ANKA (MRA-671) parasites were passaged
via intraperitoneal injection in female Swiss–Webster or NMRI
mice and pre-patent periods were determined in female C57BL/6
mice (6–8 weeks old at the time of experimentation; Taconic).
Parasitized mice were euthanized at the first signs of distress.
Animal experimentation performed at Columbia University or the
Bernhard-Nocht-Institute complied with protocols and regulations
approved by the Institutional Animal Care and Use Committee of
Columbia University or the ethical committee of Hamburg State
authorities.
Plasmid constructs and parasite transfections
To delete PbLipB (PlasmoDB ID: PBANKA_070700), we first
constructed the plasmid pL0001-DPbLipB, containing 5′ and
3′ UTRs specific to this genomic locus. These 0.68 and
0.85 kb products (respectively) were PCR amplified from
P. berghei ANKA genomic DNA using primers P2268 + P2269,
and P2182 + P2350 (Table S1). Fragments were subcloned
between the EcoRV/XbaI and Acc65I/HindIII sites of pL0001
(de Koning-Ward et al., 2000). The final plasmid was linearized
by XbaI, ScaI and Acc65I digestion and verified by agarose
gel electrophoresis prior to transfection. Electroporation and
selection with pyrimethamine (0.07 mg ml-1 in the drinking
water) was performed as previously described (Carvalho
and Menard, 2005; Janse et al., 2006b). PbDLipB KO clones
were obtained by limited dilution in mice. Homologous re-
combination leading to deletion of the endogenous PbLipB
coding sequence and its replacement by the T. gondii dhfr-ts
marker (Donald and Roos, 1993) was confirmed by PCR
(see Fig. 1), using the following primers: P2304 (p1) + P2303
(p2), P2449 (p3) + P2450 (p4), P2454 (p5) + P2453 (p6),
P2344 (p7) + P2449, P2453 + P2317 (p8), P2346 (p9) + P2345
(p10).
To localize BCDH, we generated the plasmid pL0031–BCDH–
GFP. For this, 875 bp of the 3′ end of bcdh-E2 (PlasmoDB ID:
PBANKA_141110) coding sequence was PCR amplified from
ANKA genomic DNA using the primers P2872 + P2873. The
product was cloned between the SacII/NcoI sites in pL0031
(Kooij et al., 2005) to create a bcdh–gfp fusion. This construct,
containing the T. gondii dhfr-ts marker, was linearized with BsmBI
prior to electroporation into P. berghei ANKA. Recombinant para-
sites were selected with pyrimethamine as described above.
Correct integration into bcdh-E2 following homologous recombi-
nation and single site cross-over resulted in the introduction of
gfp as a 3′ fusion, and was confirmed by PCR using primers
P2957 + P3053.
Kinetics of blood stage growth in PbDLipB and wild-type
ANKA parasites
Parasites were administered intravenously to Swiss–Webster
mice and their parasitemias were monitored daily by microscopic
examination of Giemsa-stained thin blood smears. Three inde-
pendent experiments were performed; each comprising two
groups of five mice infected with either PbDLipB or parental
asexual blood stage WT parasites.
Immunofluorescence analysis of blood stage parasites
Plasmodium berghei ANKA, PbDLipB, or PbBCDH–E2–GFP
asexual blood stage parasites were prepared for immunofluores-
cence following formaldehyde/glutaraldehyde fixation and Triton
X-100 permeabilization, as described (Tonkin et al., 2004). Cells
were incubated with rabbit anti-ACP IgG (diluted 1:2000; (Waller
et al., 2000) followed by Alexa Fluor 594 secondary anti-rabbit
antibodies (diluted 1:1000; Molecular Probes). Cells were imaged
in complete medium (Janse et al., 2006b) containing Hoechst
(5 mg ml-1). PbBCDH–E2–GFP parasites were incubated with
20 nM MitoTracker Red CMXRos (Invitrogen) for 20 minutes at
37°C prior to fluorescence microscopy.
Western blot analysis of lipoylated proteins
Infected RBCs were collected from mice with 8–10% para-
sitemias and saponin-lysed prior to protein extraction in RIPA
lysis buffer (Boston BioProducts) supplemented with protease
inhibitors (Roche Applied Science). Samples were subjected
to SDS-PAGE and the gels transferred onto nitrocellulose
membranes. Membranes were incubated with rabbit polyclonal
anti-lipoic acid IgG (diluted 1:1000; Calbiochem) followed by sec-
ondary anti-rabbit IgG conjugated to horseradish peroxidase
(diluted 1:2500; GE Healthcare).
Treatment of asexual blood stage parasites with the
lipoic acid analogue 8-BOA
Plasmodium berghei-infected RBCs were incubated overnight at
37°C in complete medium (Janse et al., 2006b) containing
8-BOA (100, 200 or 400 mM in 0.004% final DMSO) or a control
solution of 0.004% DMSO. A total of 10 000 infected RBCs were
then inoculated into naïve mice by tail vein injection. Para-
sitemias were monitored by microscopic assessment of Giemsa-
stained thin smears for 8 days.
P. berghei blood stage growth kinetics in
clofibrate-treated mice
Uninfected Swiss–Webster mice were intraperitoneally adminis-
tered 0.5 or 5.0 mg kg-1 clofibrate or an equal volume (50 ml)
of DMSO control, daily for 9 days. On days 5 and 9, tail vein
blood (30 ml per mouse) was drawn. Plasma was separated by
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centrifugation and used in enzymatic-based colorimetric assays
to determine the levels of circulating non-esterified fatty acids
and triglycerides (HR Series NEFA-HR and L-Type TG M kits;
WAKO Diagnostics). After the 9-day treatment, mice were inocu-
lated with 10 000 infected RBCs and growth kinetics were moni-
tored daily for an additional 9 days by thin-smear microscopy. To
determine reticulocyte densities, groups of 12 Swiss–Webster
mice each were administered 0.5 or 5.0 mg kg-1 clofibrate or an
equal volume (50 ml) of vehicle control, daily for 9 days as above.
On days 0, 3, 6, 9 and 14, 1 ml of blood was collected from each
mouse into complete media containing citrate-phosphate-
dextrose (Sigma) via slight nicking of the tail vein. After incubation
with Fc receptor block (anti-CD16/CD32, Invitrogen), cells were
stained with antibodies specific to the transferrin receptor CD71
(FITC Anti-CD71; BD Pharmingen) and Ter119 (PE Anti-Ter119;
BD Pharmingen) (Posluszny et al., 2011). Cells were subjected to
flow cytometry on an Accuri C6 desktop cytometer, and at least
20 000 events were analysed for each sample using FlowJo
software.
Mosquito infections with P. berghei
Anopheles stephensi mosquitoes were fed on anesthetized
Swiss–Webster or NMRI mice infected with PbDLipB or
P. berghei ANKA parasites, and were maintained in incubators
with 70–80% humidity set at 19°C at Columbia University or 21°C
at the Bernhard-Nocht-Institute. Oocysts were examined in dis-
sected midguts using phase-contrast microscopy.
In vivo liver stage development assays
Salivary glands from infected mosquitoes were dissected by
hand on day 21 post blood meal and sporozoites were quantified
using a haemocytometer. Sporozoites were inoculated into
C57BL/6 mice using tail-vein injections. Pre-patent periods were
determined by thin-smear microscopy.
In vitro liver stage assays
HepG2 cells (ATCC) were seeded in 24-well plates containing
glass coverslips at 6 ¥ 104 cells per well and cultured at
37°C. After 24 h, salivary gland sporozoites were added
(2–3 ¥ 104 per well). Two hours later, 200 mM 8-BOA (or a
DMSO vehicle control; final concentration 0.12%) was then
added to deplete scavenged lipoic acid from liver stage para-
sites. Cells were then incubated in the presence of 8-BOA at
37°C in 5% CO2 for 48 h. Infected cells were then incubated
with 250 nM MitoTracker Red CMXRos (Invitrogen) for 15 min
and fixed/permeabilized with 4% paraformaldehyde and metha-
nol. Primary antibody (rabbit anti-lipoic acid diluted 1:1000) was
applied for 2 h at room temperature in 10% FCS/PBS. Cells
were washed three times with PBS and secondary anti-
bodies (donkey anti-rabbit Alexa Fluor 647 diluted 1:1000) and
DAPI (1 mg ml-1) were applied in 10%FCS/PBS for 1 h at room
temperature. Microscopic analysis was done on a FluoView
FV1000 confocal microscope.
To perform quantitative analysis of the lipoylated areas of
liver stage parasites (Fig. 4C), we first defined the edges of the
parasitophorous vacuoles using the Canny edge detection algo-
rithm (Canny, 1986). Internal regions were then isolated without
holes as a separate image and imported in Python. Cropped
anti-lipoic acid images were analysed in the MATLAB Image
Analysis Toolbox (Mathworks, California) for total intensity
(using 32 bit unsigned integer RGB data), total area of the
parasite (in pixels) and total illuminated area of the parasite (in
pixels) using the standard gray threshold generation function
after conversion to a greyscale image. The ratio of the intensity
to the proportional area illuminated was then reported for each
parasite separately. Data were converted into intensity per
micrometer-squared of parasite and the standard error was
determined per group. Mann–Whitney U-tests between parasite
lines at each condition were used to determine statistical sig-
nificance. This analysis was repeated to calculate the apico-
plast surface area in KO versus WT parasites (Fig. 5B), this
time measuring the intensity of staining with anti-ACP instead of
anti-lipoic acid antibodies.
In the sequential staining procedure with the anti-lipoic acid
and anti-ACP antibodies, infected HepG2 cells were fixed and
permeabilized with the same conditions as listed above. Cells
were incubated with rabbit anti-lipoic acid (1:2000 in 10% FCS/
PBS) for 2 h, washed three times with 1¥ PBS and incubated with
goat anti-rabbit HiLyte Fluor 647 (1:1000 in 10% FCS/PBS) for
1 h. Cells were washed three times with PBS. Following anti-
lipoic acid staining, cells were incubated with goat anti-rabbit
horseradish peroxidase (1:20 in 10% FCS/PBS) for 1 h, washed
three times with PBS and incubated with 10% rabbit serum/1¥
PBS for 1 h. Cells were washed three times with PBS and then
incubated with rabbit anti-ACP (1:500) and chicken anti-Exp-1
(1:2000) in 10% FCS/PBS overnight at 4°C. Cells were washed
again three times with PBS and incubated with goat anti-rabbit
Alexa Fluor 594 (1:5000), donkey anti-chicken Cy2 (1:250) and
DAPI (final concentration 1 mg ml-1) in 10% FCS/PBS for 1 h. All
incubations were at room temperature. Coverslips were washed
three times with PBS, dipped in H20 and mounted on glass slides
using Daco Fluorescent Mounting Medium prior to fluorescence
microscopy imaging (Fig. S3).
To determine the morphology of the apicoplast, liver stage
infections were established as above. At the indicated times, cell
were fixed/permeabilized with 4% paraformaldehyde and metha-
nol and incubated with the primary antibodies at the time points
indicated (mouse anti-CSP 1:1000; chicken anti-Exp-1 1:1000;
mouse anti-MSP-1 1:2000; rabbit anti-ACP 1:1000) was applied
for 2 h. Secondary antibodies (anti-mouse Alex Fluor 594
1:5000 plus anti-rabbit HiLyte Fluor 647 1:1000; or anti-chicken
Alexa Fluor 594 1:5000 plus anti-rabbit HiLyte Fluor 647 1:1000)
were applied for 1 h. Images were captured on a FluoViewTM
FV1000 confocal microscope.
To assess the size of liver stage parasites, a P. berghei line
that constitutively expresses GFP–luciferase (Franke-Fayard
et al., 2004); MRA-868) was transfected with the pL0001-
DPbLipB plasmid and KO clones disrupted in the LipB locus
were isolated as described above. Liver stage parasites were
visualized by fluorescence microscopy and parasite size was
analysed from 150 to 200 cells per line (KO or parent) using
ImageJ software.
To determine the absolute number of developing liver stage
parasites, HepG2 cells were infected with 104 WT or LipB KO
sporozoites respectively. Infected cells were fixed and permea-
bilized 24 and 48 hpi and were stained using either a mouse
anti-RFP antibody (WT controls expressed cytosolic mCherry;
Graewe et al., 2009) or rat antiserum raised against P. berghei
1600 B. Falkard et al.
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blood stage parasites (used for PbDLipB). Parasites were
counted using a Leitz-DM RB fluorescence microscope (Leica).
At 65 hpi ‘detached cells’ were stained with Hoechst 33342 and
were counted using an Axiovert 200 fluorescence microsope
(Zeiss). Immunofluorescence for developmental markers of liver
stage parasites was completed with primary antibodies (chicken
anti-Exp-1 1:1000, mouse anti-MSP 1:2000), which were applied
for 2 h at room temperature. Secondary antibodies (anti-chicken
Cy2 1:250, anti-mouse Alexa Fluor 594 1:5000) and DAPI
(1 mg ml-1) were applied for 1 h at room temperature. In vitro
cultures were also used for the generation of parasite cDNA after
48 h of development.
For RT-PCR studies, we harvested infected HepG2 cells at 48
hpi, and purified the RNA from KO and WT parasites using Trizol
and RNeasy kits (Qiagen). For RT-PCR assays we used a Super-
Script III kit (Invitrogen) to generate cDNA and tested for tran-
scription of PbLipB using primers p2304 (p1) + P2303 (p2)
reactions ! reverse transcriptase (Fig. 1D). Control reactions
included primers p3753 + p3754 specific for the P. berghei actin I
gene (Angrisano et al., 2012).
For q-RT-PCR assays, we purified mRNA using an Oligotex
RNA isolation kit. Reactions were performed using two-fold dilu-
tions of mRNA spanning the range of 4–128 ng mRNA, in a
Bio-Rad Opticon 2 DNA Engine. Amplifications employed one-
step iScript-RT-PCR kits (Bio-Rad) with SYBR Green, with the
following conditions: 50°C for 30 min and 95°C for 15 min, fol-
lowed by 40 cycles of 95°C for 30 s, 43°C for 30 s, 72°C for 30 s.
Primers specific to P. berghei msp-1 (PBANKA_083100) were:
P3658 + P3659. Actin I (PBANKA_145930) was used as the
internal reference, employing the primers p3753 + p3754. We
also included reactions with a plasmid containing the msp-1
target fragment to create a standard curve. msp-1 transcript
levels were determined relative to actin using the 2DDC(t) method
(Price et al., 2004).
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Fig. S1. Micrographs of P. berghei wild-type (WT) and LipB-
deficient (PbDLipB) asexual blood stage parasites labelled with
antibodies to the apicoplast marker ACP and stained with the
nuclear dye DAPI. Parasites were harvested from infected mice
and cultured overnight prior to fixation, staining and imaging (see
Experimental procedures). WT and PbDLipB parasites showed
no evident differences in asexual blood stage morphology, includ-
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ing the apicoplast organelle. These data are provided as an
extension of Fig. 2C. Space bar, 10 mm.
Fig. S2. Images of P. berghei wild-type (WT) and LipB-deficient
(PbDLipB) liver stage parasites sampled at 48 h post invasion.
Parasites were stained with the nuclear dye DAPI, the
MitoTracker Red dye, and anti-lipoic acid (LA) antibodies to
determine lipoylated structures. WT and PbDLipB parasites were
treated with DMSO or the lipoic acid analogue 8-BOA. PbDLipB
parasites showed little to no remaining lipoylated structures in the
parasite after 8-BOA treatment. Each row represents different
stainings for a given parasite. Images are provided as an exten-
sion of Fig. 4. Scale bar, 10 mm.
Fig. S3. Antibody staining of P. berghei wild-type (WT) and LipB-
deficient (PbDLipB) liver stage parasites sampled at 48 h post
invasion. Parasites were stained with the nuclear dye DAPI and
antibodies to lipoic acid (LA) to visualize lipoylated proteins within
the parasite and the host. The apicoplast was labelled with anti-
bodies to the apicoplast marker Acyl-Carrier Protein (ACP).
PbDLipB parasites showed less lipoylation in the apicoplast as
compared to WT parasites (see greater extent of orange overlays
in WT parasites compared to more green staining in the LipB-
deficient parasites). Pertains to Fig. 4. Space bar, 10 mm.
Fig. S4. Images of P. berghei wild-type (WT) and LipB-deficient
(PbDLipB) liver stage parasites sampled at 48 h post invasion
(hpi). Parasites were stained with the nuclear dye DAPI and
anti-EXP-1 antibodies to determine the morphology of the para-
sitorphorous vacuole. Anti-ACP antibodies were used to deter-
mine the morphology of the apicoplast organelle. PbDLipB
parasites showed smaller and less branched apicoplasts during
liver stage development. Each column contains images from a
single parasite. Data are provided as an extension of Fig. 5.
Space bar, 10 mm.
Fig. S5. Images of P. berghei wild-type (WT) and LipB-deficient
(PbDLipB) liver stage parasites sampled at 54 h post invasion
(hpi). Parasites were stained with the nuclear dye DAPI and
anti-MSP-1 antibodies to determine the morphology of the para-
sitorphorous vacuole. Anti-ACP antibodies were used to deter-
mine the morphology of the apicoplast organelle. PbDLipB
parasites showed smaller and less branched apicoplasts during
liver stage development. Data are provided as an extension of
Fig. 5. Space bar, 10 mm.
Fig. S6. Images of P. berghei wild-type (WT) and LipB-deficient
(PbDLipB) liver stage parasites during late schizont development
sampled at 54 h post invasion. Parasites were stained with the
nuclear dye DAPI and anti-MSP-1 antibodies to define the para-
site plasma membrane. PbDLipB parasites showed major defects
in plasma membrane morphology. Data are provided as an
extension of Fig. 6C. Space bar, 10 mm.
Fig. S7. Images of P. berghei wild-type (WT) and LipB-deficient
(PbDLipB) liver stage parasites sampled at 62 h post invasion.
Parasites were stained with the DAPI nuclear dye and anti-
MSP-1 antibodies to define the parasite plasma membrane.
PbDLipB parasites showed major defects in plasma membrane
morphology. Data are provided as an extension of Fig. 6C. Scale
bar, 10 mm.
Table S1. List of oligonucleotides used in this study.
Table S2. Mean percent reticulocytes in clofibrate- or mock-
treated mice.
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Summary
The widespread use of chloroquine to treat Plasmo-
dium falciparum infections has resulted in the
selection and dissemination of variant haplotypes of
the primary resistance determinant PfCRT. These
haplotypes have encountered drug pressure and
within-host competition with wild-type drug-sensitive
parasites. To examine these selective forces in vitro,
we genetically engineered P. falciparum to express
geographically diverse PfCRT haplotypes. Variant
alleles from the Philippines (PH1 and PH2, which differ
solely by the C72S mutation) both conferred a moder-
ate gain of chloroquine resistance and a reduction in
growth rates in vitro. Of the two, PH2 showed higher
IC50 values, contrasting with reduced growth. Further-
more, a highly mutated pfcrt allele from Cambodia
(Cam734) conferred moderate chloroquine resistance
and enhanced growth rates, when tested against wild-
type pfcrt in co-culture competition assays. These
three alleles mediated cross-resistance to amodi-
aquine, an antimalarial drug widely used in Africa.
Each allele, along with the globally prevalent Dd2 and
7G8 alleles, rendered parasites more susceptible to
lumefantrine, the partner drug used in the leading
first-line artemisinin-based combination therapy.
These data reveal ongoing region-specific evolution of
PfCRT that impacts drug susceptibility and relative
fitness in settings of mixed infections, and raise impor-
tant considerations about optimal agents to treat
chloroquine-resistant malaria.
Introduction
In functionally constrained genes, the rise of non-
synonymous mutations may decrease an organism’s
fitness by steering it away from a long-optimized machin-
ery of closely interacting components. Without a specific
selective pressure, the more fit wild-type usually predomi-
nates at the population level and the less fit variants
are either eliminated or persist at low frequencies
(Mitchell-Olds et al., 2007). An example of selective pres-
sure is the use of drugs to treat human pathogens.As such,
drug-resistant pathogens constitute an ideal group in
which to study the balance between surviving drug pres-
sure and remaining competitive with wild-type organisms.
Generally, fitness costs associated with initial
resistance-conferring mutations will lead to the attrition
of mutants upon the removal of drug pressure, allowing
for the reemergence of surviving wild-type organisms
(Hastings and Donnelly, 2005). However, prolonged drug
exposure can provide pathogens the opportunity to acquire
additional mutations, either within the primary resistance
determinant or within secondary factors, which compen-
sate for the initial fitness cost (Brown et al., 2010). Com-
petition between mutants carrying those compensatory
mutations can then take place, leading to a mutant popu-
lation with a reduced fitness cost that eventually can suc-
cessfully compete with wild-type organisms in a drug-free
environment (Levin et al., 2000). Fitness costs and the
prevalence of initial resistance-conferring mutations can
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also be influenced by the use of other drugs to replace
the failed therapeutic agent, particularly in instances
where their efficacy is impacted by the same resistance
determinants.
The malarial parasite Plasmodium falciparum, which
caused an estimated 198 million clinical cases and
584 000 deaths in 2013 (WHO, 2014), is a prime example
of a human pathogen that repeatedly encounters drug
pressure and within-host competition among parasite
strains. For much of the 20th century, the antimalarial
treatment of choice was chloroquine (CQ), a drug charac-
terized by its rapidity of action, safety and low cost. This
drug prevents the detoxification of reactive iron-containing
heme that is liberated as a result of hemoglobin proteolysis
in the acidic digestive vacuole (DV) of intra-erythrocytic
parasites (Fitch, 2004). CQ resistance (CQR) emerged
slowly, but by the early 1990s had taken hold across
virtually all the malaria-endemic world (Wellems and
Plowe, 2001). The cellular basis for CQR has been attrib-
uted to reduced CQ accumulation in the DV, resulting in
diminished access of CQ to its otherwise toxic heme target
(Saliba et al., 1998).
At the molecular level, CQR has been traced primarily
to amino acid changes in the DV transmembrane protein
PfCRT (Fidock et al., 2000). These include K76T, ubiqui-
tous among CQ-resistant strains and a highly sensitive
marker of CQ treatment failure, as well as three to eight
additional PfCRT polymorphisms that produce region-
specific haplotypes (Ecker et al., 2012). These haplotypes
reflect a handful of origins of mutant pfcrt that dissemi-
nated under drug pressure in selective sweeps across the
world (Nash et al., 2005; Kidgell et al., 2006; Mu et al.,
2010; Park et al., 2012). At least 34 different mutant
PfCRT haplotypes have been reported, contrasting with a
conserved wild-type haplotype in CQ-sensitive parasites
(Isozumi et al., 2010; Ecker et al., 2012; Baro et al.,
2013). In Malawi, the prevalent African mutant form of
PfCRT (CVIET haplotype at positions 72–76, found in
strains including Dd2) largely disappeared within several
years of CQ withdrawal, presumably due to a fitness cost
that rendered this variant less competitive than pfcrt wild-
type parasites in the absence of drug pressure (Kublin
et al., 2003; Mita et al., 2003; Laufer et al., 2010).
The notion that mutation of PfCRT negatively impacts
parasite fitness in field settings is supported by recent in
vitro metabolomic and allelic competition investigations,
which revealed a defect in hemoglobin catabolism and
reduced relative growth rates in vitro, interpreted as a
proxy of fitness costs for the CQ-resistant Dd2 and 7G8
PfCRT haplotypes (Lewis et al., 2014). Consistent with
these findings, a fitness disadvantage was observed for
CQ-resistant parasites during the dry season in The
Gambia, when drug pressure is transiently removed and
transmission is low (Ord et al., 2007). This fitness disad-
vantage was recapitulated in southern Zambia at the level
of vectorial selection, whereby the wild-type (K76) form of
PfCRT was significantly enriched in the infected Anoph-
eles arabiensis mosquitoes compared with its baseline
prevalence in the local infected human populations
(Mharakurwa et al., 2013). Field studies in South America
and Asia, however, have documented no or only modest
attrition in mutant PfCRT forms, including 7G8 (SVMNT
haplotype at positions 72–76), despite the discontinued
use of CQ for the treatment of P. falciparum malaria for
over two decades (Wang et al., 2005; Chen et al., 2008;
Griffing et al., 2010). Those studies have led to the sug-
gestion that the fitness cost of parasites harboring the
72SVMNT76 haplotype may be less severe than that of
parasites carrying the 72CVIET76 signature (Sa and Twu,
2010).
Aside from regional differences in the choice of anti-
malarial drug regimens that may help sustain variant
PfCRT haplotypes (Ecker et al., 2012), studies of human
and murine parasites highlight a potential selective
advantage of mutant pfcrt alleles in enhancing human to
mosquito transmission of parasites following CQ treat-
ment. Among Sudanese parasite isolates bearing the
K76T mutation in PfCRT, a higher gametocyte carriage
rate was observed as compared with parasites encoding
wild-type PfCRT (Osman et al., 2007). Furthermore,
P. berghei parasites engineered to express the P. falcipa-
rum 7G8 pfcrt variant protected early gametocytes
against CQ action and were transmitted at higher levels
compared with drug-sensitive parasites (Ecker et al.,
2011). These observations underscore the complexity of
factors that collectively determine the fitness of Plasmo-
dium parasites, of which relative growth rates in infected
erythrocytes is but one component, with others including
antimalarial drug susceptibility profiles, the impact of host
immunity and transmission dynamics, differences in
gametocyte production and infectivity, competition
between strains within mosquitoes, and growth differ-
ences that could manifest during the liver stages
(Walliker et al., 2005; Rosenthal, 2013).
Here, we dissect the specific contribution of geographi-
cally distinct PfCRT haplotypes to parasite in vitro relative
growth rates and antimalarial drug susceptibility. Our
study includes novel haplotypes that have not been pre-
viously assessed in a controlled genetic background,
including two closely related PfCRT isoforms from the
Philippines (Chen et al., 2005), as well as an allele from
Cambodia that harbors nine mutations, an exceptionally
high number (Durrand et al., 2004). These alleles were
assessed alongside the geographically widespread Dd2
and 7G8 alleles in vitro in drug susceptibility assays as
well as mixed-infection competition assays. We also
investigated how various mutant PfCRT haplotypes
impact CQ accumulation and parasite response to other
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antimalarials in current clinical use. Our results highlight
the importance of regional PfCRT haplotypes in contrib-
uting to parasite fitness and define a novel allele in Cam-
bodia that appears to have overcome the hurdle of
reduced fitness associated with less mutated pfcrt forms
while still maintaining a moderate degree of CQR.
Results
Generation of isogenic parasite lines expressing
Asian pfcrt alleles from the endogenous locus by
allelic exchange
We engineered the mutant pfcrt alleles PH1 and PH2
(from the Philippines) and Cam734 (from Cambodia) into
P. falciparum CQ-sensitive parasites via allelic exchange.
The recipient CQ-sensitive strain C1GC03 was genetically
modified from the GC03 parasite line, a progeny of the
HB3 × Dd2 genetic cross (Su et al., 1997), in a prior round
of transfection. Briefly, the highly interrupted endogenous
wild-type pfcrt gene sequence was replaced with a short-
ened sequence containing all exons and intron 1, render-
ing this line more amenable to pfcrt allelic exchange
(Sidhu et al., 2002). PH1 and PH2 represent two common
PfCRT haplotypes in the Philippines (Chen et al., 2003)
that differ from one another at position 72 and that are
notable for lacking the common A220S mutation but har-
boring the two novel mutations A144T and L160Y
(Table 1). Cam734 comprises ∼ 20% of all pfcrt alleles in
Cambodia and is a highly mutated pfcrt allele, differing
from the wild-type allele at nine positions (Durrand et al.,
2004).
To generate recombinants, C1GC03 parasites were elec-
troporated with the plasmids pBSD-crt-PH1Py3′, pBSD-crt-
PH2Py3′ and pBSD-crt-Cam734Py3′, containing exons 2–13
of the three Asian pfcrt alleles (Fig. 1A). Transfected para-
site cultures were obtained following exposure to blastici-
din and WR99210 to select for expression of blasticidin
S-deaminase (bsd) from the transfection plasmid and
human dihydrofolate reductase (dhfr) in the C1GC03 paren-
tal line respectively.
Polymerase chain reaction (PCR) was used to identify
transfected lines that had undergone homologous
recombination and single-site cross-over into the pfcrt
locus. Recombinant clones were then obtained by limit-
ing dilution. Clones from each successfully integrated
transfection were selected for further characterization
and were termed C8PH1-I, C8PH1-II, C10PH2-I, C10PH2-II,
C12Cam734-I and C12Cam734-II. Following our earlier reports
(Sidhu et al., 2002), the superscript indicates the pfcrt
allele, with the Roman numeral indicating the clone. For
comparison, we included C1GC03, which was generated
using the same allelic exchange strategy (Sidhu et al.,
2002) and which expresses the canonical wild-type
allele (Table 1).
To confirm the clonality of these lines, we performed
PCR with primers P1 and P3 that targeted parasites with
integrated plasmid and primers P1 and P2 that were spe-
cific for the original C1GC03 locus (Fig. 1A and B; Table S1).
Primers P1 and P3 yielded the expected 1.3 kb band from
the clones that had undergone two rounds of recombina-
tion, but not from the first-round C1GC03 or parental GC03
parasites. PCR with primers P1 and P2 resulted in
expected bands of 3.3 kb from the unmodified genomic
pfcrt locus in GC03 and 1.7 kb from the first round of
recombination present in the C1GC03 line (Fig. 1B). South-
ern blot analysis of genomic DNA (gDNA) digested with
SalI + ClaI revealed band sizes of ∼ 16.3 kb, 8.1 kb,
7.7 kb and 1.2 kb, consistent with plasmid integration into
the C1GC03 pfcrt locus (Fig. 1C). GC03 parasites and lin-
earized plasmid DNA showed the predicted 9.4 kb and
7.7 kb bands respectively.
Sequencing of the functional recombinant pfcrt locus
amplified from gDNA, which was performed shortly after
limiting dilution cloning, confirmed the expected full-length
Table 1. Transformation status and PfCRT haplotype of recombinant and wild-type lines.
Clone Parent Transfection plasmid
Functional PfCRT haplotype
72 74 75 76 144 148 160 194 220 271 326 333 356 371
GC03 HB3 × Dd2 – C M N K A L L I A Q N T I R
C1GC03 GC03 phDHFR-crt-GC03Pf3′ C M N K A L L I A Q N T I R
C8PH1-II C1GC03 pBSD-crt-PH1Py3′ C M N T T L Y I A Q D T I R
C10PH2-I,II C1GC03 pBSD-crt-PH2Py3′ S M N T T L Y I A Q D T I R
C12Cam734-I,II C1GC03 pBSD-crt-Cam734Py3′ C I D T F I L T S E N S I R
C2GC03 C1GC03 pBSD-crt-GC03Pf3′ C M N K A L L I A Q N T I R
C4Dd2 C1GC03 pBSD-crt-Dd2Py3′ C I E T A L L I S E S T T I
C67G8 C1GC03 pBSD-crt-7G8Py3′ S M N T A L L I S Q D T L R
HB3 – – C M N K A L L I A Q N T I R
Dd2 – – C I E T A L L I S E S T T I
7G8 – – S M N T A L L I S Q D T L R
Plasmids harboring different pfcrt allelic sequences were transfected into CQ-sensitive C1GC03 parasites to generate the recombinant mutant and
control lines. Grey shading indicates residues that differ from the wild-type sequence.
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sequence of pfcrt in the individual lines.Amplification of the
pfcrt locus from cDNA and gDNA and subsequent
sequencing of the polymorphic region coding for amino
acids 72–76 confirmed the exclusive expression of the
integrated allele in the new second-round recombinants
(data not shown). Real-time PCR analysis was also per-
formed using two independent preparations of parasite
RNA from synchronized ring-stage cultures. These were
assayed for pfcrt and the housekeeping gene actin
(PFL2215w) on four to eight independent occasions
with each sample tested in triplicate per assay. Kruskal–
Wallis tests showed no significant differences in pfcrt tran-
script levels between any pfcrt-modified lines (Table S2).
The same finding of statistically indistinguishable expres-
sion levels was observed by quantitative Western blot
analysis of protein extracts from these recombinant lines
(Table S2).
Ongoing characterization of these recombinant lines,
during the lengthy period of propagation required to com-
plete their phenotypic assessment, revealed a highly
unusual event in the C8PH1-I clone. Over time, a subpopu-
lation arose that outgrew the original line. This subpopula-
tion was found to have undergone reversion of the N326D
mutation back to the wild-type N326 codon in pfcrt, with the
other three PH1 mutations being retained (K76T, A144T
and L160Y; Table 1). Interestingly, this revertant was found
to be CQ sensitive, implicating N326D as an important
contributor to CQR, consistent with a previous report
(Summers et al., 2014). Nevertheless, the advent of a
spontaneous sequence reversion in this line made us
cautious about using the C8PH1-I line, and it was excluded
from further consideration in this present study. Repeated
sequence analysis of other recombinant lines during long-
term culture confirmed the genotypes of all other lines
pBSD-crt-PH1Py3' (7.7kb)
Py3’ bsd
Pf3’pfcrt e2-13 pfcrt e2-135’UTR 1 hdhfr
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Fig. 1. pfcrt allelic exchange strategy and molecular characterization of clones.
A. Schematic representation of single-site cross-over between a pBSD-based pfcrt transfection plasmid and the functional pfcrt locus of
C1GC03, leading to expression of a recombinant allele (PH1, PH2, or Cam734; see Table 1) from the endogenous full-length promoter. The
diagram illustrates transfection of the CQ-sensitive C1GC03 clone with pBSD-crt-PH1Py3′. This construct contained a pfcrt sequence with a
deletion in exon 1, no introns between exons 2–13 and a downstream 0.7 kb 3′ UTR sequence from the P. yoelii ortholog pycrt. Homologous
recombination upstream of codon positions 74–76 resulted in generation of a functional pfcrt allele containing all the point mutations from the
mutant PH1 allele, under the control of pfcrt 5′ UTR and pycrt 3′ UTR regulatory elements. Downstream remnant pfcrt fragments were
truncated in exon 1, had a 5′ in-frame stop codon and lacked a promoter.
B. PCR-based analysis of the recombinant clones and parental lines (primer positions illustrated in A). Parasite strain and primer details are
provided in Table 1 and Table S1 respectively.
C. Southern blot hybridization of gDNA digested with SalI and ClaI and subsequently probed with a pfcrt fragment from exon 2. The positions
of the restriction sites and exon 2-specific probe are indicated in A. B and C include the clone C8PH1-I, which was subsequently found to have
undergone a spontaneous back mutation in codon 326 and was removed from further analysis.
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under investigation. Analysis of the PH1 haplotype was
therefore confined to the C8PH1-II clone, whose genotype
was closely monitored and remained stable over time.
Mutant Southeast Asian pfcrt alleles influence
susceptibility to locally used drugs
Using these recombinant isogenic lines, we assayed the
impact of different PfCRT haplotypes (Table 1) on parasite
susceptibility to CQ as well as other antimalarials. For
comparison, we included C2GC03, C4Dd2 and C67G8, which
were generated using the same genetic strategy (Sidhu
et al., 2002). These encode the wild-type GC03 haplotype,
the Dd2 haplotype commonly found in Asia and Africa and
the 7G8 haplotype that is widespread in SouthAmerica and
the Pacific region respectively (Sa et al., 2009). For refer-
ence, we also included the non-recombinant lines GC03,
Dd2 and 7G8.
We note that our CQ values, both for resistant and
sensitive strains, are lower than earlier reports (Sidhu
et al., 2002; Lakshmanan et al., 2005; Valderramos et al.,
2010). One important technical difference is that we
reduced the HEPES concentration from the earlier 50 mM
to the current 25 mM. Our detailed studies have since
revealed that this decrease in the HEPES concentration
leads to a substantial reduction in half-maximal inhibitory
concentration (IC50) values for CQ-sensitive and even
more so for CQ-resistant parasites, as detailed in the
Supporting Information (Supplemental Text and Figs S2–
S4). This is one of the variables that can produce differ-
ences in CQ IC50 values (others include genetic differences
between strains maintained long-term in separate labora-
tories and the choice of assay). Relative differences
between strains in a given dataset are thus recognized to
provide the most informative data (Ekland and Fidock,
2008). Consequently, we also discuss below the relative
differences between parasite lines expressing distinct
pfcrt alleles.
For CQ, all recombinant lines expressing mutant pfcrt
alleles (C8PH1, C10PH2, C12Cam734, C4Dd2 and C67G8) had a
statistically significant, 2.5- to 4.7-fold increase in mean
IC50 value relative to the isogenic recombinant C2GC03 line
expressing the wild-type allele (mean IC50 value of 14 nM)
(Fig. 2A; Table S3). Of note, C10PH2 and C12Cam734 yielded
CQ IC50 values (53–54 nM) that were comparable in these
assays to the recombinant C4Dd2 and C67G8 parasites
expressing the most globally prevalent mutant pfcrt alleles
(Sidhu et al., 2002). We note, however, that C4Dd2 and
C67G8 are no longer as CQ-resistant as when they were
originally generated (in 2002) and characterized by several
groups (Sidhu et al., 2002; Lakshmanan et al., 2005;
Gligorijevic et al., 2008). This has also been observed in an
independent recent study that employed these lines
(Hrycyna et al., 2014). C4Dd2 and C67G8 currently display
CQ IC50 values that are now 51% and 68% of the parental
Dd2 and 7G8 lines respectively (Fig. 2A and Table S3), as
compared with the initial report that documented corre-
sponding values of 76% and 90%. These relative levels of
CQR are illustrated for the original C4Dd2 and C67G8 lines,
alongside the now-attenuated lines, in Fig. 2A. Thus, our
present data with the more recently generated PH1, PH2
and Cam734 pfcrt-expressing lines identify these as only
modestly CQR, with relatively low CQ IC50 values. Strik-
ingly, the two C10PH2 clones demonstrated higher CQ
mean IC50 values as compared with C8PH1-II parasites (53–
54 nM compared with 35 nM). This finding implicates
amino acid 72, which is the only polymorphism that distin-
guishes the PH2 and PH1 alleles (Table 1), as an important
determinant of the degree of CQR.
Similar observations were made with the CQ metabolite
monodesethyl-chloroquine (md-CQ), which yields much
higher IC50 values in CQ-resistant parasites, allowing for
greater discrimination between resistant and sensitive
lines (Sidhu et al., 2002). C10PH2 and C12Cam734 clones all
yielded mean IC50 values (267–346 nM) that were com-
parable with C4Dd2 and C67G8 (282 and 262 nM, respec-
tively; Fig. 2B; Table S3). In comparison, the CQ-sensitive
lines C2GC03 and GC03 showed mean IC50 values of
17–22 nM. Of note, the mean md-CQ IC50 value (164 nM)
of the C8PH1 clone was considerably lower than the IC50
values of the two C10PH2 lines (267 and 305 nM), again
supporting a direct role for the C72S mutation in augment-
ing the degree of CQR.
Prior work has shown that CQ-resistant parasites can be
chemosensitized to CQ and md-CQ by the resistance-
reversing agent verapamil (VP) (Krogstad et al., 1987;
Martin et al., 1987). The primary determinant of this revers-
ibility trait has been mapped by quantitative trait loci analy-
sis to mutant pfcrt (Patel et al., 2010) and is more
pronounced in the presence of the Dd2 allele as compared
with the 7G8 allele (Mehlotra et al., 2001; Sidhu et al.,
2002; Sa et al., 2009). To assess VP reversibility in our
recombinant lines, we performed drug assays in the pres-
ence or absence of 0.8 μM VP and compared IC50 values.
Results showed a high degree of resistance reversal (74–
85%) for C4Dd2 and the reference Dd2 line and an interme-
diate degree (43–56%) for C67G8 and 7G8 parasites
(Fig. 2C). These values were significantly different from the
CQ-sensitive C2GC03 line that along with GC03 showed no
reversibility with this concentration of VP. Intriguingly, both
C8PH1 and C10PH2 showed only a slight degree of reversal,
which did not attain statistical significance. A similar lack of
significant reversal was also observed with the metabolite
md-CQ (Table S3). This agrees with an earlier report of
Philippine isolates (Chen et al., 2003) and is consistent
with a recent study that associated PfCRT N75 (present in
both haplotypes; Table 1) with minimal VP reversal
(Sa et al., 2009). We note that C12Cam734 parasites,
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which harbor the novel N75D mutation, were also subject
to a significant degree (56–72%) of VP reversal of CQ and
md-CQ resistance, at levels intermediate to the Dd2 and
7G8 alleles (Fig. 2C; Table S3).
We extended these studies to monodesethyl-
amodiaquine (md-AQ), the clinically relevant metabolite of
amodiaquine, a 4-aminoquinoline drug formerly used in
monotherapy in many South American, African and Asian
countries, including the Philippines (Sa et al., 2009). This
drug continues to be clinically important because of
its incorporation into the widely used amodiaquine–
artesunate combination (Wells et al., 2009). Our studies
reveal a substantial impact of both Philippine pfcrt alleles,
as well as the Cam734 allele, on md-AQ responses
(Fig. 2D), resulting in a 2.5 to fourfold increase in IC50
values compared with C2GC03. Of all alleles tested, the
smallest gain in md-AQ resistance was afforded by expres-
sion of the recombinant Dd2 allele that mediates relatively
high-level CQR (see C4Dd2 responses in Fig. 2A and D).
These data implicate an important role for the PfCRT
mutations unique to the Philippine and Cambodian alleles
in reducing parasite susceptibility to amodiaquine.
Importantly, every mutant pfcrt allele significantly
increased susceptibility to the arylaminoalcohol drug lume-
fantrine (LMF; Fig. 2E), the partner drug comprising the
most widely used artemisinin-based combination therapy
(ACT), artemether-lumefantrine (Wells et al., 2009). Mean
IC50 reductions were 37–47%, as compared with C2GC03
(Table S3). It is worth noting that a similar decrease in LMF
IC50 values in parasites expressing mutant pfcrt as com-
pared with isogenic parasites expressing the wild-type
allele was earlier found to be associated with a significant
reduction in the prevalence of mutant pfcrt in field isolates



































































































































































































































































































































































































































































































Fig. 2. Susceptibility of pfcrt-modified clones to selected antimalarial drugs. Mean IC50 values ± SEM for the indicated parasite strains
subjected to clinically significant antimalarials, as measured in vitro using [3H]-hypoxanthine incorporation assays. We note that the CQ values,
both for resistant and sensitive strains, are markedly lower than earlier reports (Sidhu et al., 2002; Lakshmanan et al., 2005; Valderramos
et al., 2010), and coincide with our reducing the HEPES concentration from the earlier 50 mM to the current 25 mM (see Supporting
information). CQ values for the original C4Dd2 and C67G8 lines, presented as a proportion of their IC50 values of the reference Dd2 and 7G8
lines, are included to illustrate the attenuation of the CQR phenotypes of these lines over time. The C4Dd2-original CQ mean ± SEM IC50 value of
96.8 ± 8.7 nM is comparable to the values of 91.8 ± 10.7 nM and 100.3 ± 15.5 nM recently reported with two pfcrt-modified GC03 clones
engineered to express the Dd2 allele (i.e. analogous to C4Dd2) using customized zinc-finger nucleases (Straimer et al., 2012). VP reversal was
calculated as the IC50 of CQ + 0.8 μM VP divided by the IC50 of CQ. VP reversal values for CQ, md-CQ and md-ADQ are provided in
Table S4. Mann–Whitney U tests were used to assess for statistically significant differences between a recombinant line expressing mutant
pfcrt and the CQ-sensitive line C2GC03 expressing wild-type pfcrt. *P < 0.05; **P < 0.01; ***P < 0.001. IC50 and IC90 values, numbers of assays
and tests for significance are reported in Table S3.
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lumefantrine (Sisowath et al., 2009). These findings
support the therapeutic advantage of using LMF in areas of
CQ-resistant malaria.
A similar trend was observed with the arylaminoalcohol
mefloquine and the endoperoxide artemisinin. However,
the differences in IC50 values did not attain statistical
significance (Table S3). The PH1 and PH2 pfcrt alleles, but
not Cam734, also significantly increased parasite suscep-
tibility to quinine (Fig. 2F), a centuries-old drug used to
treat severe malaria. Quinine resistance is known to be
multifactorial, with quantitative trait loci analyses implicat-
ing mutant pfcrt and pfmdr1 as major determinants (Ferdig
et al., 2004; Sanchez et al., 2011; 2014). Our data support
the hypothesis that the direction and magnitude of the
effect of mutant pfcrt on quinine response depends on the
genetic background and PfCRT haplotype (Cooper et al.,
2002; 2007; Sidhu et al., 2002; Lakshmanan et al., 2005).
Finally, no differences were observed with piperaquine
(Table S3), an ACT partner drug that comprises two CQ
4-aminoquinoline rings tethered together with a spacer
(Wells et al., 2009), consistent with this drug being equally
potent against parasites expressing wild-type or common
mutant variants of pfcrt (Pascual et al., 2013).
Reduced chloroquine accumulation alone does
not account for differences in the degree of
chloroquine resistance
Resistance to CQ has been associated with reduced drug
accumulation in the DV and has previously been attrib-
uted to mutant PfCRT-mediated efflux of CQ from this
acidic organelle (Krogstad et al., 1987; Martin et al., 1987;
2009; Valderramos and Fidock, 2006). To investigate the
influence of the Southeast Asian pfcrt alleles on CQ accu-
mulation, we measured the kinetics of [3H]-CQ uptake in
cultured parasites. The CQ-sensitive control lines GC03
and C2GC03 showed a rapid increase in CQ accumulation,
as measured by a very high ratio (up to 2300) of total
intracellular CQ to extracellular CQ ([CQin]/[CQout])
(Fig. 3A). In contrast, the four pfcrt-variant recombinant
lines (C4Dd2, C8PH1-I, C10PH2-I and C12Cam734-I) accumulated
minimal levels of CQ ([CQin]/[CQout] values of ∼ 200–300).
Thus, these mutant PfCRT haplotypes, all expressed in
the same genetic background, were associated with a
very similar reduction of intracellular CQ levels (Fig. 3B),
despite marked differences in their CQ IC50 values
(Fig. 2). These data lead us to suggest that reduced CQ
accumulation might represent only one means by which
mutant PfCRT dictates the degree of CQR.
PfCRT haplotypes influence parasite growth rates in
co-culture in vitro competition assays
To measure the extent to which pfcrt mutations influence
the relative growth rates of asexual blood stage parasites,
serving as a partial proxy for assessing fitness costs, we
performed in vitro co-culture competition assays. In these
assays, two lines were mixed in 1:1 ratios, and the pro-
portions of the individual pfcrt alleles were quantified by
pyrosequencing every 4 days, on average, over a two to
three month period. Data from these assays were con-
verted using the ratio of the natural logs of the allelic
frequencies, based on an assumption of exponential
growth, and were subjected to linear regression (Maree
et al., 2000; Mita et al., 2004). Linear regression R 2
values were generally high (average 0.64, reflecting an
acceptable goodness of fit; Table S5). In total, 34
co-culture assays were followed, yielding 518 measure-
ments of pfcrt allelic frequencies over time (Table S5).
From these measurements, we computed the mean rela-
tive growth rate value for each line, as detailed in the
Supporting Information.
Results indicated that the isogenic clones C8PH1-II and
C10PH2-I, expressing the PH1 and PH2 mutant pfcrt alleles
respectively, each displayed reduced in vitro growth when
independently co-cultured with C2GC03 parasites (Figs 4












































Fig. 3. Chloroquine accumulation of pfcrt-modified parasite lines.
[3H]-CQ accumulation is represented as the ratio of the total
intracellular CQ to extracellular CQ ([CQin]/[CQout]). Values
represent the mean ± SEM determined from three independent
experiments performed in duplicate. Data are shown in (A) for the
full set of pfcrt-modified lines and the CQ-sensitive control GC03,
and in (B) exclusively for the lines expressing mutant pfcrt (note the
reduced y-axis scale).
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and 5A). Of the two mutant pfcrt parasites, C10PH2-I para-
sites showed the more substantial loss of relative growth
rate in vitro. This finding was consistent with direct com-
petition assays between C10PH2-I and C8PH1-II, which
revealed reduced relative growth rates with the former
(Table S5). This contrasted with CQ and md-CQ IC50
values that were higher for C10PH2-I (Fig. 2; Table S3).
These results suggest a state of balanced polymorphisms
whereby the PH1 allele could be predicted to fare better
than the more unfit PH2 in mixed infections in the absence
of CQ drug pressure, whereas the moderately more CQR
PH2 allele could be more competitive in the presence of
CQ and thus be retained in the population. Intriguingly,
parallel studies with the CQ-resistant C12Cam734-I line docu-
mented that these parasites were consistently as fit in
terms of growth rates, if not slightly more so, when com-
pared with C2GC03 in vitro. These data suggest that the
Cam734 allele, harboring an unusually high number of
point mutations (Table 1), has achieved a functional state
that might reduce the fitness cost typically observed with
mutant pfcrt alleles in endemic settings.
In contrast to Cam734, we observed a substantial reduc-
tion in relative growth rates associated with the Dd2 pfcrt
allele when comparing C4Dd2 to C2GC03, a finding consistent
with reports of reduced fitness associated with this allele in
African parasite populations (Kublin et al., 2003; Mita
et al., 2003; Ord et al., 2007). A more modest reduction in
relative growth rates was observed with the 7G8 allele
present in C67G8. The reduced relative growth rates of the
Dd2 and 7G8 alleles is consistent with a recent report that
also assessed these recombinant parasite lines in mixed
culture experiments (Lewis et al., 2014). In our studies,
C67G8 consistently outcompeted C4Dd2 in mixed cultures in
four independent experiments (Fig. 4; Table S5). Impor-
tantly, when testing non-recombinant lines, we found the
Dd2 line to have moderately increased growth rates rela-
tive to lines expressing wild-type pfcrt (GC03 and HB3),
suggesting that Dd2 harbors additional compensatory
mutations in its genome that corrected the growth defect
associated with expression of its pfcrt allele. A summary of
the influence of pfcrt alleles on in vitro growth rates in these
co-competition assays is depicted in Fig. 5A. Independent
support for these data came from measurements of in vitro
growth rates for individual lines, which were monitored
daily for 7 days in three independent assays per line.
Calculated multiplication rates per 48 h revealed that in
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Fig. 4. Relative growth rate plots for mixed competition assays between pfcrt-modified lines. Parasite cultures were initiated at ∼ 1:1 ratios,
and allelic proportions were measured over time for up to 45 generations by pyrosequencing. The y-axis illustrates the proportion of the first
listed allele comprising the mixed cultures. Each color represents a separate assay. Data are collectively summarized in Fig. 5A and Table S5.
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comparison with parasites expressing the pfcrt wild-type
GC03 allele, parasites expressing the Cam734 allele
showed an equivalent growth rate, whereas parasites
expressing the PH2, Dd2 and 7G8 alleles displayed slower
rates of growth (Fig. S1).
Discussion
Genome-wide studies of P. falciparum populations have
demonstrated a remarkable degree of recent evolution in
the pfcrt coding sequence, beginning with several inde-
pendent origins of variant alleles. These alleles have
spread across malaria-endemic regions as selective
sweeps driven by intense drug pressure (Wootton et al.,
2002; Kidgell et al., 2006; Volkman et al., 2007; Mu et al.,
2010). Primary origins have been localized to South
America and Papua New Guinea (independent sources of
the 7G8 variant haplotype), the Philippines (PH1 and PH2),
the Thai-Cambodian border (Dd2) and most likely Cambo-
dia (Cam734; Fig. 5B) (Ecker et al., 2012). CQR in Africa
resulted from the introduction of variant pfcrt of Southeast
Asian origin (Ariey et al., 2006), whose insidious impact on
malaria rates was highlighted by reports from Senegal
showing nearly a sixfold increase in malarial deaths follow-
ing the arrival of resistant strains (Snow et al., 2001; Trape,
2001). Our study of geographically distinct PfCRT haplo-
types reveals an intricate balance between CQR and para-
site growth rates, which provide an in vitro proxy of fitness.
Our data also highlight the emergence (in Cambodia) of the
Cam734 allele (Durrand et al., 2004), which appears to
have succeeded in mediating a moderate degree of resist-
ance while concurrently maintaining in vitro growth rates at
least as good if not better than wild-type pfcrt (Fig. 5C).
Notably, Cambodia is a known hotbed of multidrug resist-
ance, beginning with CQ and pyrimethamine-sulfadoxine
and more recently with emerging resistance to artemisinin
derivatives (Dondorp et al., 2011; Ariey et al., 2014;
Straimer et al., 2015). We ascribe the lack of an observable
growth rate defect in the Cam734 allele to its complex set
of mutations (Table 1), which include the L148I, I194T and
T333S mutations not present in other parasites studied
herein. We posit that these mutations have evolved to
compensate for a loss of fitness bestowed by an initial set
of mutations that were sufficient to confer CQR, including
but not limited to K76T (Lakshmanan et al., 2005). The
ability of Plasmodium parasites to acquire a set of muta-



































































































































































Fig. 5. Influence of pfcrt alleles on relative growth rates and
chloroquine resistance.
A. Relative growth rate values for the individual pfcrt-modified
parasite lines were measured following pyrosequencing-based
assessment of changes in pfcrt allele frequencies in mixed cultures
maintained for up to 45 generations. For each combination, 1–6
independent competition assays were performed in duplicate
(summarized in Table S5; data plotted in Fig. 4). The histogram
depicts the relative growth rate of the first line compared with the
second, e.g. for C8PH1-II vs. C2GC03 the negative value reflects the
reduced relative growth rate of C8PH1-II.
B. Distribution of various pfcrt alleles in the major malaria-endemic
regions.
C. Mean relative growth rate differences between wild-type and
mutant pfcrt alleles (in the GC03 background) presented as a
function of the effect of these alleles on CQ IC50 values (based on
data presented in Tables S3 and S5 and depicted in Figs 2 and
5A). Circle size indicates the estimated worldwide frequency of the
pfcrt allele, approximated from literature reports and database
summaries on the number of clinical cases and the distribution of
pfcrt alleles (see Table S6).
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fitness has previously been documented in murine studies,
in which CQ-resistant P. chabaudi parasites outgrew their
sensitive counterparts, even when mice were inoculated
with a ninefold excess of sensitive parasites (Rosario et al.,
1978). Recent metabolomic studies show that the wide-
spread Dd2 and 7G8 alleles cause increased levels of
intracellular peptides in asexual blood stage parasites,
presumably stemming from impaired hemoglobin digestion
that restricts the supply of amino acids required for parasite
proliferation (Lewis et al., 2014). These recent findings
provide a potential mechanistic explanation for the fitness
costs observed with the Dd2 and 7G8 haplotypes. Further
studies are required to assess whether the Cam734 allele
corrects this abnormal accumulation of hemoglobin-
derived peptides.
Our findings also illustrate a singular impact of PfCRT
residue 72, which is the sole sequence distinction between
the Philippine PH1 allele that mediates marginal CQR and
the PH2 allele that is moderately more resistant (Fig. 5C).
This residue is also associated with differences in relative
growth rates in vitro (Figs 4 and 5A). How this single amino
acid difference might impact protein conformation, stability
or post-translational modifications remains to be deter-
mined. During these experiments, we isolated a separate
recombinant C8PH1 parasite, referred to as C8PH1-II, which
underwent a spontaneous loss of the N326D mutation
during extended culture. This reversion back to the wild-
type residue was associated with an increased rate of
parasite propagation and a loss of CQR. The reversion to a
CQS phenotype by the N326D mutation is consistent with
a recent report that showed a lack of CQ transport in
Xenopus oocyte-based heterologous expression assays,
in contrast to the PH1 PfCRT variant that showed CQ
transport behavior (Summers et al., 2014). These data
highlight a requirement for multiple PfCRT mutations in
producing the CQR phenotype, arguing against the notion
that CQR results solely from the K76T mutation and that
the other mutations in this protein compensate solely for
loss of function. This conclusion is supported by transport
studies in an oocyte expression system, which provided
evidence that the K76T mutation needed to be accompa-
nied by either the N75E (Southeast Asian PfCRT variants)
or the N326D mutation (LatinAmerican and oceanic PfCRT
variants) to attain a CQ transport function (Summers et al.,
2014). Although two mutational changes sufficed for a
basal CQ transport activity, additional mutations were
required for full activity. The order in which these mutations
were added was important to avoid reductions in CQ
transport activity (Summers et al., 2014).
Epidemiological studies have found that some para-
sites harboring the PfCRT K76T mutation have low to
moderate CQ IC50 values that do not meet the standard
definition of CQR and in some instances are similar to
values observed with CQ-sensitive parasites, for example
some Cambodian isolates harboring the Cam734 allele
(Durrand et al., 2004). Studies are ongoing to dissect the
role of the PfCRT SNPs that are unique to the Cam734
haplotype. Furthermore, in vitro selection studies have
shown that parasites harboring the Dd2 pfcrt allele
acquired a C101F mutation that resulted in a loss of CQR
despite the presence of K76T (Eastman et al., 2011).
Thus, although K76T continues to be an important
molecular marker of CQR, recent evidence suggests that
additional PfCRT SNPs can substantially modify the CQ
response, in some cases causing an attenuation or loss of
the resistance phenotype. We also note that while PfCRT
is widely recognized to be the primary mediator of CQR,
several studies point to a requirement for secondary
determinants to augment CQR, including pfmdr1 (Sidhu
et al., 2002; Sa et al., 2009; Patel et al., 2010;
Valderramos et al., 2010; Gaviria et al., 2013).
In our mixed infection studies with isogenic pfcrt-
modified clones, we also observed that parasites dis-
played the greatest loss of asexual blood stage growth
when expressing the Dd2 allele, consistent with its pro-
gressive disappearance from high-transmission African
settings in the absence of CQ pressure (Mita et al., 2003;
Ord et al., 2007; Mwai et al., 2009; Laufer et al., 2010;
Frosch et al., 2011). This contrasts with the situation in
Southeast Asia where the Dd2 allele remains at high
frequencies in the absence of CQ pressure. Fewer mixed
infections in Asia compared with Africa likely result in less
opportunity for competition with the wild-type allele. The
lesser fitness cost observed with the 7G8 allele, which is
prevalent in South America and the Pacific region, is
concordant with studies from these regions showing the
continued presence of mutant pfcrt despite minimal CQ
use in recent decades to treat P. falciparum malaria (Mu
et al., 2010). We note that modest selective pressure on
mutant pfcrt may also have come from the use of CQ to
treat P. vivax infections, which are common outside of
Africa (Price et al., 2007). Overall, our in vitro mixed com-
petition relative growth rate data would suggest that the
idea of reintroducing CQ into regions where prolonged
drug removal has led to the near disappearance of
resistant strains (Juliano et al., 2007; Laufer et al., 2010)
is suitable only in areas harboring mutant pfcrt alleles
such as Dd2 that cause reduced fitness and would be less
applicable to regions harboring relatively ‘fit’ alleles such
as Cam734.
The loss of CQ efficacy across the globe, followed by a
short-lived dependence on the sulfadoxine-pyrimethamine
antifolates, has resulted in recent years in the global adop-
tion of ACTs (White, 2008; Eastman and Fidock, 2009).
Notably, our study shows that all mutant pfcrt alleles tested
herein, including the two that are most prevalent (Dd2 and
7G8), increase parasite susceptibility to lumefantrine. This
is particularly significant as this drug, partnered with
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artemether (CoArtem®), is globally the most widely used
antimalarial (Wells et al., 2009). Although the fold change
in lumefantrine IC50 values is relatively low (≤ 2-fold;
Fig. 2E; Table S3), we note that a clinical trial from Tanza-
nia observed significant selection against mutant pfcrt
parasites harboring the 72CVIET76 PfCRT haplotype follow-
ing artemether–lumefantrine treatment (Sisowath et al.,
2009).
Amodiaquine–artesunate is another ACT that is often
used in Africa (Olliaro and Mussano, 2000). We observed
significantly reduced parasite susceptibility to the amodi-
aquine metabolite md-AQ with every tested mutant pfcrt
allele. This includes both Philippine alleles, obtained from
a country where amodiaquine has been used as an anti-
malarial treatment for over 40 years (Sa et al., 2009). We
thus posit that amodiaquine could have been a major
contributor to the emergence and/or maintenance of the
PH1 and PH2 alleles. An important role for amodiaquine
in driving the spread of the 72SVMNT76 PfCRT haplotype
(present in 7G8) has recently been proposed based on
studies of parasites from South America and Asia (Sa
et al., 2009; Beshir et al., 2010), and amodiaquine pres-
sure could conceivably account for the apparent recent
spread of this haplotype into Africa and in India (Alifrangis
et al., 2006; Gama et al., 2010; Mixson-Hayden et al.,
2010). In addition, as with many Asian countries, CQ has
continued to be used to treat patients infected with
P. vivax, thus sustaining local CQ pressure that could
influence the course of mixed infections of P. vivax and
P. falciparum. Overall, our data support the use of
artemether–lumefantrine in preference to amodiaquine-
artesunate to treat CQ-resistant malaria. We also found
no evident effect of mutant pfcrt alleles studied herein on
the efficacy of piperaquine, an ACT partner drug with
excellent clinical efficacy and post-treatment prophylactic
activity (Wells et al., 2009).
Our mechanistic investigations into CQR provide evi-
dence that mutant PfCRT-mediated CQR can be pheno-
typically distinguished from reduced intracellular CQ
accumulation, as also noted by a previous study (Sanchez
et al., 2011). This was particularly evident with C8PH1 para-
sites that, despite having only a nominal degree of CQR,
displayed kinetics of intracellular CQ accumulation that
paralleled the other, more CQ-resistant parasites. In con-
trast, CQ-sensitive parasites showed 7- to 10-fold higher
levels of CQ accumulation (Fig. 4). Thus, all mutant PfCRT
variants shared an ability to reduce CQ accumulation. This
study agrees with recent evidence that reduced CQ accu-
mulation is not the sole cause of CQR (Cabrera et al.,
2009; Sanchez et al., 2011; Baro et al., 2013). We posit
that mutant PfCRT generally reduces CQ accumulation
and that this is an essential feature of CQR but that various
PfCRT haplotypes differ in a second respect that further
contributes to the CQR phenotype. One possibility is that
the higher degree of CQR reflects varying degrees to which
PfCRT functions to also reduce the cellular toxicity associ-
ated with CQ action, possibly by negating the effect of CQ
on preventing the buildup of reactive heme-iron or oxygen
species liberated following hemoglobin proteolysis.
Another possibility is that the drug competes with a yet to
be identified physiological substrate for transport via
PfCRT and that this competition impacts on the natural
function of the transporter. In this context, it is interesting to
note that PfCRT appears capable of simultaneously
accepting different substrates at distinct but antagonisti-
cally interacting binding sites (Bellanca et al., 2014).
Binding of two different substrates might result in an inac-
tive transporter or one with substantially reduced activity,
depending on the nature of the substrates bound (Bellanca
et al., 2014). How a geographic PfCRT variant copes with
its drug and physiological transport functions is likely deter-
mined by its specific amino acid substitutions. Further
dissection of the biochemical parameters associated with
heme detoxification and CQ action can now be achieved
using the series of isogenic pfcrt-modified lines described
herein.
Experimental procedures
Parasite culture, transfection, and selection and
characterization of integrant clones
Parasites were cultured at 37°C in human red blood cells in
Albumax-containing culture medium, as described (Fidock
et al., 1998). Isogenic lines expressing variant pfcrt alleles
were generated following transfection of the C1GC03 clone
(Sidhu et al., 2002). This clone was previously generated
from GC03 (a progeny of the HB3 × Dd2 genetic cross,
Wellems et al., 1990) and expresses wild-type pfcrt from a
recombinant locus lacking introns 2–12 (Fig. 1). C1GC03 para-
sites were propagated to ∼ 8% ring stage parasitemia and
electroporated with 50 μg of plasmid (pBSD-crt-PH1Py3′,
pBSD-crt-PH2Py3′ or pBSD-crt-Cam734Py3′; Table 1; Fig. 1).
Transformed parasites were selected using 2.5 nM WR99210
(Jacobus Pharmaceuticals, Princeton, NJ, USA) and 2.5 μM
Blasticidin HCl (Invitrogen). Successfully transfected para-
sites were detectable in culture 2–3 weeks post-transfection
and cloned by limiting dilution once plasmid integration was
detected. Details of plasmid construction, and of the molecu-
lar characterization of parasite lines, are provided in the Sup-
porting Information (primers listed in Table S1). pfcrt-modified
transgenic lines will be made available upon request and are
being deposited in the MR4 Malaria Reagent Repository.
In vitro drug susceptibility assays
Parasite susceptibilities to antimalarial drugs were assessed
in vitro as described (Fidock et al., 1998) using 72 h [3H]-
hypoxanthine assays (see Supporting Information). IC50
values were calculated by non-linear extrapolation. Statistical
analyses employed Mann–Whitney U tests.
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In vitro mixed culture competition assays,
pyrosequencing and determination of relative
growth rate values
For growth competition assays, two parasite lines were mixed
1:1 and seeded in duplicate or triplicate at an initial para-
sitemia of 0.6% ring stage parasites, in drug-free medium.
Parasitemias were maintained between 0.3% and 8% to
assure optimal growth conditions. Two to six separate com-
petition assays were performed for each drug-free mixture,
and each assay was monitored for an average of 66 days
(range 43–90; Fig. 4; Table S5). To determine the ratio of both
strains in the mixture over time, saponin-lysed parasite
pellets of the mixed cultures were collected on average every
4 days (range 2–9), and DNA was extracted using DNeasy
Blood & Tissue Kits (Qiagen). The DNA was then used for
ratiometric determination of individual allele frequencies in
these mixed cultures by pyrosequencing of codon position 72
or 76 (detailed in the Supporting Information). To calculate the
relative growth rates of individual parasite lines, the relative
proportion of the two distinct pfcrt alleles (whose values were
always between 0 and 1, inclusive) were natural log-
transformed, and linear regression was applied to estimate
the relative growth rate value, as detailed in the Supporting
Information. These values, along with the calculated SEM
and R 2 values, are listed in Table S5.
Chloroquine accumulation assays
These were performed, as previously described (Sanchez
et al., 2003), using magnet-purified, sorbitol-synchronized
trophozoites (detailed in Supporting Information). The
amount of accumulated intracellular [3H]-CQ was calculated
as the ratio of [CQin]/[CQout], normalized to 1 × 106 infected
erythrocytes.
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